US20030040790A1 - Stent coating - Google Patents
Stent coating Download PDFInfo
- Publication number
- US20030040790A1 US20030040790A1 US10/209,591 US20959102A US2003040790A1 US 20030040790 A1 US20030040790 A1 US 20030040790A1 US 20959102 A US20959102 A US 20959102A US 2003040790 A1 US2003040790 A1 US 2003040790A1
- Authority
- US
- United States
- Prior art keywords
- stent
- body member
- cross
- slots
- biological agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
- A61F2/90—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
- A61F2/91—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
- A61F2/90—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
- A61F2/91—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
- A61F2/915—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/10—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
- A61F2/90—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
- A61F2/91—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
- A61F2/915—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other
- A61F2002/91533—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other characterised by the phase between adjacent bands
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
- A61F2/90—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
- A61F2/91—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
- A61F2/915—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other
- A61F2002/9155—Adjacent bands being connected to each other
- A61F2002/91566—Adjacent bands being connected to each other connected trough to trough
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
- A61F2/90—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
- A61F2/91—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
- A61F2/915—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other
- A61F2002/9155—Adjacent bands being connected to each other
- A61F2002/91575—Adjacent bands being connected to each other connected peak to trough
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2230/00—Geometry of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2230/0002—Two-dimensional shapes, e.g. cross-sections
- A61F2230/0028—Shapes in the form of latin or greek characters
- A61F2230/0054—V-shaped
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
- A61F2250/0067—Means for introducing or releasing pharmaceutical products into the body
- A61F2250/0068—Means for introducing or releasing pharmaceutical products into the body the pharmaceutical product being in a reservoir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
- A61F2250/0096—Markers and sensors for detecting a position or changes of a position of an implant, e.g. RF sensors, ultrasound markers
- A61F2250/0098—Markers and sensors for detecting a position or changes of a position of an implant, e.g. RF sensors, ultrasound markers radio-opaque, e.g. radio-opaque markers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2310/00—Prostheses classified in A61F2/28 or A61F2/30 - A61F2/44 being constructed from or coated with a particular material
- A61F2310/00389—The prosthesis being coated or covered with a particular material
- A61F2310/0097—Coating or prosthesis-covering structure made of pharmaceutical products, e.g. antibiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/42—Anti-thrombotic agents, anticoagulants, anti-platelet agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/426—Immunomodulating agents, i.e. cytokines, interleukins, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/602—Type of release, e.g. controlled, sustained, slow
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/606—Coatings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- This invention relates to an implant for use within a body and, more particularly, an expandable stent which is particularly useful for repairing various types of body passageways, and even more particularly to an expandable stent that includes and/or is at least partially coated and/or a impregnated with one or more biological agents which stent and one or more biological agents are useful in repairing blood vessels narrowed or occluded by disease.
- an expandable stent that includes and/or is at least partially coated and/or a impregnated with one or more biological agents which stent and one or more biological agents are useful in repairing blood vessels narrowed or occluded by disease.
- the biological agent delivery system of the present invention can be used in conjunction with various types of implants such as, but not limited to, prosthetic devices.
- the biological agent delivery system can form one or more components of other types of implants and/or be coated and/or impregnated onto at least a portion of other types of implants to deliver one or more biological agent to a particular site.
- the biological agent delivery system can be used in conjunction with, or used separate from, a stent and/or other types of implants to deliver a biological agent into a body cavity, organ or other part of the body.
- the present invention is particularly directed for use in humans; however, the present invention can be used in animals and some types of plants.
- WO 99/56663 are incorporated herein by reference to illustrate various types and configurations of stents, the process or method of manufacturing stents, and the method by which such stents are used.
- Intraluminal endovascular grafting a type of angioplasty procedure, has been demonstrated by experimentation to present a possible alternative to conventional vascular surgery and is used to treat heart disease.
- Intraluminal endovascular grafting involves a tubular prosthetic graft or stent and delivery within the vascular system.
- graft and “stent” are used interchangeably.
- Advantages of this method over conventional vascular surgery include obviating the need for surgically exposing, incising, removing, replacing, or bypassing the defective blood vessel.
- Over 20 million angioplasty or related procedures involving occluded vasculature have been preformed worldwide. About 30% of these angioplasties fail within 30 days. These failures typically require the procedure to be repeated.
- a stent is an expandable metal tubular device that is mounted over an angioplasty balloon and deployed at the site of coronary narrowing.
- the balloon is inflated to expand the stent to physically open and return patency to the body passageway.
- the balloon is deflated and removed and the stent is permanently disposed to retain the opened body passageway.
- the first generation of expandable stents did not offer a controllable radial expansion.
- the stent might not expand enough to contact the interior surface of the body passageway so as to be secured thereto and/or not expand the body passageway to the desired diameter.
- the stent disclosed in the '665 patent overcame the problems associated with these past stent designs.
- the stent based upon the '665 patent is currently being used in angioplasty procedures.
- Stents including the stent of the '665 patent, are presently used in approximately 30-60 percent of all angioplasty procedures.
- these stents have several shortcomings which contribute to procedural failure rates.
- the currently used stents are not readily visible under fluoroscopic guidance procedures. Stent placement is hindered as a result of poor visibility. As a result, precise positioning of the stent during the insertion procedure was difficult to achieve. Consequently, the stent could be inadvertently positioned in the wrong or non-optimal location in the body passageway.
- These stents also shorten longitudinally after radial expansion, which is not desirable for their intended use.
- the struts that form the hexagonal configuration cause the ribs of the hexagonal configuration to bend, buckle or twist when the struts are being expanded, thus resulting in a reduction in the longitudinal length of the stent.
- the bending, buckling or twisting of the ribs can only be avoided if the struts are made of a very flexible or bendable material; however, the use of such material compromises the strength of the stent.
- the complex stent design is both difficult to manufacture and to uniformly expand in a body passageway.
- the patent application discloses an improved stent that can be coated with one or more substances in various regions of the stent to improve the visibility of the stent by various techniques (e.g. fluoroscopy) during the insertion procedure, thereby improving the positional accuracy of the stent in the body passageway.
- the improved stent also incorporates a unique design which enables the stent to retain its original longitudinal length during expansion.
- the improved stent also is easier to manufacture and substantially uniformly expands in the body passageway.
- the improved stent overcomes the deficiencies of prior art stents with respect to accurate stent positioning, problems can still exist with respect to tissue damage by the stent during insertion and/or expansion of the stent.
- the two ends of prior art stents typically include one or more rough, sharp and/or pointed surfaces. These surfaces can cause irritation and/or damage to surrounding tissue as the stent is moved within the body passageways. Such irritation or damage to the surrounding tissue can create various types of complications during the surgical procedure. These surfaces can also cause damage to surrounding tissue during the expansion of the stent.
- the middle of the stent is first expanded by the angioplasty balloon. As the middle of the stent expands, the ends of the stent move toward one another.
- vascular narrowing is defined as a vascular segment that has not been previously treated by any interventional means and eventually closes, thereby preventing a fluid body passageway.
- Restenosis is the renarrowing of a previously treated vascular segment not involving a stent. Both of these problems are the result of a body passageway that was not treated with an invasive angioplasty, narrowing or closing, and from the insertion of a stent in one portion of the body passageway causing vascular narrowing or restenosis in another part of the body passageway.
- Vascular narrowing, restenosis and in-stent restenosis are caused by biological factors causing the premature closing of the body passageways.
- One such biological factor is platelet derived growth factor, referred to as PDGF.
- PDGF is an intercellular messenger capable of stimulating proliferation of smooth muscle cells. Smooth muscle cells are known to migrate within body passageways such as arteries and cause a restenotic reaction.
- 5,464,650 which is incorporated herein by reference, discloses the method of applying several coatings of a polymer that has been mixed with a drug so as to control the delivery of the drug in a body over a period of time.
- the method of coating the stent involves a series of steps that significantly increases the cost, complexity and time for the manufacture of the stent.
- This invention pertains to an improved expandable stent designed to meet the present day needs and demands relating to stents.
- the present invention is directed to a stent and will be particularly described with respect thereto; however, the present invention has much broader scope and can be applied in part to a wide variety of implants (e.g., prosthetic implants, heart pacers, organ implants, and/or other electronic and/or mechanical implants).
- the stent has a body member that includes first and second ends and a wall surface disposed between the first and second ends.
- the wall surface is typically formed by a plurality of intersecting elongated members, and at least some of the elongated members typically intersect with one another at a point intermediate to the first and second ends of the body member.
- the wall surface includes one or more slots.
- the body member has a first cross-sectional area which permits delivery of the body member into a body passageway, and a second, expanded cross-sectional area.
- body passageway means any passageway or cavity in a living organism, including humans, animals and plants.
- a “body passageway” in an animal or human includes, but is not limited to, the bile duct, bronchiole tubes, nasal cavity, blood vessels, heart, esophagus, trachea, stomach, fallopian tube, uterus, ureter, urethra, the intestines, lymphatic vessels, nasal passageways, eustachian tube, acoustic meatus, and/or the like.
- the invention when used in association with stents is particularly applicable for use in blood vessels, and will hereinafter be particularly described with reference thereto.
- the expansion of the stent body member can be accomplished in a variety of manners.
- the body member is expanded to its second cross-sectional area by a radially, outwardly extending force applied at least partially from the interior region of the body member.
- the body member can include heat sensitive materials that expand upon exposure to heat.
- the second cross-sectional area of the stent can be fixed or variable. When the second cross-sectional area is variable, the second cross-sectional area is typically dependent upon the amount of radially outward force applied to the body member.
- the body member is expanded so as to expand at least a portion of the body passageway while retaining the original length of the body member.
- the first cross-sectional shape of the body member is substantially uniformly circular so as to form a substantially tubular body member; however, the body member can have other cross-sectional shapes such as, but not limited to, elliptical, oval, polygonal, trapezoidal, and the like.
- the cross-sectional shape of the body member can be uniform or non-uniform in the first and/or second cross-sectional shape.
- all the body members can have substantially the same size and shape, or one or more of the body members can have a different size and/or shape from one or more other body members.
- the stent includes a plurality of elongated members wherein one or more elongated members is a wire.
- the elongated members include a plurality of wires wherein the two or more of the wires are secured to one another where a plurality of wires intersect with one another. Two or more of the wires can be connected together by a variety of techniques such as, but not limited to, welding, soldering, brazing, adhesives, lock and groove configurations, snap configurations, melting together the wires, and the like.
- the body member is at least partially in the form of a wire mesh arrangement.
- the wire mesh arrangement is utilized as the stent.
- the wire mesh arrangement is designed to be expanded to a second diameter within the body passageway.
- the second expanded diameter is variable and determined by the desired expanded internal diameter of the body passageway.
- the second expanded diameter is selected so that the expanded wire mesh arrangement will not or substantially not migrate from the desired location within the body passageway.
- the expansion of the stent does not or substantially does not cause a rupture of the body passageway.
- the plurality of wires forms a plurality of polygonal shaped regions on the body of the stent.
- the polygonal regions are aligned along the longitudinal axis of the body of the stent.
- the body of the stent includes a plurality of polygonal regions that are aligned along the longitudinal axis and lateral axis of the stent body.
- the plurality of polygonal regions aligned along the longitudinal axis of the stent body are oriented substantially the same with respect to one another, and the plurality of polygonal regions aligned along the lateral axis are oriented differently from one another.
- the polygonal regions that are aligned along the same longitudinal axis have a top that lies in the same longitudinal axis and have a bottom that lies in the same longitudinal axis, and the polygonal regions that are aligned along the same latitudinal axis have sides that do not lie in the same latitudinal axis; however, alternating polygonal regions have sides that are substantially parallel to one another.
- the side wall of at least one body member includes an even number of polygonal regions about the peripheral surface of the body member.
- the polygonal shape upon expansion, retains the original longitudinal length of the body of the stent.
- a plurality of polygonal shapes have a substantially parallelogram shape.
- the body member includes about 2-15 polygonal shapes along the longitudinal length of the body member, typically about 2-10 polygonal shapes, and more typically about 2-8 polygonal shapes; however, more polygonal shapes can be used depending on the shape and/or size of the body member.
- the stent includes a plurality of elongated members wherein one or more elongated members is a thin bar.
- the elongated members include a plurality of thin bars wherein two or more of the thin bars are secured to one another where a plurality of bars intersect with one another. Two or more of the thin bars can be connected together by a variety of techniques such as, but not limited to, welding, soldering, brazing, adhesives, lock and groove configurations, snap configurations, melting together the thin bars, and the like.
- the plurality of thin bars forms a plurality of polygonal shaped regions on the body of the stent.
- the polygonal regions are aligned along the longitudinal axis of the body of the stent.
- the body of the stent includes a plurality of polygonal regions that are aligned along the longitudinal axis and lateral axis of the stent body.
- the plurality of polygonal regions aligned along the longitudinal axis of the stent body are oriented substantially the same with respect to one another, and the plurality of polygonal regions aligned along the lateral axis are oriented differently from one another.
- the polygonal regions that are aligned along the same longitudinal axis have a top that lies in the same longitudinal axis and have a bottom that lies in the same longitudinal axis, and the polygonal regions that are aligned along the same latitudinal axis have sides that do not lie in the same latitudinal axis; however, alternating polygonal regions have sides that are substantially parallel to one another.
- the side wall of at least one body member includes an even number of polygonal regions about the peripheral surface of the body member.
- the polygonal shape upon expansion, substantially retains the original longitudinal length of the body of the stent.
- a plurality of polygonal shapes have a substantially parallelogram shape.
- the body member includes about 2-15 polygonal shapes along the longitudinal length of the body member, typically about 2-10 polygonal shapes, and more typically about 2-8 polygonal shapes; however, more polygonal shapes can be used depending on the shape and/or size of the body member.
- the side wall of at least one body member of the stent includes a plurality of elongated members that are arranged to form at least one polygonal shape.
- the polygonal shape upon expansion, retains the original longitudinal length of the body of the stent.
- a plurality of polygonal shapes have a substantially parallelogram shape.
- the body member of the stent is formed from a flat piece of material. On the surface of the flat material there are formed a plurality of polygonal shaped regions. The flat material is rolled or otherwise formed and the side edges of the flat material are connected together to form the stent.
- the side edges of the flat material can be connected together by a variety of techniques such as, but not limited to, welding, soldering, brazing, adhesives, lock and groove configurations, snap configurations, melting together the edges, and the like.
- the polygonal regions in the flat material can also be formed by a variety of techniques such as, but not limited to, mechanical cutting, laser cutting, etching, molding, stamping, and/or the like. In one non-limiting design, the polygonal regions are aligned along the longitudinal axis of the flat material. In another and/or alternative non-limiting design, the flat material includes a plurality of polygonal regions aligned along the longitudinal axis and lateral axis of the flat material.
- the plurality of polygonal regions aligned along the longitudinal axis of the flat material are oriented substantially the same with respect to one another, and the plurality of polygonal regions aligned along the lateral axis are oriented differently from one another.
- the polygonal regions that are aligned along the same longitudinal axis have a top that lies in the same longitudinal axis and have a bottom that lies in the same longitudinal axis, and the polygonal regions that are aligned along the same latitudinal axis have sides that do not lie in the same latitudinal axis; however, alternating polygonal regions have sides that are substantially parallel to one another.
- the side wall of at least one body member includes an even number of polygonal regions about the peripheral surface of the body member.
- the body member includes about 2-15 polygonal shapes along the longitudinal length of the body member, typically about 2-10 polygonal shapes, and more typically about 2-8 polygonal shapes; however, more polygonal shapes can be used depending on the shape and/or size of the body member.
- the side wall of at least one body member of the stent includes at least one set of slots.
- the one or more sets of slots are arranged to substantially maintain the original longitudinal length of the body member when the body member is expanded.
- the body member of the stent is formed from a substantially flat single piece of material. On the surface of the flat material there is formed a plurality of slots. The flat material is rolled or otherwise formed and the side edges of the flat material are connected together to form the stent.
- the side edges of the flat material can be connected together by a variety of techniques such as, but not limited to, welding, soldering, brazing, adhesives, lock and groove configurations, snap configurations, melting together the edges, and the like.
- the slots in the flat material can also be formed by a variety of techniques such as, but not limited to, mechanical cutting, laser cutting, etching, molding, stamping, and/or the like.
- at least one set of slots forms substantially a V-shape when the body member is unexpanded.
- body portion includes a plurality of V-shapes.
- a plurality of V-shapes are aligned along the longitudinal axis of the side wall of the body member and are positioned in a partial stacked position with respect to one another to form a set of V-shapes.
- the body member includes about 2-20 V-shapes in each set of V-shapes, typically about 2-10 V-shapes, and more typically about 2-5 V-shapes; however, more V-shapes per set can be used depending on the shape and/or size of the body member.
- a plurality of V-shapes are aligned along the latitudinal axis of the side wall of the body member.
- At least a plurality of the V-shapes are substantially equally spaced from one another.
- an even number of V-shapes are aligned along the latitudinal axis of the side wall of the body member.
- at least a plurality of V-shapes have substantially the same angle when the body member is unexpanded.
- the angle formed by the V-shapes is between 0-90° when the body member is unexpanded, typically about 10-75°, and more typically about 15-60°, and even more typically about 15-45°.
- a plurality of slots have a length dimension that is at least about twice as great as the width dimension of the slot when the body member is unexpanded, and typically at least about 3 times as great, and more typically at least about 5 times as great, and even more typically at least about 10 times as great, and still even more typically at least about 15 times as great.
- a plurality of V-shapes in a set of V-shapes are oriented in the same direction with respect to one another and oriented such that the base of one V-shape is positioned from the base of an adjacent V-shape a distance that is at least about 15% of the length of the legs of the V-shaped slot, typically about 15-80% of the length of the slots forming a leg of the V-shape, typically about 20-60% of the length of the leg of the V-shape, and even more typically about 30-50% of the length of the leg of the V-shape.
- a plurality of slots have a substantially oval shape.
- at least a plurality of slots that form the V-shape do not intersect with one another. In one particular design, none of the slots that form the V-shape intersect with one another.
- the body member has a biocompatible coating that is coated and/or impregnated on at least a portion of its wall surface.
- the biocompatible coating can be used to reduce inflammation, infection, irritation and/or rejection of the stent.
- the biocompatible coating includes, but is not limited to, a metal coating.
- the metal coating is plated on at least a portion of the stent.
- the metal coating includes, but is not limited to, gold, platinum, titanium, nickel, tin, or combinations thereof.
- the biocompatible coating includes, but is not limited to, a polymer and/or a copolymer coating.
- the polymer and/or a copolymer coating includes, but is not limited to, polytetrafluoroethylene, polyethylene, poly(hydroxyethly methacrylate), poly(vinyl alcohol), polycaprolactone, poly(D, L-lactic acid), poly(L-lactic acid), poly(lactide-co-glycolide), poly(hydroxybutyrate), poly(hydroxybutyrate-co-valerate), polydioxanone, polyorthoester, polyanhydride, poly(glycolic acid), poly(glycolic acid-cotrimethylene cabonate), polyphosphoester, polyphosphoester urethane, poly(amino acids), cyanoacrylates, poly(trimethylene carbonate), poly(iminocarbonate), copoly(ether-esters), polyalkylene oxal
- the polymer and/or copolymer is substantially non-biodegradable so as to substantially maintain its fluction throughout most or all of the useful life of the stent.
- one or more polymers are at least partially coated onto the surface of the stent by a process disclosed in U.S. Pat. Nos. 5,355,832 and 5,447,799, which are incorporated herein by reference.
- the biocompatible coating includes, but is not limited to, living cells.
- the coating layer has a thickness in a range from about 50 to 500,000 Angstroms ( ⁇ ), and typically in the range from about 100,000 to 500,000 ⁇ .
- Still yet another and/or alternative feature of the present invention is that the stent, upon expansion, substantially maintains its original longitudinal length. In one embodiment of the present invention, the stent, upon expansion, substantially maintains its original longitudinal length throughout the expansion of the stent.
- the stent includes at least two body members that are connected together by at least one connector member that allows transverse bending and flexibility invariant to the plane of bending.
- the connector member includes a non-linear portion.
- the connector member is at least partially V-shaped member (e.g., V-shaped, N-shaped, and/or M-shaped, W-shaped, X-shaped, Y-shaped, Z-shaped, etc.) and/or U-shaped (e.g., U-shaped, S-shaped, etc.) member.
- the two body members are connected together by a plurality of connectors.
- two or more of the connectors are spaced at substantially equal distances from one another. In another and/or alternative aspect of this embodiment, two or more of the connectors are substantially symmetrically oriented from one another. In still another and/or alternative aspect of this embodiment, at least three connectors connect together two body members, and typically about 3-20 connectors connect together two body members, and even more typically about 3-10 connectors connect together two body members. In still another and/or alternative embodiment of the present invention, the size of the connector is limited so as not to interfere with the proper expansion of the stent.
- the substantially V-shaped or U-shaped member has a height that is less than about five times the maximum height of a polygonal shape in the unexpanded stent, and typically less than about three times the maximum height of a polygonal shape in the unexpanded stent, and more typically less than about two times the maximum height of a polygonal shape in the unexpanded stent, and even more typically less than about 1.75 times the maximum height of a polygonal shape in the unexpanded stent, and yet even more typically less than about 1.5 times the maximum height of a polygonal shape in the unexpanded stent, and still yet even more typically less than about 1.3 times the maximum height of a polygonal shape in the unexpanded stent.
- the substantially V-shaped or U-shaped member has a height that is less than about 1.5 times the maximum width of the V-shape in the unexpanded stent, and typically less than about 1.0 times the maximum width of the V-shape in the unexpanded stent, and more typically less than about 0.75 times the maximum width of the V-shape in the unexpanded stent, and even more typically less than about 0.65 times the maximum width of the V-shape in the unexpanded stent, and yet typically less than about 0.5 times the maximum width of the V-shape in the unexpanded stent, and still yet more typically less than about 0.4 times the maximum width of the V-shape in the unexpanded stent.
- the body member is made of and/or includes a material that is visible under fluoroscopy in vivo.
- the material to increase visibility includes, but is not limited to, metals, polymers and/or copolymers.
- the material to increase visibility is adhered to the surface of at least a portion of the stent by coating, plating, mounting, welding and/or braising.
- the material to increase visibility is secured to the stent so as to principally come in contact with the inner luminal surface of the body passageway.
- the material to increase visibility primarily contacts the inner luminal surface of the blood vessel and not any blood-borne components that could accelerate stent failure rates.
- the material to increase visibility is at least partially located on at least one end, and typically both ends, of at least one body member. This positioning of the material on the body member helps to identify the location of the ends of the body member and the stent as a whole, thus enhancing the critical placement of the stent so as to reduce the failure rate.
- the material to increase visibility is at least partially located on the outer surface of the body member at one or more connector members of the stent.
- the material to increase visibility includes gold, gold alloy, and/or tantalum, etc.
- the gold and/or gold alloy is plated on at least a portion of the stent.
- Still another and/or alternative feature of the present invention is that the stent material is treated with gamma, beta and/or e-beam radiation to reduce the vascular narrowing of the stented section.
- the radiation treatment can inactivate the cell migration and properties thereof within a 3 mm depth of the arterial wall.
- the radiation treatment can further and/or alternatively sterilize the stent to reduce infection when the stent is inserted into a body passageway.
- the stent can be inserted and expanded by standard procedures.
- the stent is designed so it can be inserted into a body passageway until it is disposed at the desired location within the body passageway.
- the stent can then be radially expanded outwardly into contact with the body passageway until the body passageway, at the desired location, has been expanded, whereby the stent inhibits or prevents the body passageway from collapsing.
- the stent is at least partially expanded by an angioplasty balloon.
- Still another and/or alternative feature of the present invention is a stent that includes rounded, smooth and/or blunt surfaces that minimize and/or prevent damage to body passageways as the stent is inserted into a body passageway and/or expanded in a body passageway.
- the modified end surfaces are designed to reduce the cutting and/or piercing of tissue as the stent is positioned in and/or expanded in a body passageway.
- the path from the point of entry into a body passageway, and the final position of the stent in the body passageway are not straight. As a result, the stent is caused to be weaved through the body passageway to reach the final position in the body passageway.
- This weaving of the stent can result in the front ends, back ends, and/or side walls of the stent to cut, scrape or otherwise damage tissue in the body passageway as the stent is moved in the body passageway.
- the rounding, smoothing and/or blunting of the surfaces significantly reduces possible damage to the tissue. Damage to the tissue in the body passageway can also occur during the expansion of the stent.
- the rounding, smoothing and/or blunting of the surfaces likewise significantly reduces possible damage to the tissue during the expansion of the stent.
- the rounding, smoothing and/or blunting of the surfaces can be accomplished by a number of different procedures. Some of these procedures include, but are not limited to, buffing, grinding, and/or sanding the surfaces.
- the surfaces of the stent are smoothed by coating and/or impregnating the stent with one or more metals or compounds.
- at least a portion of the stent is coated and/or impregnated with a polymer and/or copolymer so as to reduce or eliminate the sharp, rough, and/or pointed surfaces on the stent.
- a further and/or alternative feature of the present invention is that the stent is at least partially coated and/or impregnated with one or more vascular active agents that inhibit and/or reduce restenosis, vascular narrowing and/or in-stent restenosis.
- at least one of the vascular active agents affects and/or alters tissue contraction and/or expansion to inhibit and/or reduce restenosis, vascular narrowing and/or in-stent restenosis.
- Prior substances have been coated onto stents to address one or more problems associated with the use of stents. These substances include aspirin, heparin, colchicine and dexamethazone, among others.
- vascular active agent is defined as a substance other than aspirin, colchicine, dexamethazone, or heparin.
- the vascular active agent is formulated to inhibit, reduce, and/or prevent restenosis, vascular narrowing and/or in-stent restenosis in a body passageway.
- the vascular active agent can be used independent of or in combination with a “secondary vascular active agent.”
- the secondary vascular active agent includes, but is not limited to, an agent that inhibits, reduces, and/or prevents thrombosis.
- agent can include, but is not limited to, antithrombotic compounds, anti-platelet compounds, and/or anti-coagulant compounds.
- the “secondary vascular active agent” can include compounds that include, but are not limited to, metabolic inhibitors, antineoplastics, proliferation inhibitors, cytotoxic compounds, antiplatelets, anti-coagulants, fribrinolytics, thrombin inhibitors, antimitotics, anti-inflammatory compounds, radioactive isotopes, and/or anti-tumor compounds.
- the “secondary vascular active agent” can include, but is not limited to, DNA, plasmid DNA, RNA, plasmid RNA, ACE inhibitors, growth factors, cholesterol-lowering agents, vasodilating agents, oligonucleotides, and/or anti-sense oligonucleotides.
- Specific secondary vascular active agents that can be used include, but are not limited to, aspirin, colchicine, heparin, glucocorticoids (e.g. dexamethazone, betamethazone), hirudin, tocopherol, angiopeptin, D-Phe-ProArg chloromethyl ketone, and/or derivatives of these compounds.
- glucocorticoids e.g. dexamethazone, betamethazone
- hirudin tocopherol
- angiopeptin e.g. angiopeptin
- D-Phe-ProArg chloromethyl ketone e.g. D-Phe-ProArg chloromethyl ketone
- the prior use of a single secondary vascular active agent has not resolved problems associated with in-stent restenosis, vascular narrowing and/or restenosis, the combination of two or more of these compounds coated and/or impregnated on the stent can provide better results.
- the scope of this invention encompasses the concept of at least partially coating and/or impregnating the stent with two or more secondary vascular active agents by themselves or in combination with one or more vascular active agents.
- the vascular active agent includes a compound that at least partially inhibits PDGF activity in the body passageway. After a stent is inserted into a body passageway, the stent may induce some irritation in the body passageway.
- the biological factor, PDGF is turned on due to such irritation and activates the components of clotting. These components can cause clotting in the stent area or in adjacent areas. This clotting can cause the body passageway to narrow or ultimately close. At least one or more substances coated and/or impregnated onto the stent are formulated to deactivate and/or inhibit the activity of the PDGF, thereby reducing the occurrence of in-stent restenosis, vascular narrowing and/or restenosis.
- At least one of the vascular active agents that is at least partially coated and/or impregnated onto the stent to inhibit PDGF activity in the body passageway includes triazolopyrimidime (Trapidil), prostacyclin, and/or derivatives thereof.
- triazolopyrimidime Trapidil
- prostacyclin and/or derivatives thereof.
- platelets are a source of PDGF
- endothelial cells, macrophages and smooth muscle cells are also a source of PDGF following vascular trauma.
- the influence of Trapidil on platelet aggregation is linked to inhibition of the synthesis of thromboxane A2 and the partial blocking of thromboxane A2 receptors. Trapidil is able to normalize an incorrect balance between thromboxane A2 and prostacycline.
- Thromboxane A2 is a powerful inducer of platelet aggregation. Thromboxane A2 is also responsible for the contraction of smooth muscles or vessels and stimulates the proliferation of the arterial intimal cells.
- Prostacyclin also inhibits platelet aggregation and has vasodilator properties.
- Trapidil also has antithrombotic properties and can significantly reduce thrombosis induced by creation of an arteriovenous conduit, as compared to aspirin and dipyridamoles, which only had a modest effect.
- Trapidil has other desirable properties such as vasodilation, a decrease in angina and an increase in HDL levels in patients with ischemic heart disease.
- Trapidil also effectively inhibits restenosis.
- Trapidil has an affinity to exert clinical effects starting in the second hour of treatment. The platelet inhibition in the first day of treatment with Trapidil continues through the thirtieth day.
- Trapidil can be used in combination with one or more other vascular active agents and/or in combination with one or more secondary vascular active agents.
- the amount of Trapidil coated and/or impregnated into the stent can be varied depending on the intended use of the stent and/or size of the stent.
- the stent includes up to about 200 mg of Trapidil. In one aspect of this embodiment, the stent includes at least about 1 ⁇ g of Trapidil. In another and/or alternative aspect of this embodiment, the stent includes about 10 ⁇ g to about 50 mg of Trapidil. In still another and/or alternative aspect of this embodiment, the stent includes about 20 ⁇ g to about 10 mg of Trapidil.
- the stent is at least partially coated and/or impregnated with one or more vascular active agents that promote blood vessel growth.
- the fully or partially blocked blood vessel and tissue about the fully or partially blocked blood vessel become oxygen starved due to the impaired flow of blood through the fully or partially blocked blood vessels.
- the region around the formerly fully or partially blocked blood vessel once again begins to receive a proper oxygen supply.
- prolonged oxygen starvation can damage the blood vessels and surrounding tissue to an extent that a substantial time period is required to naturally repair such damaged tissue.
- GM-CSF granulo-cyte-macrophage colony-stimulating-factor
- the stent includes up to about 200 mg of GM-CSF. In one aspect of this embodiment, the stent includes at least about 1 ⁇ g of GM-CSF. In another and/or alternative aspect of this embodiment, the stent includes about 10 ⁇ g to about 50 mg of GM-CSF. In still another and/or alternative aspect of this embodiment, the stent includes about 20 ⁇ g to about 10 mg of GM-CSF.
- Yet another and/or alternative feature of this invention corresponds to the local delivery of one or more vascular active agents to inhibit and/or prevent restenosis, vascular narrowing and/or in-stent restenosis including, but not limited to, Trapidil, and/or GM-CSF, through an angioplasty balloon with the physical capability to transfer solute of the vascular active agent through the angioplasty balloon membrane to the affected sight.
- a vascular active agent such as, but not limited to, Trapidil and/or GM-CSF, can be delivered alone and/or in combination with another vascular active agent and/or a secondary vascular active agent. This delivery can be in the form of a stream, a slow oozing delivery or a bolus injection.
- the delivery can be made through magnetic, electrical or physical arrangements.
- the delivery of a vascular active agent and/or secondary vascular active agent is accomplished through a separate passageway capable of channeling the solute of the vascular active agent and/or secondary vascular agent to the affected area.
- This delivery through an angioplasty balloon also delivers the vascular active agent and/or secondary vascular active agent to the sight of restenosis, vascular narrowing, in-stent restenosis, thrombosis and the like, and/or to the site to promote growth of blood vessels.
- the angioplasty balloon includes one or more slits or openings wherein the vascular active agent and/or secondary vascular active agent can stream, ooze or otherwise flow out of the angioplasty balloon and into the body passageway.
- the one or more slits and/or openings can be designed so as to allow the vascular active agent and/or secondary vascular active agent to exit the angioplasty balloon when the angioplasty balloon is in an expanded and unexpanded state.
- the one or more slits and/or openings in the angioplasty balloon inhibit or prevent the vascular active agent and/or secondary vascular active agent from entering the body passageway when the angioplasty balloon is in the unexpanded state.
- vascular active agents and/or secondary vascular active agents are at least partially coated and/or impregnated totally on or partially on the stent.
- the thickness of the coating on the stent can be uniform or varied. Generally, the thickness of the coating is not as important as the concentration of the vascular active agent and/or secondary vascular active agent needed to acquire the desired affect. High concentrations of vascular active agents and/or secondary vascular active agents can be coated with thinner coatings, and lower concentrations of vascular active agents and/or secondary vascular active agents can be coated with thicker coatings. In one aspect of this embodiment, the coating thickness is less than or equal to the material that forms the stent.
- the stent includes a single coating on specific regions of the stent or on the total surface of the stent. In one aspect of this embodiment, the composition of the coating on different regions of the stent is substantially the same. In another and/or alternative aspect of this embodiment, the composition of the coating on different regions of the stent is different. In still another and/or alternative embodiment of the present invention, the stent includes a multiple coatings on specific regions of the stent or on the total surface of the stent. In one aspect of this embodiment, the coating thicknesses are of the multiple coatings are substantially the same. In another and/or alternative aspect of this embodiment, the coating thickness of the two or more coatings is different.
- the composition of the coatings is substantially the same. In yet another and/or alternative aspect of this embodiment, the composition of two or more coatings is different. In yet another and/or alternative embodiment of the present invention, one or more coatings are applied to the stent by vaporization, plasma deposition, ionization, dipping, brushing, and/or spraying. In still yet another and/or alternative embodiment of the invention, the vascular active agent and/or secondary vascular active agent is at least partially impregnated into the stent. The impregnation can be the result of a porous surface of the stent and/or the stent including one or more internal cavities.
- the stent is impregnated on specific regions of the stent or on the total surface of the stent. In another and/or alternative aspect of this embodiment, the stent is impregnated with the same compound. In still another and/or alternative aspect of this embodiment, the stent is impregnated with different compounds at different regions of the stent. In yet another and/or alternative aspect of this embodiment, the stent is impregnated with multiple compounds. In a further and/or alternative embodiment of the present invention, one or more compounds are impregnated in the stent by vaporization, ionization, dipping, brushing, and/or spraying.
- Still another and/or alternative feature of the present invention is that one or more vascular active agents and/or secondary vascular active agents are at least partially coated and/or impregnated onto the stent by the use of an intermediate compound.
- the intermediate compound is a synthetic biocompatible material that does not adversely affect the vascular active agent and/or secondary vascular active agent or cause problems or adverse reactions in the body passageway.
- the intermediate compound is biodegradable.
- the intermediate compound is non-biodegradable.
- the intermediate compound is at least partially coated and/or impregnated on specific regions of the stent or totally coats the stent.
- the thickness of the coating on the stent can be uniform or varied.
- the coating thickness can be used to control the amount of vascular active agent and/or secondary vascular active agent that is coated on the stent and/or to control the release rate of the vascular active agent from the stent.
- Thicker coating can hold more vascular active agent and/or secondary vascular active agent.
- Thicker coating can also increase the time of full release of the vascular active agent and/or secondary vascular active agent from the stent.
- the coating thickness is less than or equal to the material that forms the stent.
- the stent includes a single coating of intermediate compound on specific regions of the stent or on the total surface of the stent.
- the composition of the intermediate compound on different regions of the stent is substantially the same. In another and/or alternative aspect of this embodiment, the composition of the intermediate compound on different regions of the stent is different. In still another and/or alternative embodiment of the present invention, the stent includes a multiple coatings of intermediate compound on specific regions of the stent or on the total surface of the stent. In one aspect of this embodiment, the coating thicknesses of the intermediate compound are substantially the same. In another and/or alternative aspect of this embodiment, the coating thickness of two or more coatings of intermediate compound is different. In still another and/or alternative aspect of this embodiment, the composition of the coatings of intermediate compound is substantially the same.
- the composition of two or more coatings of intermediate compound are different.
- one or more coatings of intermediate compound are applied to the stent by vaporization, ionization, dipping, brushing, and/or spraying.
- the intermediate compound is at least partially impregnated into the stent. The impregnation can be the result of a porous surface of the stent and/or the stent including one or more internal cavities.
- the stent is impregnated with the intermediate compound on specific regions of the stent or on the total surface of the stent.
- the stent is impregnated with the same intermediate compound. In still another and/or alternative aspect of this embodiment, the stent is impregnated with different intermediate compounds at different regions of the stent. In yet another and/or alternative aspect of this embodiment, the stent is impregnated with multiple intermediate compounds. In a further and/or alternative embodiment of the present invention, one or more intermediate compounds are impregnated in the stent by vaporization, ionization, dipping, brushing, and/or spraying.
- the one or more vascular active agents and/or secondary vascular active agents are coated and/or impregnated onto the stent prior to coating and/or impregnating the stent with one or more intermediate compounds.
- the one or more intermediate compounds are coated and/or impregnated onto the stent prior to coating and/or impregnating the stent with one or more vascular active agents and/or secondary vascular active agents.
- the stent is at least partially coated and/or impregnated with, and/or at least partially includes one or more biological agents.
- the biological agent can be directly coated and/or impregnated on to the stent, and/or coated with the assistance of one or more intermediate compounds.
- the thickness of the coating of the biological agent on the stent can be uniform or varied. Generally, the thickness of the coating is not as important as the concentration of the vascular active agent and/or secondary vascular active agent needed to acquire the desired affect. High concentrations of biological agent can be coated with thinner coatings, and lower concentrations of biological agent can be coated with thicker coatings.
- the coating thickness is less than or equal to the material that forms the stent.
- the stent includes a single coating on specific regions of the stent or on the total surface of the stent.
- the composition of the coating on different regions of the stent is substantially the same.
- the composition of the coating on different regions of the stent is different.
- the stent includes multiple coatings on specific regions of the stent or on the total surface of the stent. In one aspect of this embodiment, the coating thicknesses of the multiple coatings are substantially the same.
- the coating thickness of the two or more coatings is different.
- the composition of the coatings is substantially the same.
- the composition of two or more coatings is different.
- one or more coatings of biological agent are applied to the stent by vaporization, ionization, dipping, brushing, and/or spraying.
- the biological agent is at least partially impregnated into the stent. The impregnation can be the result of a porous surface of the stent and/or the stent including one or more internal cavities.
- the stent is impregnated on specific regions of the stent or on the total surface of the stent. In another and/or alternative aspect of this embodiment, the stent is impregnated with the same compound. In still another and/or alternative aspect of this embodiment, the stent is impregnated with different compounds at different regions of the stent. In yet another and/or alternative aspect of this embodiment, the stent is impregnated with multiple compounds. In a further and/or alternative embodiment of the present invention, one or more compounds are impregnated in the stent by vaporization, ionization, dipping, brushing, and/or spraying.
- biological agent is defined as any substance, drug or otherwise, that is formulated or designed to prevent, inhibit and/or treat one or more biological problems, such as, but not limited to, viral, fungus and/or bacteria infection; vascular disorders; digestive disorders; reproductive disorders; lymphatic disorders; cancer; implant rejection; pain; nausea; swelling; arthritis; bone disease; organ failure; immunity diseases; cholesterol problems; blood diseases; lung diseases and/or disorders; heart diseases and/or disorders; brain diseases and/or disorders; neuroglial diseases and/or disorders; kidney diseases and/or disorders; ulcers; liver diseases and/or disorders; intestinal diseases and/or disorders; gallbladder diseases and/or disorders; pancreatic diseases and/or disorders; psychological disorders; respiratory disorders; gland disorders; skin diseases; hearing disorders; oral disorders; nasal disorders; eye disorders; fatigue; genetic disorders; bums; scars; trauma; weight disorders; addiction disorders; hair loss; cramps; muscle spasms; tissue repair; and/or the like.
- biological agent includes vascular active
- the biological agent is at least partially coated and/or impregnated onto the stent by the use of an intermediate compound.
- the intermediate compound is a synthetic biocompatible material that does not adversely affect the biological agent or cause problems or adverse reactions in the body passageway.
- the intermediate compound is biodegradable.
- the intermediate compound is non-biodegradable.
- the intermediate compound is at least partially coated and/or impregnated on specific regions of the stent or totally coats the stent.
- the thickness of the coating on the stent can be uniform or varied.
- the coating thickness can be used to control the amount of biological agent that is coated on the stent and/or to control the release rate of the biological agent from the stent. Thicker coating can hold more biological agent. Thicker coating can also increase the time of full release of the biological agent from the stent. In one particular non-limiting design, the coating thickness is less than or equal to the material that forms the stent.
- the stent includes a single coating of intermediate compound on specific regions of the stent or on the total surface of the stent. In one aspect of this embodiment, the composition of the intermediate compound on different regions of the stent is substantially the same. In another and/or alternative aspect of this embodiment, the composition of the intermediate compound on different regions of the stent is different.
- the stent includes a multiple coatings of intermediate compound on specific regions of the stent or on the total surface of the stent.
- the coating thicknesses of the intermediate compound are substantially the same.
- the coating thickness of two or more coatings of intermediate compound is different.
- the composition of the coatings of intermediate compound is substantially the same.
- the composition of two or more coatings of intermediate compound are different.
- one or more coatings of intermediate compound are applied to the stent by vaporization, ionization, dipping, brushing, and/or spraying.
- the intermediate compound is at least partially impregnated into the stent.
- the impregnation can be the result of a porous surface of the stent and/or the stent including one or more internal cavities.
- the stent is impregnated with the intermediate compound on specific regions of the stent or on the total surface of the stent.
- the stent is impregnated with the same intermediate compound.
- the stent is impregnated with different intermediate compounds at different regions of the stent.
- the stent is impregnated with multiple intermediate compounds.
- one or more intermediate compounds are impregnated in the stent by vaporization, ionization, dipping, brushing, and/or spraying.
- the one or more biological agents are coated and/or impregnated onto the stent prior to coating and/or impregnating the stent with one or more intermediate compounds.
- the one or more intermediate compounds are coated and/or impregnated onto the stent prior to coating and/or impregnating the stent with one or more biological agents.
- a further another and/or alternative feature of the present invention is that the biological agent is at least partially encapsulated by a material.
- the biological agent includes one or more vascular active agents and/or one or more secondary vascular active agents to inhibit and/or reduce restenosis, vascular narrowing and/or in-stent restenosis.
- the biological agent is at least partially encapsulated in biodegradable polymer and/or copolymer.
- the polymer and/or copolymer is at least partially formulated from aliphatic polyester compounds such as, but not limited to, PLA (i.e.
- the rate of degradation of the polymer and/or copolymer is principally a function of 1) the water permeability and solubility of the polymer and/or copolymer, 2) chemical composition of the polymer and/or copolymer, 3) mechanism of hydrolysis of the polymer and/or copolymer, 4) the biological agent encapsulated in the polymer and/or copolymer, 5) the size, shape and surface volume of the polymer and/or copolymer, 6) porosity of the polymer and/or copolymer, and/or 7) the molecular weight of the polymer and/or copolymer.
- the rate of degradation of the polymer and/or copolymer controls the amount of biological agent released during a specific time period into the body passageway or other parts of the body.
- the biological agent can be formed into a pill, capsule or the like for oral ingestion by a human or animal.
- the rate of degradation of the polymer and/or copolymer that is at least partially encapsulating the biological agent controls the amount of biological agent that is released into a body passageway or other part of the body over time.
- the biological agent can be at least partially encapsulated with different polymer and/or copolymer coating thickness, different numbers of coating layers, and/or with different polymers or copolymers to alter the time period one at least partially encapsulated biological agent is released in a body passageway or other part of the body over time as compared to another at least partially encapsulated biological agent.
- one or more at least partially encapsulated biological agents can be at least partially encapsulated in a biodegradable capsule and/or coating, which biodegradable capsule and/or coating delays the exposure of one or more of the at least partially encapsulated biological agents to fluids in a body passageway or other part of the body.
- the at least partially encapsulated biological agent can be introduced into a human or animal by means other than by oral introduction, such as, but not limited to, injection, topical applications, intravenously, eye drops, nasal spray, surgical insertion, suppositories, intrarticularly, intraocularly, intranasally, intradermally, sublingually, intravesically, intrathecally, intraperitoneally, intracranially, intramuscularly, subcutaneously, directly at a particular site, and the like.
- the polymer and/or copolymer is formed into one or more shapes such as, but not limited to, spherical, cubical, cylindrical, pyramidal, and the like.
- the stent is at least partially coated and/or impregnated with one or more polymers or copolymers that include one or more biological agents.
- the coating thickness of each intermediate compound on the stent is less than about 0.08 inch, and typically less than about 0.01 inch, and even more typically less than about 0.005 inch.
- the particular coating sequence on a stent will generally depend on 1) the amount of a particular biological agent to be released over time, 2) the sequence of biological agents to be released over time, 3) the time period the release of the biological agent is to begin, 4) the time period the release of the biological agent is to end, and/or 5) the location in the body the biological agent is to be released. As can be appreciated, other factors may dictate the particular coating sequence on a stent.
- the intermediate compound is formulated to delay and/or regulate the time and/or amount of one or more biological agents being released into the body passageway, and/or to facilitate in the bonding of one or more biological agents to the stent.
- the intermediate compound can be formulated so as to form one or more bonds with one or more biological agents or be chemically inert with respect to one or more biological agents.
- the stent is at least partially formed by a material that includes one or more biological agents.
- one or more biological agents are at least partially embedded in the stent so as to inhibit the release, control the release, and/or delay the release of one or more biological agents into the body passageway.
- the material forming at least a portion of the stent in which one or more biological agents are imbedded can be a biodegradable material and/or a non-biodegradable material.
- the material can be formulated so as to form one or more bonds with one or more biological agents or be chemically inert with respect to one or more biological agents.
- the material is a substantially non-biodegradable material so that the structural integrity of the stent or other implant is maintained throughout the life of the stent or other implant.
- the material includes a metal and/or polymer and/or copolymer.
- one or more biological agents at least partially forms a chemical bond with an intermediate compound that at least partially encapsulates one or more of the biological agents; that at least partially coats and/or impregnates the stent or other implant; and/or that at least partially forms the stent or other implant.
- one or more of the biological agents forms a polymer and/or copolymer salt complex with one or more intermediate compounds that at least partially encapsulates one or more of the biological agents; that at least partially coats and/or impregnates the stent or other implant; and/or that at least partially forms the stent or other implant.
- the biological agent includes, but is not limited to, Trapidil and/or derivatives thereof; GM-CSF and/or derivatives thereof; taxol and/or derivatives thereof (e.g. taxotere, baccatin, 10- deacetyltaxol, 7-xylosyl-10-deacetyltaxol, cephalomannine, 10-deacetyl-7-epitaxol, 7 epitaxol, 10-deacetylbaccatin III, 10-deacetylcephaolmannine); 5-Fluorouracil and/or derivatives thereof; Beta-Estradiol and/or derivatives thereof; Tranilast and/or derivatives thereof; Probucol and/or derivatives thereof; Angiopeptin and/or derivatives thereof; paclitaxel and/or derivatives thereof; cytochalasin and/or derivatives thereof (e.g.
- cytochalasin A cytochalasin B, cytochalasin C, cytochalasin D, cytochalasin E, cytochalasin F, cytochalasin G, cytochalasin H, cytochalasin J, cytochalasin K, cytochalasin L, cytochalasin M, cytochalasin N, cytochalasin O, cytochalasin P, cytochalasin Q, cytochalasin R, cytochalasin S, chaetoglobosin A, chaetoglobosin B, chaetoglobosin C, chaetoglobosin D, chaetoglobosin E, chaetoglobosin F, chaetoglobosin G, chaetoglobosin J, chaetoglobosin K, deoxaphomin, proxiphomin, protophomin, zygospor
- dexamethasone, betamethasone)and/or derivatives thereof hirudin and/or derivatives thereof; coumadin and/or derivatives thereof; prostacyclenes and/or derivatives thereof; antithrombogenic agents; steroids; seramin and/or derivatives thereof; thioprotese inhibitors; nitric oxide; ibuprofen; antimicrobials; antibiotics; tissue plasma activators; rifamycin and/or derivatives thereof; monoclonal antibodies; antifibrosis compounds; cyclosporine; hyaluronate; protamine and/or derivatives thereof; tocopherol and/or derivatives thereof; angiopeptin and/or derivatives thereof; tick anticoagulant protein and/or derivatives thereof; methotrexate and/or derivatives thereof; azathioprine and/or derivatives thereof; vincristine and/or derivatives thereof; vinblastine and/or derivatives thereof; fluorouracil and/or derivatives thereof; adriamycin and/or
- VEGF vascular endothelial growth factor
- TGF TGF
- IGF IGF
- PDGF vascular endothelial growth factor
- FGF FGF
- Protamine Sulphate Clupeine
- Sulphated Chitin Derivatives Sulphated Polysaccharide Peptidoglycan Complex
- Staurosporine proline analogs (L-azetidine-2-carboxylic acid (LACA); cishydroxyproine; d,L-3,4-dehydroproline; Thiaproline; alpha-dipyridyl; beta aminopropionitrile fumarate; 4-propyl-5-(4-pyridinyl)-2(3H)-oxazolone; Methotrexate Mitoxantrone; Interferons; alpha 2 Macroglobulin; ChIMP-3; Chymostatin; beta-Cyclodextrin Tetradecasulfate; Eponemycin; Camptothecin; Fumagillin; Gold
- cefadroxil, cefazolin, cefaclor aminoglycosides (e.g. gentamycin, tobramycin; sulfonamides (e.g. sulfamethoxazole); rapamycin, metronidazole; prednisone; prednisolone;hydrocortisone; adrenocorticotropic hormone; sulfasalazine; naproxen; fenoprofen; indomethacin; phenylbutazone; acyclovir; ganciclovir; zidovudine; nystatin; ketoconazole; griseofulvin; flucytosine; miconazole; clotrimazole; pentamidine isethionate; quinine; chloroquine; mefloquine; thyroid hormone; estrogen; progesterone; cortisone; growth hormone; insulin; T.sub.H 1 (e.g., Interle
- Interleukins-4 and -10) cytokines include estramustine; epothilone; curacin-A; colchicine; methotrexate; vinblastine; 4-tert-butyl->3-(2-chloroethyl)ureido!benzene (“tBCEU”); alpha-adrenergic blocking agents; angiotensin II receptor antagonists; receptor antagonists for histamine; serotonin; serotonin blockers; endothelin; inhibitors of the sodium/hydrogen antiporter (e.g., amiloride and derivatives thereof); agents that modulate intracellular Ca.sup.2+ transport such as L-type (e.g., diltiazem, nifedipine, verapamil) or T-type Ca.sup.2+ channel blockers (e.g.
- L-type e.g., diltiazem, nifedipine, verapamil
- amiloride calmodulin antagonists
- calmodulin antagonists e.g., H.sub.7
- inhibitors of the sodium/calcium antiporter e.g. amiloride
- ap-1 inhibitors for tyrosine kinases, protein kinase C, myosin light chain kinase, Ca.sup.2+/calmodulin kinase II, casein kinase II
- anti-depressants e.g. amytriptyline, fluoxetine, LUVOX.RTM.
- cytokine and/or growth factors as well as their respective receptors, (e.g., the interleukins, alpha, beta or gamma-IFN (interferons), GM-CSF, G-CSF, epidermal growth factor, transforming growth factors alpha and beta, TNF, and antagonists of vascular epithelial growth factor, endothelial growth factor, acidic or basic fibroblast growth factors, and platelet derived growth factor); inhibitors of the IP 3 receptor; protease; collagenase inhibitors; nitrovasodilators (e.g. isosorbide dinitrate); anti-mitotic agents (e.g.
- lighter d group transition metals lighter d group transition metals
- anti-neoplastic compounds e.g. 5-fluorouracil, vincristine, vinblastine, cisplatin, doxyrubicin, adriamycin, or tamocifen
- radioactive agents e.g.
- ricin abrin, diphtheria toxin, cholera toxin, gelonin, pokeweed antiviral protein, tritin, Shigella toxin, and Pseudomonas exotoxin A); metalloproteinase inhibitors; ACE inhibitors; growth factors; oligonucleotides; antiplatlet compounds; antitabolite compounds; anti-inflammatory compounds; anticoagulent compounds; antimitotic compounds; antioxidants; antimetabolite compounds (e.g staurosporin, trichothecenes, and modified diphtheria and ricin toxins, Pseudomonas exotoxin); anti-migratory agents (e.g.
- the biological agent can include other compounds.
- the Trapidil forms a salt complex with the intermediate compound such that the Trapidil forms the cationic component and the coating compound forms the anionic component.
- the intermediate compound used to at least partially encapsulate one or more biological agents; at least partially coat and/or impregnate the stent or other implant; and/or at least partially form the stent or other implant is a polymer and/or copolymer.
- the polymer and/or copolymer includes one or more carboxylate groups, phosphate groups, sulfate groups, and/or other organic anion groups.
- the polymer and/or copolymer includes one or more groups which form one or more anionic bonding sites for cationic salts of the biological agent.
- the polymer and/or copolymer includes one or more groups that form one or more cationic bonding sites for anionic salts of the biological agent.
- the polymer and/or copolymer includes one or more amine groups and the like.
- the polymer and/or copolymer includes one or more hydrophobic and/or hydrophilic groups.
- the polymer and/or copolymer can include only hydrophobic groups, only hydrophilic groups, or include a combination hydrophobic groups and hydrophilic groups.
- the hydrophobic and/or hydrophilic groups in the polymer and/or copolymer can be the same or different.
- Non-limiting examples of hydrophilic groups include carboxylate groups (e.g. acrylate groups, methacrylate groups), alcohol groups, sulfate groups, and the like. Specific non-limiting examples include acrylic acid groups, methacrylic acid groups, and/or maleic acid groups.
- Non-limiting examples of hydrophobic groups include ethylene groups, vinyl groups, styrene groups, propylene groups, urethane groups, ester groups, and/or alkyl groups. Specific non-limiting examples include ethylene groups, propylene groups, acrylonitrile groups, and/or methyl methacrylate groups.
- x is the number of hydrophobic monomer units
- y is the number of hydrophilic monomer units
- n is the total number of all monomer units in the polymer and/or copolymer chain.
- the x and y values can stay constant or vary throughout the polymer and/or copolymer chain.
- the type of hydrophobic monomer or hydrophilic monomer can stay constant or vary throughout the polymer and/or copolymer chain.
- Biological agents that form anionic or cationic salts generally bond with the hydrophilic groups in the polymer and/or copolymer chain.
- the more hydrophilic groups in the polymer and/or copolymer chain the higher the concentration of biological agents that can bond with the polymer and/or copolymer chain.
- one or more biological agents may bond with hydrophobic groups. Therefore, the more hydrophobic groups in the polymer and/or copolymer chain, the higher the concentration of biological agent that can bond with the polymer and/or copolymer chain. Irrespective of whether a biological agent bonds with a hydrophobic group or hydrophilic group, the ratio of the hydrophilic groups to the hydrophobic groups in the polymer and/or copolymer determines the amount of biological agent that bonds with the polymer and/or copolymer.
- the number of groups of hydrophilic groups (y) and hydrophobic groups (x) typically varies from about 50 to over 10,000.
- Non-limiting examples of polymer and/or copolymers that can be used include poly(ethylene terephthalate); polyacetal; poly(lactic acid); polyglycolic acid; polyesters; hydrogels; polytetrafluoroethylene; fluorosilicones hyaluronates; polymethylmethacrylate; poly(ethylene oxide)/poly(butylene terephthalate) copolymer; polycaprolactone; poly(lactide-co-glycolide); poly(hydroxybutyrate); poly(hydroxybutyrate-co-valerate); polydioxanone; polyorthoester; polyanhydride; poly(glycolic acid); copolymers of lactic acid and glycolic acid; poly (caprolactone); poly (valerolactone); poly (anhydrides); copolymers of poly (caprolactone) or poly (lactic
- PEO/PLA polyalkylene oxalates; polyphosphazenes; parylene; biomolecules such as fibrin, fibrinogen, cellulose, starch, collagen and hyaluronic acid; silicones; polyolefins; polyisobutylene and ethylene-alphaolefin copolymers; acrylic polymers and copolymers (e.g., n-butyl-acrylate, n-butyl methacrylate, 2-ethylhexyl acrylate, lauryl-acrylate, 2-hydroxy-propyl acrylate); vinyl halide polymers and copolymers (e.g. polyvinyl chloride); polyvinyl ethers (e.g.
- polyvinyl methyl ether polyvinylidene halides (e.g. polyvinylidene fluoride, polyvinylidene chloride); polyacrylonitrile; polyvinyl ketones; polyvinyl aromatics (e.g. polystyrene); polyvinyl esters (e.g. polyvinyl acetate); copolymers of vinyl monomers; olefins (e.g. ethylene-methyl methacrylate copolymers); acrylonitrile-styrene copolymers; ABS resins; ethylene-vinyl acetate copolymers; polyamides (e.g.
- Nylon 66 polycaprolactam
- alkyd resins polycarbonates; polyoxymethylenes; polyimides; polyethers; epoxy resins; polyurethanes; rayon; rayon-triacetate; albumin; gelatin; starch; dextrans; polysaccharides; fibrinogen; poly (hydroxybutyrate); poly (alkylcarbonate); poly (orthoesters); EVA copolymers; silicone rubber; poly (methylmethacrylate); cellulose acetate; cellulose butyrate;
- cellulose acetate butyrate cellophane; cellulose nitrate; cellulose propionate; cellulose ethers; and/or carboxymethyl cellulose.
- One particular non-limiting copolymer chain that can be used to form a polymer salt complex with a biological agent such as, but not limited to, Trapidil is an ethylene-acrylic acid copolymer.
- ethylene is the hydrophobic group and acrylic acid is the hydrophilic group.
- the mole ratio of the ethylene to the acrylic acid in the copolymer determines the hydrophobicity of the copolymer.
- a mole ratio for hydrophobic groups/hydrophilic groups ranges from about 90:10-2:98; however, other mole ratios can be used. As can be appreciated, a mole ratio of 2:98 forms a hydrophilic copolymer and a mole ratio of 90:10 forms a hydrophobic copolymer.
- the polymer and/or copolymer includes parylene and/or derivatives thereof. Parylene is substantially biologically inert, and forms a bond with many types of biological agents such as, but not limited to Trapidil.
- the bond between parylene is strong enough to retain the biological agent to the parylene during the insertion of the stent into a body passageway; however, the bond is weak enough to enable the bonded biological agent to disengage from the parylene while in the body passageway.
- the polyamide, parylene or parylene derivative can be applied by catalyst-free vapor deposition to a coating thickness of about 5,000 to 250,000 ⁇ , which is adequate to provide a controlled release of the Trapidil, and/or other biological agent.
- “Parylene” is both a generic name for a known group of polymers based on p-xylylene and can made by vapor phase polymerization.
- parylene or a parylene derivative can be created by first heating p-xylene or a suitable derivative at an appropriate temperature (e.g., about 950° C.) to produce the cyclic dimer di-p-xylylene (or a derivative thereof).
- the resultant solid can be separated in pure form, and then cracked and pyrolyzed at an appropriate temperature (e.g., about 680° C.) to produce a monomer vapor of p-xylylene (or derivative); the monomer vapor is cooled to a suitable temperature (e.g., below about 50° C.) and allowed to condense on the desired object (e.g., stent).
- the resultant polymer has the repeating structure (CH 2 C 6 H 4 CH 2 ) n , with n equal to about 100-10,000, and a molecular weight in the range of about 100,000-1,000,000.
- the parylene or parylene derivative is thought to form a network resembling a fibrous mesh, with relatively large pores. As more is deposited, the porous layer not only becomes thicker, but it is believed that parylene or parylene derivative is also deposited in the previously formed pores, making the existing pores smaller. Careful and precise control over the deposition of the parylene or parylene derivative therefore permits close control over the release rate of the one or more biological agents.
- the biological agent can be dispersed in the parylene or parylene derivative, and/or the parylene or parylene derivative can be at least partially coated over one or more layers of biological agent.
- the porous layer also protects the biological agent during deployment of the stent or other device during insertion of the device through a catheter and into the vascular system or elsewhere in the patient.
- the polyamide, parylene or parylene derivative can be applied by plasma deposition.
- Plasma is an ionized gas maintained under vacuum and excited by electrical energy, typically in the radiofrequency range. Because the gas is maintained under vacuum, the plasma deposition process can occur at or near room temperature.
- Plasma can be used to deposit polymers such as poly(ethylene oxide), poly(ethylene glycol), and poly(propylene oxide), as well as polymers of silicone, methane, tetrafluoroethylene (including TEFLON brand polymers), tetramethyldisiloxane, and others.
- polymers such as poly(ethylene oxide), poly(ethylene glycol), and poly(propylene oxide), as well as polymers of silicone, methane, tetrafluoroethylene (including TEFLON brand polymers), tetramethyldisiloxane, and others.
- the amount of biological agent that can be loaded on the polymer and/or copolymer is dependent on the structure of the polymer and/or copolymer.
- the concentration of biological agent that can be loaded on the polymer and/or copolymer is a function of the concentration of anionic groups in the polymer and/or copolymer.
- the concentration of biological agent that can be loaded on the polymer and/or copolymer is a function of the concentration of cationic groups (e.g. amine groups and the like) in the polymer and/or copolymer.
- the maximum concentration of Trapidil that can be loaded on to the polymer and/or copolymer is dependent on the concentration of anionic groups (i.e. carboxylate groups, phosphate groups, sulfate groups, and/or other organic anionic groups) in the polymer and/or copolymer, and the fraction of these anionic groups that can ionically bind the cationic form of Trapidil.
- anionic groups i.e. carboxylate groups, phosphate groups, sulfate groups, and/or other organic anionic groups
- the concentration of biological agent bound to the polymer and/or copolymer can be varied by controlling the amount of hydrophobic and hydrophilic monomer in the polymer and/or copolymer, by controlling the efficiency of salt formation between the biological agent, and/or the anionic/cationic groups in the polymer and/or copolymer.
- Loading levels of the biological agent in the polymer and/or copolymer can be from zero to about 90 percent on a weight by weight basis. Therefore, the chemical properties of the biological agent typically dictate the type of polymer and/or copolymer to be used so as to deliver the desired levels of biological agent into a body passageway to achieve a desired biological response.
- the stent is at least partially coated and/or impregnated with one or more intermediate compounds that include one or more biological agents, wherein the one or more intermediate compounds are cross-linked to alter the rate of release of the one or more biological agents into the body passageway. It has been discovered that by causing the one or more intermediate compounds to cross-link after being at least partially coated and/or impregnated onto the stent, the rate at which the one or more biological agents disassociates from the stent and migrates into the body passageway can be controlled. As can be appreciated, the cross-linking of the intermediate compound can be used to alter the rate of release of the one or more biological agents into the body passageway or other body parts.
- the cross-linking can be instituted by a number to techniques including, but not limited to, using catalysts, using radiation, using heat, and/or the like.
- the intermediate compound is exposed to radiation to cause one or more cross-links to be formed.
- the radiation can include, but is not limited to, gamma radiation, beta radiation and/or e-beam radiation.
- one or more hydrogen radicals are removed from the polymer and/or copolymer chain in the intermediate compound. The removal of the hydrogen radical causes the polymer and/or copolymer chain to cross-link with another portion of the polymer and/or copolymer chain or cross-link with a different polymer and/or copolymer.
- the cross-linking effect results in the one or more biological agents to become partially or fully entrapped within the cross-linked intermediate compound.
- the entrapped biological agent takes longer to release itself from the cross-linked intermediate compound and to pass into the body passageway.
- the amount of biological agent, and/or the rate at which the biological agent is released from the stent over time can be controlled by the amount of cross-linking in the intermediate compound.
- the amount of cross-linking in the intermediate compound is at least partially controlled by the type and amount of radiation applied to the intermediate compound. Gamma radiation is a higher intensity radiation and e-beam radiation is a lower intensity radiation. Increased radiation intensities and increased radiation exposure periods typically result in increased cross-linking of the intermediate compound.
- Each polymer composition has its unique threshold and capacity for cross-linking.
- the amount of cross-linking that is induced by radiation will be dependent on the chemical structure and composition of the polymer and/or copolymer.
- the extent or degree of cross-linking for each polymer and/or copolymer in combination with the biological agent will vary, depending on the type, strength and duration of radiation, the chemical structure of the biological agent, the type of polymer and/or copolymer, and the amount of loading (weight percent) of the biological agent in the polymer and/or copolymer. Reduced solubility of the copolymer/polymer in a body passageway can reduce the need for induced cross-linking of the polymer and/or copolymer.
- the polymer and/or copolymer may be hydrophilic
- salt formation with a hydrophobic biological agent can result in a reduction of solubility of the bound polymer and/or copolymer in physiological environments.
- the reduction in solubility of the bound polymer and/or copolymer may reduce the need or totally obviate the need for induced cross-linking by radiation or otherwise.
- the hydrophobic nature of the bound polymer and/or copolymer will control the rate of release of the biological agent from the polymer and/or copolymer.
- the amount of radiation exposure to the intermediate compound and the biological agent is limited so as to prevent degradation of the biological agent, and/or the intermediate compound during the irradiation procedure.
- less than about 2000 rads are applied to the intermediate compound, the biological agent, and typically less than about 1000 rads, and more typically less than about 500 rads, and even more typically less than about 400 rads.
- at least about 0.1 rad is applied to the intermediate compound, the biological agent, and typically at least about 1 rad, and more typically at least about 10 rads.
- up to 300 microvolt equivalents is used.
- a further another and/or alternative feature of the present invention is that the stent is at least partially coated and/or impregnated with one or more intermediate compounds that include one or more biological agents, wherein the one or more intermediate compounds are bonded with one or more biological agents to alter the rate of release of the one or more biological agents into the body passageway. It has been discovered that by causing the one or more intermediate compounds to form a bond with one or more biological agents after being at least partially coated and/or impregnated onto the stent, the rate at which the one or more biological agents disassociates from the stent and migrates into the body passageway can be controlled.
- the bonding of the one or more biological agents can be used to alter the rate of release of the one or more biological agents into the body passageway.
- the post bonding of the one or more biological agents to one or more intermediate compounds can be instituted by a number to techniques including, but not limited to, using catalysts, using radiation, using heat, and/or the like.
- the coating compound is exposed to radiation to cause one or more bonds to be formed.
- the radiation can include, but is not limited to, gamma radiation, beta radiation and/or e-beam radiation.
- one or more hydrogen radicals are removed from the polymer and/or copolymer chain in the intermediate compound.
- the removal of the hydrogen radical causes the polymer and/or copolymer chain to bond to one or more surrounding biological agents.
- the hydrogen radical typically bonds with a salt of the biological agents.
- the bonded biological agent takes longer to release itself from the intermediate compound and to pass into the body passageway.
- the amount of biological agent, and/or the rate at which the biological agent is released from the stent over time can be controlled by the amount of bonding of the biological compound to the intermediate compound.
- the amount of bonding of the biological compound to the intermediate compound is at least partially controlled by the type and amount of radiation applied to the intermediate compound. Increased radiation intensities and increased radiation exposure periods typically result in increased amounts of bonding.
- Each polymer composition has its unique threshold and capacity for bonding with one or more biological agents.
- the amount of bonding that is induced by radiation will be dependent on the chemical structure and composition of the polymer and/or copolymer and the biological agents.
- the extent or degree of bonding for each polymer and/or copolymer in combination with the biological agent will vary, depending on the type, strength and duration of radiation, the chemical structure of the biological agent, the type of polymer and/or copolymer, and the amount of loading (weight percent) of the biological agent in the polymer and/or copolymer.
- the stent is at least partially sterilized by subjecting the stent to radiation.
- the stent Prior to the stent-being inserted into a body passageway, the stent should be free or substantially free of foreign organisms so as to avoid infection in the body passageway.
- the stent was sterilized by ethylene oxide.
- ethylene oxide ethylene oxide
- Stent sterilization by radiation overcomes the problems and limitations associated with the use of ethylene oxide. The radiation destroys most, if not all, of the foreign organisms on the stent.
- sterilization by radiation reduces the occurrence of infection by foreign organisms as compared to past sterilization techniques.
- less than about 5000 rads are applied to the stent to at least partially sterilize the stent, and typically less than about 1000 rads, and more typically less than about 500 rads.
- at least about 0.1 rad is applied to the stent, and typically at least about 1 rad, and more typically at least about 5 rads.
- the primary object of the present invention is the provision of a stent having improved procedural success rates.
- Another and/or alternative object of the present invention is the provision of a stent having higher visibility under fluoroscopy in vivo.
- Still another and/or alternative object of the present invention is the provision of a stent retaining its longitudinal dimensions from its original pre-expanded configuration to its expanded configuration.
- Yet another and/or alternative object of the present invention is the provision of a stent that minimizes damage to tissue during insertion and expansion of the stent.
- Still yet another and/or alternative object of the present invention is the provision of a stent that inhibits or prevents the occurrence of in-stent restenosis, vascular narrowing and/or restenosis long after the stent has been inserted into a body passageway.
- a further and/or alternative object of the present invention is the provision of a stent that is simple and cost effective to manufacture.
- Still a further and/or alternative object of the present invention is the provision of a stent that is at least partially coated and/or impregnated with a biocompatible coating.
- Yet a further and/or alternative object of the present invention is the provision of a stent that includes two or more body members connected by one or more connectors to allow transverse bending and flexibility of the stent invariant to the plane of bend.
- Still yet a further and/or alternative object of the present invention is the provision of a stent that is at least partially visible under fluoroscopy in vivo.
- Another and/or alternative object of the present invention is the provision of a stent that is coated and/or impregnated with one or more vascular active agents and/or secondary vascular agents.
- Still another and/or alternative object of the present invention is the provision of a stent having one or more intermediate compounds used with one or more vascular active agents and/or secondary vascular agents to coat and/or impregnate one or more vascular active agents and/or secondary vascular agents on the stent.
- Yet another and/or alternative object of the present invention is the provision of a stent that is coated and/or impregnated with one or more biological agents.
- Still yet another and/or alternative object of the present invention is the provision of a stent having one or more intermediate compounds used with one or more biological agents to coat and/or impregnate one or more biological agents on the stent.
- a further and/or alternative object of the present invention is the provision of a stent having one or more intermediate compounds to at least partially regulate or control the release of one or more biological agents from the stent.
- Still a further and/or alternative object of the present invention is the provision of a stent having one or more intermediate compounds that bond with one or more biological agents.
- Yet a further and/or alternative object of the present invention is the provision of a stent having one or more intermediate compounds that include polymers and/or copolymers which include hydrophobic groups and hydrophilic groups.
- Still yet a further and/or alternative object of the present invention is the provision of a stent having one or more intermediate compounds having post induced cross-linking to at least partially regulate or control the release of one or more biological agents from the stent.
- Another and/or alternative object of the present invention is the provision of a stent having one or more intermediate compounds having post bonding with one or more biological agents to at least partially regulate or control the release of one or more biological agents from the stent.
- Still another and/or alternative object of the present invention is the provision of a stent having one or more intermediate compounds that are subjected to radiation to cause post induced cross-linking between the one or more intermediate compounds and/or to cause post induced bonding with one or more biological agents.
- Yet another and/or alternative object of the present invention is the provision of a stent that is sterilized prior to insertion into a body passageway.
- FIG. 1 is a perspective view of a section of an unexpanded stent which permits delivery of the stent into a body passageway;
- FIG. 1A is an enlarged perspective view of one end of the stent of FIG. 1;
- FIG. 2 is a perspective view of a section of the unexpanded stent of FIG. 1 in a non-tubular state
- FIG. 3 is a sectional view of the unexpanded stent of FIG. 2 showing a connector used to connect the ends of two tubular body members of the stent;
- FIG. 3B is a perspective view of the stent of FIG. 1 in a non-tubular state wherein the stent has rounded edges;
- FIG. 4 is a sectional view of the stent of FIG. 2 showing the polygonal structure of the stent before and after expansion;
- FIG. 5 is a perspective view of an additional embodiment of the present invention showing an unexpanded section of the stent having a series of slots of FIG. 4;
- FIG. 6 is a sectional view of the stent of FIG. 5 showing a connector used to connect the ends of two body members of the stent together;
- FIG. 7 is a sectional view of the stent of FIG. 5 showing a part of the structure of the stent before and after expansion;
- FIG. 8 is a perspective view of a stent of FIG. 1 showing a coating that includes a biological agent on the stent;
- FIG. 9 is a perspective view of an angioplasty balloon delivering fluid materials to a local site
- FIG. 10 is a graphical representation of the steps for coating the stent with a biological agent and coating compound
- FIG. 10A is a graphical representation of the biological agent entrapped in a cross-linked polymer and/or copolymer; and, FIG. 11 is a graphical representation of the steps to form cross-linking of a polymer and/or copolymer that includes a biological agent.
- FIGS. 1 - 8 disclose a stent for a body passageway.
- the apparatus and structures of the present invention may be utilized not only in connection with an expandable stent for at least partially expanding occluded segments of a body passageway, but also for additional uses.
- the expandable stent may be used for, but not limited to, such purposes as 1) a supportive stent placement within a blocked vasculature opened by transluminal recanalization, which are likely to collapse in the absence of an internal support; 2) forming a catheter passage through mediastinal and/or other veins occluded by inoperable cancers; 3) reinforcement of catheter created intrahepatic communications between portal and/or hepatic veins in patients suffering from portal hypertension; 4) supportive stent placement of narrowing of the esophagus, the intestine, the ureter and/or the urethra; and/or 5) supportive stent reinforcement of reopened and previously obstructed bile ducts.
- use of the term “stent” encompasses the foregoing usages within various types of body passageways, and also encompasses use for expanding a body passageway.
- the expandable stent 20 as shown in FIGS. 1, 1A, 2 , 3 , 3 B, and 4 , generally comprises two tubular shaped body members 30 , 40 , each having a first end 32 , 42 , a second end 34 , 44 , and a wall surface 36 , 46 disposed between the first and second ends.
- the wall surface is formed by a plurality of intersecting elongated members 50 , with at least some of the elongated members intersecting with one another intermediate the first and second ends of each body member.
- the stent can be formed of only one body member or be formed by more than two body members.
- Body members 30 , 40 each have a first diameter which permits delivery of the body members into a body passageway.
- the two body members have substantially the same first diameter.
- FIG. 1 discloses that the first diameter of each body member is substantially constant along the longitudinal length of the two body members.
- the diameter of the two body members can differ, and in addition or alternatively, one or both of the body members can have a varying first diameter along at least a portion of the longitudinal length of the body member.
- Body members 30 , 40 each have a second expanded diameter. The second diameter typically varies in size; however, the second diameter can be non-variable in size.
- Elongated members 50 which form wall surface 36 , 46 of body members 30 , 40 , can be any suitable material which is compatible with the human body and the bodily fluids with which the stent may come into contact.
- the elongated members are made of a material, include a material, and/or are coated with a material readily visible in vivo under fluoroscopic view.
- the elongated members also are made of a material which has the requisite strength and elasticity characteristics to permit the body members to be expanded from their original cross-sectional size to their expanded cross-sectional size and to further permit the body members to retain their expanded configuration with the enlarged cross-sectional size.
- Suitable materials for the fabrication of the body members of the stent include, but are not limited to, collagen, gold; platinum; platinum-iridium alloy; alloys of cobalt, nickel, chromium and molybdenum; stainless steel; tantalum; titanium; nickel-titanium alloy; magnesium, MP35N, MP20N, or combinations of alloys; and/or any suitable polymer and/or copolymer material (e.g.
- Elongated members 50 are generally small diameter wires or bars that have a maximum cross-sectional length or diameter of up to about 0.02 inches, and generally about 0.0005 to 0.008 inch, and typically about 0.002 to 0.004 inch; however, other cross-sectional lengths or diameters can be used.
- the cross-sectional length or diameter of the elongated members is designated by “a” in FIG. 2. It should, of course, be understood that each elongated member can have a variety of different cross-sectional configurations along part, or the complete length of, each elongated member. Such configurations include circular, oval, elliptical, diamond, triangular, trapezoidal, polygonal (e.g. square, rectangular, hexagonal, etc.).
- the cross-sectional length or diameter of the elongated members can be the same or different.
- each parallelogram 80 , 90 is formed by four sides 82 a , 82 b , 82 c , 82 d , 92 a , 92 b , 92 c , 92 d . As shown in FIG.
- a set of parallelogram shapes are aligned along a single longitudinal axis of body member 30 which are defined by sides 82 a - d , sides 82 a of each parallelogram of body member 30 substantially lie in a single longitudinal axis. Likewise, sides 82 c of each parallelogram of body member 30 substantially lie in a single longitudinal axis. In addition, sides 82 a and 82 c of each parallelogram are substantially parallel to each other. Sides 82 b and 82 d of each parallelogram are substantially parallel to one another. Sides 82 b and 82 d are shown to slope from left to right.
- the slope angle between sides 82 b and 82 c and sides 82 a and 82 d ranges between 0-90°, and typically about 10-60°.
- the parallelogram shape has a height “b.” Height b will vary depending or the size of the unexpanded body member. The maximum of height b is about 1 inch, and generally about 0.005 to 0.5 inch, and typically about 0.01 to 0.1 inch; however, other heights can be used.
- Sides 82 a and 82 c can have the same or different length from sides 82 b and 82 d . The length of the sides can be up to 2 inches, and generally ranges from 0.005 to 1 inch, and typically 0.01 to 0.5 inch. As shown in FIG. 2, all the sides have substantially the same length.
- Each of the parallelograms has substantially the same dimensions.
- sides 82 a ′ of each parallelogram of body member 30 substantially lie in a single longitudinal axis.
- sides 82 c ′ of each parallelogram of body member 30 substantially lie in a single longitudinal axis.
- sides 82 a ′ and 82 c ′ of each parallelogram are substantially parallel to each other.
- Sides 82 b ′ and 82 d ′ of each parallelogram are substantially parallel to one another.
- Sides 82 b ′ and 82 d ′ are shown to slope from right to left.
- the slope angle between sides 82 b ′ and 82 c ′ and sides 82 a ′ and 82 d ′ ranges between 0-90°, and typically about 10-60°.
- the parallelogram shape has a height “b′.” Height b′ will vary depending or the size of the unexpanded body member. The height ranges of b′ are generally the same as b.
- the length ranges of sides 82 a - d are also generally the same as 82 a ′- d′.
- each of the parallelograms has substantially the same dimensions.
- shape and size of the parallelograms is substantially the same as the parallelogram defined by sides 82 a - d.
- the orientation of the parallelograms alternates along the latitudinal axis from parallelograms having sides 82 b and 82 d sloping from left to right and parallelograms having sides 82 b ′ and 82 d ′ sloping from right to left.
- a similar parallelogram pattern exists on body member 40 . Referring now to FIGS.
- the orientation of the parallelograms that are aligned along the same longitudinal axis for body members 30 and 40 is substantially the same.
- this parallelogram pattern allows the body members to be expanded without the body members having a reduction in length in the longitudinal direction. Since a parallelogram is a four sided figure with opposite sides. being parallel, the longitudinal axis of structure of body members 30 , 40 remains substantially the same during the expansion of the body members.
- the orientation of the parallelograms on one or more body members of the stent can be patterned differently so long as the longitudinal length of the body member remains substantially the same during the expansion of the body member. The symmetrical orientation of the parallelogram pattern on the body members illustrated in FIGS.
- the cross-sectional length or diameter of the elongated members are substantially uniform and about 0.0025 to 0.0035 inch
- the size of the parallelograms in the two body members are substantially the same
- the heights b and b′ of the parallelograms are substantially the same and are about 0.015 to 0.025 inch
- the lengths of the sides of each parallelogram are substantially the same and are about 0.03 to 0.08 inch
- the slope angles of the sides of the parallelograms are about 15-40°.
- body members 30 , 40 are connected together by a several connector members 70 .
- One such connector member is a connector member having a “U” shaped member 72 as shown in FIGS. 1, 2 and 3 .
- connector member 70 joins end 34 of body member 30 to end 42 of body member 40 .
- Connector member 70 also includes a bar member 74 .
- the bar member spans between the second end of “U” shaped member 72 and end 42 of body member 40 .
- the first end of “U” shaped member 72 is connected to end 34 of body member 30 .
- connectors 70 do not connect to all of the ends 34 of body member 30 or all of the ends 42 of body member 40 .
- the connector member has certain dimensions that enhance the flexibility of the stent.
- the cross-sectional length or diameter of the “U” shaped member is generally the same as the cross-sectional length or diameter “a” of the elongated members; however, other cross-sectional lengths or diameters of the “U” shaped member can be used.
- the height of the legs of the “U” shaped member is generally equal to 2 a +(b or b′) wherein “a” is the cross-sectional length or diameter of the elongated members and b or b′ is the height of the parallelograms in the unexpanded state. As can be appreciated, other heights of the legs of the “U” shaped member can be used.
- the width “c” of the “U” shaped member also affects the flexibility of the connector member and the stent.
- the width generally is about 1-4 times the cross-sectional length or diameter “a” of the “U” shaped member, and typically about 1.2-2 times the cross-sectional length or diameter “a” of the “U” shaped member; however, other widths can be used.
- the spacing of the “U” shaped member from ends 34 of body member 30 and end 42 of body member 40 also affects the flexibility of the connector member and the stent. As shown in FIG. 2, the “U” shaped portion of the connector member is spaced a distance from the ends of the body members that is substantially equal to cross-sectional length or diameter “a” of the elongated members.
- Bar member 74 has a sufficient length to form the desired spacing of the “U” shaped portion of the connector member from ends of body member 40 .
- the connector member allows the body members to transverse, bend and improve flexibility invariant to the plane of bending.
- other shaped connectors which include an arcuate portion and/or V-shaped portion can be used.
- ends 32 , 34 , 42 , and 44 are treated so as to have generally smooth surfaces 60 .
- the ends are treated by filing, buffing, polishing, grinding, and/or the like the end surfaces.
- sharp edges, pointed surfaces and the like are substantially eliminated from the end section.
- all the ends of the body members are treated to have smooth surfaces.
- the smooth surfaces of the ends reduce damage to surrounding tissue as the body member is positioned in and/or expanded in a body passageway.
- the elongated members 50 and/or joints between the elongated members are formed, filed, buffed, ground, polished, and/or the like to also have generally smooth surfaces.
- connector members 70 and/or the connection points between the connector members and the elongated members are formed, filed, buffed, ground, polished, and/or the like to have generally smooth surfaces.
- the substantial removal of sharp edges, pointed surfaces and the like from the entire stent reduces damage to surrounding tissue as the stent is positioned in and/or expanded in a body passageway.
- the ends of the body members, the elongated members, the joints between the elongated members, the connector members, and/or the connection points between the elongated members and the connector members can additionally or alternatively be coated with a material that reduces or eliminates any sharp and/or rough surfaces.
- the coating if used, is generally a polymer and/or copolymer material.
- the coating can be nonbiodegradable, biodegradable or semi-biodegradable.
- the coating thickness is less than the cross-sectional thickness of the elongated members.
- One non-limiting example of a coating thickness is about 0.00005 to 0.0005 inches.
- Elongated members 50 and/or connector members 70 can be formed by a variety of processes. Typically, the elongated members and connector members are formed by etching, laser cutting and/or punching a single piece of material so that the individual intersections of the elongated members and/or the connections between the elongated members and the connector members need not be welded, soldered, glued or otherwise connected together.
- the stent can be formed from a thin-walled metal tube, and the openings between the elongated members and the connector members are formed by an etching process, such as electromechanical or laser etching, whereby the resultant structure is a stent having a plurality of intersecting elongated members and connector members as shown in FIG. 1.
- An alternative method or process to form the stent is to use a flat piece of material and form the openings between the elongated members and the connector members by an etching process, such as electromechanical or laser etching, stamping, laser cutting, drilling, and/or the like. Such a flat piece of material is illustrated in FIGS. 3 and 3B.
- the flat sheet includes seven (7) formed parallelograms along the latitudinal axis of the sheet and one partially formed parallelogram.
- the flat sheet also includes ten (10) parallelograms along the longitudinal axis of the sheet.
- Four “U” shaped connector members are formed along the latitudinal axis of the sheet.
- the connector members divide the parallelograms along the longitudinal axis of the sheet into two sets of five (5), thus each body member has five (5) parallelograms along the longitudinal axis and seven (7) fully formed parallelograms and one partially formed parallelogram along the latitudinal axis.
- body members 30 , 40 each have an elongated top bar 38 , 48 .
- body members 30 , 40 each have a plurality of ends 39 , 49 formed from sides 82 b ′, 82 d ′, 92 b ′, and 92 d ′ that are not connected to sides 82 c ′ and 92 c ′, respectively.
- ends 39 , 49 are connected to top bar 38 , 48 thereby resulting in a fully formed parallelogram, thereby resulting in eight (8) fully formed parallelograms about the outer surface of body members 30 , 40 .
- the flat sheet is designed so as to form an even number of fully formed parallelograms about the outer surface of body members 30 , 40 . This even number of formed parallelograms facilitates in the desired expansion of the stent in the body passageway.
- the connections between ends 39 , 49 and top bar 38 , 48 can be formed by welding, soldering, brazing, adhesives, lock and groove configurations, snap configurations, melting together the ends and the top bars, and the like.
- the surfaces around the connection are smoothed to remove sharp and/or rough surfaces.
- FIG. 3B illustrates ends 32 , 34 , 42 , and 44 as being smooth surfaces. Ends 39 are also shown as being relatively smooth surfaces.
- FIG. 4 there is shown a single parallelogram shape 80 .
- the left parallelogram shape is representative of the parallelogram shapes in body members 30 , 40 when the stent is in an unexpanded configuration.
- the length of the sides of the parallelogram are illustrated as being generally the same, thereby forming a rhombus.
- the angle between sides 82 b and 82 c and sides 82 a and 82 d is about 15-30°.
- the parallelogram shape deforms thereby causing the angle between sides 82 b and 82 c and sides 82 a and 82 d to increase.
- a fully expanded stent would result in the angle between sides 82 b and 82 c and sides 82 a and 82 d to be about 90° thereby causing the parallelogram to form into a square or rectangle.
- the stent is not fully expanded, thus an angle of less than 90° is formed between sides 82 b and 82 c and sides 82 a and 82 d .
- the right side dashed parallelogram illustrates the typically expanded configuration of the parallelogram. In the expanded state, the angle between sides 82 bb and 82 cc and sides 82 aa and 82 dd generally remain the same and generally range between about 60-90°, and typically about 65-80°.
- a stent 100 includes two body members 110 , 112 .
- Body members 110 , 112 include ends 140 , 142 of body member 110 and ends 144 , 146 of body member 112 .
- the two body members are connected together by several connector members 120 .
- connector members 120 include an arcuate shaped member 122 , and typically is “U” shaped, similar to shape and size of connector members 70 as shown in FIG. 3B.
- Connector member 120 also includes a bar member 124 . The connector members provide flexibility to the stent body members 110 , 112 .
- the bar member spans between the second end of “U” shaped member 122 and end. As best shown in FIGS. 5 and 6, the “U” shaped member alternates between being connected to end 142 and end 144 and similarly, the bar member alternates between being connected to end 144 and end 142 .
- the “U” shaped members are typically spaced apart a sufficient distance so as to avoid contacting one another in the unexpanded state. In addition, the “U” shaped members are typically spaced apart a sufficient distance so as to avoid contacting one another in the expanded state.
- the connector members allow the body members to transverse, bend and improve flexibility invariant to the plane of bending. As can be appreciated, other shaped connectors which include an arcuate portion can be used.
- body members 110 , 112 are substantially symmetrical to one another and typically have substantially identical dimensions.
- Each body member includes a plurality of slots 130 , 132 .
- Slots 130 , 132 are generally equal in length and width; however, the width and/or length of the slots can vary.
- Each slot 130 includes two ends 130 a, 130 b and each slot 132 includes two ends 132 a , 132 b .
- Each series of slots 130 along a longitudinal axis of the stent are arranged substantially parallel to one another.
- each series of slots 132 along a longitudinal axis of the stent are arranged substantially parallel to one another.
- Slots 130 and 132 that are positioned closest to one another form a series of “V” shapes along a longitudinal axis of the stent. Ends 130 a and 132 a form the base of the “V” shape. As shown in FIG. 5, four different series of “V” shapes are positioned along a longitudinal axis of the stent. As shown in FIG. 5, all the “V” shapes are symmetrically oriented on each body member.
- the angle between slots 130 and 132 is between about 0-90°, and generally about 5-60°, and typically about 10-30°.
- the width of each slot is up to about 0.5 inch, and generally about 0.0005 to 0.25 inch, and typically about 0.001 to 0.1 inch.
- each slots is up to about 2 inches, and generally about 0.005 to 1 inch, and typically about 0.01 to 0.5 inch.
- the slot arrangement is such that the stent retains its longitudinal length from its unexpanded to its expanded state.
- the configuration of slots 130 , 132 in the pre-expanded and post-expanded position is shown in FIG. 7.
- the slot configuration in the left figure illustrates the slots in the unexpanded state.
- the slot configuration in the right figure illustrates the slots in the expanded state.
- the slots 130 and 132 begin to align and the angle between the slots increases.
- the angle between the slots in the expanded state is between about 45-90°, and typically about 60-80°.
- a stent to be used in a blood vessel In one specific design of a stent to be used in a blood vessel, four sets of “V” shaped slots are positioned in each body member and eight connector members are used to connect the two body members together. The length of all the slot members are substantially the same. The angle between slots is about 15-25° in the unexpanded state. The width of each slot is about 0.002-0.007 inch. The length of each slot is 0.05-0.2 inch.
- the slots in the body members can be formed in a variety of manners.
- the stent is formed from a flat piece of material and the slots and connector members are formed by an etching process, such as electromechanical or laser etching, stamping, laser cutting, drilling, and/or the like.
- the stent is generally treated so as to have generally smooth surfaces 60 .
- the ends, slots and connector members are treated by filing, buffing, polishing, grinding, and/or the like. As a result, sharp edges, pointed surfaces and the like are substantially eliminated.
- the smooth surfaces reduce damage to surrounding tissue as the body member is positioned in and/or expanded in a body passageway.
- the ends of the body members, the slots, and/or the connector members can additionally or alternatively be coated and/or impregnated with a material that reduces or eliminates any sharp and/or rough surfaces.
- the coating if used, is generally a polymer and/or copolymer material.
- the coating can be non-biodegradable, biodegradable or semi-biodegradable.
- the coating thickness is less than the half the width of the slots.
- One non-limiting example of a coating thickness is about 0.00005 to 0.0005 inches.
- the flat material is rolled or otherwise formed and the side edges of the flat material are connected together form the stent.
- the side edges of the flat material can be connected together by a variety of techniques such as, but not limited to, welding, soldering, brazing, adhesives, lock and groove configurations, snap configurations, melting together the edges, and the like.
- the cross-sectional shape of the stent is typically circular; however, other cross-sectional shapes can be formed such as, but not limited to, oval, elliptical, diamond, triangular, trapezoidal, polygonal (e.g. square, rectangular, hexagonal, etc.).
- the connection between the edges is generally treated to reduce or eliminate the rough or sharp surfaces.
- a stent 200 is shown to include a compound 210 on the elongated members 220 and connector 230 of the body member.
- Compound 210 is or includes a vascular active agent that inhibits and/or prevents restenosis, vascular narrowing and/or in-stent restenosis.
- compound can alternatively or also be a secondary vascular active agent and/or a biological agent.
- compound 2 1 0 can represent one or more different compounds.
- One preferable compound that is or is included in the vascular active agent is a PDGF inhibitor.
- One type of PDGF inhibitor that is used is Trapidil and/or derivative thereof; however, other PDGF inhibitors can be used.
- Another preferable compound that is or is included in the vascular active agent is GM-CSF and/or derivative thereof.
- the amount of vascular active agent and/or secondary vascular active agent and/or other biological agent delivered to a certain region of a body passageway can be controlled by varying the coating thickness, drug concentration of the vascular active agent and/or secondary vascular active agent and/or other biological agent, the solubility of the vascular active agent and/or secondary vascular active agent and/or other biological agent in a particular body passageway, the amount of surface area of the body member 200 that is coated and/or impregnated with the vascular active agent and/or secondary vascular active agent and/or other biological agent, the location of the vascular active agent and/or secondary vascular active agent and/or other biological agent on the stent, and/or the size of cavity openings in the stent.
- the vascular active agent and/or secondary vascular active agent and/or other biological agent can be combined with, or at least partially coated with, another compound that affects the rate at which the vascular active agent and/or secondary vascular active agent and/or other biological agent is released from the surface of the stent.
- An intermediate compound can be used in conjunction with compound 210 to assist in binding compound 210 to body member 200 .
- the intermediate compound can be used to control the release of compound 210 into the body passageways.
- the intermediate compound is biodegradable and dissolves over the course of time, and the intermediate compound is coated at one or more thicknesses over compound 210 to delay delivery of compound 210 into a body passageway.
- the vascular active agent and/or secondary vascular active agent and/or other biological agent is combined with a polymer and/or copolymer prior to being at least partially coated onto the stent.
- the polymer and/or copolymer can be formulated to bond the vascular active agent and/or secondary vascular active agent and/or other biological agent to the stent; however, the polymer and/or copolymer can be used in combination with other compounds to facilitate in the bonding of the vascular active agent, secondary vascular active agent and/or other biological agent and/or polymer and/or copolymer to the stent.
- vascular active agents there is illustrated a typical process whereby one or more vascular active agents, one or more secondary vascular active agents, one or more other biological agents, and/or other compounds are coated to the stent.
- the vascular active agent and/or secondary vascular active agent and/or other biological agent is mixed with a polymer and/or copolymer prior to coating the stent.
- the polymer and/or copolymer is formulated to delay and/or regulate the time and/or amount of vascular active agent and/or secondary vascular active agent and/or other biological agent being released into the body passageway.
- the polymer and/or copolymer can be a biodegradable compound, a non-biodegradable compound, or a partially biodegradable compound.
- the polymer and/or copolymer can be formulated so as to form one or more bonds with the vascular active agent and/or secondary vascular active agent and/or other biological agent, or be chemically inert with respect to the vascular active agent and/or secondary vascular active agent and/or other biological agent.
- the polymer and/or copolymer form at least one bond with one or more vascular active agents and/or secondary vascular active agents and/or other biological agents.
- the bond is generally formed in a polymer and/or copolymer salt complex.
- the vascular active agent is or includes Trapidil
- the Trapidil forms a salt complex with the polymer and/or copolymer.
- the Trapidil forms the cationic component of the salt complex and the polymer and/or copolymer forms the anionic component of the salt complex.
- the carboxylate groups, phosphate groups, and/or sulfate groups in the polymer and/or copolymer form the bond with this vascular active agent.
- the mixture is coated onto the stent.
- the coated stent can be subjected to radiation.
- the radiation causes the polymer and/or copolymer to form cross-linking between the polymer and/or copolymer chains and/or causes one or more bonds to form between the polymer and/or copolymer and the vascular active agent and/or secondary vascular active agent and/or other biological agent.
- the cross-linking and/or bond formation alters the rate of release of the one or more vascular active agents and/or secondary vascular active agents and/or other biological agents into the body passageway.
- the radiation typically includes, but is not limited to, gamma radiation, beta radiation, and/or e-beam radiation; however, other types of radiation (e.g. inferred, ultraviolet) can be used in conjunction with or as an alternative to gamma radiation, beta radiation, and/or e-beam radiation.
- one or more hydrogen radicals are typically removed from the polymer and/or copolymer chain. This process is illustrated in FIG. 11.
- other elements in the polymer and/or copolymer can be removed and/or disassociated from the polymer and/or copolymer when the polymer and/or copolymer is exposed to radiation.
- a polymer and/or copolymer chain includes a carboxyl group that has formed a salt complex with Trapidil. Radiation is applied to the polymer and/or copolymer salt complex resulting in removal of one or more hydrogen atoms from the polymer and/or copolymer chain. The removal of the hydrogen radical causes the polymer and/or copolymer chain to cross-link with another portion of the polymer and/or copolymer chain or cross-link with a different polymer and/or copolymer as shown in FIG. 11.
- FIG. 10A illustrates the vascular active agent and/or secondary vascular active agent and/or other biological agent being entrapped or partially entrapped within the cross-linking of the polymer and/or copolymer.
- the entrapped vascular active agent and/or secondary vascular active agent and/or other biological agent takes longer to release itself from the cross-linked coating compound and to pass into the body passageway.
- the amount of vascular active agent and/or secondary vascular active agent and/or other biological agent, and/or rate at which the vascular active agent and/or secondary vascular active agent and/or other biological agent released from the stent over time can be controlled by the amount of cross-linking in the coating compound and/or the amount of bonding in the coating compound.
- the amount of cross-linking and/or bonding in the coating compound is controlled by the type and amount of radiation applied to the coating compound.
- the amount of radiation exposure to the polymer and/or copolymer salt complex is controlled so as to prevent degradation of the vascular active agent, secondary vascular active agent, other biological agent, and/or polymer and/or copolymer during the irradiation procedure.
- the radiation at least partially sterilizes the stent.
- the radiation destroys most if not all of the foreign organisms on the stent and/or on any coating on the stent. As a result, sterilization by radiation reduces the occurrence of infection by foreign organisms.
- a vascular active agent and/or secondary vascular active agent and/or other biological agent 240 is delivered into a body passageway A via angioplasty balloon 250 .
- Balloon 250 includes one or more slots 260 to allow delivery of vascular active agent and/or secondary vascular active agent and/or other biological agent 240 into body passageway A.
- Balloon 250 can be used to both deliver compound 210 and expand the stent 200 , or be used in conjunction with another balloon or stent expanding device.
- the vascular active agent includes one or more PDGF inhibitors, local delivery of the inhibitor by a stent and/or via a balloon is highly advantageous.
Abstract
Description
- The present application is a continuation-in-part of co-pending U.S. patent application Ser. No. 10/039,816 filed Oct. 26, 2001 entitled “Irradiated Stent Coating”, which in turn is a continuation-in-part of co-pending U.S. patent application Ser. No. 09/771,073 filed Jan. 29, 2001 entitled “Improved Expandable Graft”, which in turn is a continuation-in-part of co-pending U.S. patent application Ser. No. 09/273,736 filed Mar. 22, 1999 entitled “Improved Expandable Graft”, which in turn claims priority on U.S. Provisional Patent Application Serial No. 60/081,824 filed Apr. 15, 1998. The present application is also a continuation-in-part of co-pending U.S. patent application Ser. No. 10/039,816 filed Oct. 26, 2001 entitled “Irradiated Stent Coating”, which in turn is a continuation-in-part of co-pending U.S. patent application Ser. No. 09/771,073 filed Jan. 29, 2001 entitled “Improved Expandable Graft”, which in turn is a continuation-in-part of U.S. patent application Ser. No. 09/363,052 filed Jul. 29, 1999 entitled “Coated Intraluminal Graft”, now U.S. Pat. No. 6,206,916, which in turn claims priority on U.S. Provisional Patent Application Serial No. 60/094,250 filed Jul. 27, 1998.
- This invention relates to an implant for use within a body and, more particularly, an expandable stent which is particularly useful for repairing various types of body passageways, and even more particularly to an expandable stent that includes and/or is at least partially coated and/or a impregnated with one or more biological agents which stent and one or more biological agents are useful in repairing blood vessels narrowed or occluded by disease. Although the present invention is particularly applicable to stents, the biological agent delivery system of the present invention can be used in conjunction with various types of implants such as, but not limited to, prosthetic devices. As such, the biological agent delivery system can form one or more components of other types of implants and/or be coated and/or impregnated onto at least a portion of other types of implants to deliver one or more biological agent to a particular site. Furthermore, the biological agent delivery system can be used in conjunction with, or used separate from, a stent and/or other types of implants to deliver a biological agent into a body cavity, organ or other part of the body. In addition, the present invention is particularly directed for use in humans; however, the present invention can be used in animals and some types of plants.
- U.S. Pat. Nos. 4,733,665; 4,739,762; 5,195,984; 5,725,572; 5,735,871; 5,755,781; 5,853,419; 5,861,027; 6,007,573; 6,059,810; 6,099,561; 6,200,337; 6,206,916; and 6,379,379; and U.S. patent application Ser. Nos. 09/273,736 filed Mar. 22, 1999; 09/771,073 filed Jan. 29, 2001; and 10/039,816 filed Oct. 26, 2001; and PCT Patent Application No. WO 99/56663 are incorporated herein by reference to illustrate various types and configurations of stents, the process or method of manufacturing stents, and the method by which such stents are used. U.S. Pat. Nos. 5,102,417; 5,355,832; 5,447,799; 5,464,650; 5,578,075; 5,616,608; 5,679,400; 5,716,981; 5,733,925; 5,916,585; 5,981,568; 6,120,847; 6,156,373; 6,206,916; 6,258,121; 6,273,913; 6,287,628; 6,299,604; 6,306,421; 6,322,847; 6,368,658; and 6,379,379; U.S. patent application Ser. Nos. 09/273,736 filed Mar. 22, 1999; 09/771,073 filed Jan. 29, 2001; and 10/039,816 filed Oct. 26, 2001; and PCT Patent Application Nos. WO 90/13332; WO 91/12779; WO 99/56663; and WO 01/17577 are incorporated herein by reference to illustrate various biological agents that can be coated onto stents, coating compositions that can be used to coat various biological agents onto stents, and/or coating techniques used to coat coatings onto stents. The disclosed biological agents are merely a few examples of the biological agents that can be used in the present invention.
- Heart disease is still one of the most prevalent medical ailments in the world. Intraluminal endovascular grafting, a type of angioplasty procedure, has been demonstrated by experimentation to present a possible alternative to conventional vascular surgery and is used to treat heart disease. Intraluminal endovascular grafting involves a tubular prosthetic graft or stent and delivery within the vascular system. As defined herein, the terms “graft” and “stent” are used interchangeably. Advantages of this method over conventional vascular surgery include obviating the need for surgically exposing, incising, removing, replacing, or bypassing the defective blood vessel. Over 20 million angioplasty or related procedures involving occluded vasculature have been preformed worldwide. About 30% of these angioplasties fail within 30 days. These failures typically require the procedure to be repeated.
- Several years ago, a product called a stent, named after Charles Stent, was introduced for use in angioplasty procedures. The stent reduced the angioplasty failure rate to about 15 percent. A stent is an expandable metal tubular device that is mounted over an angioplasty balloon and deployed at the site of coronary narrowing. The balloon is inflated to expand the stent to physically open and return patency to the body passageway. After the stent is expanded, the balloon is deflated and removed and the stent is permanently disposed to retain the opened body passageway. The first generation of expandable stents did not offer a controllable radial expansion. An improved stent disclosed in U.S. Pat. No. 4,733,665 overcame the problem associated with controlled stent expansion. However, prior art stents still do not provide control over the final, expanded configuration of the stent. For instance, the expansion of a particular coiled, spring-type stent is predetermined by the method of manufacture, material, and/or delivery system. In the case of self-expanding intraluminal stents formed of a heat sensitive material which expands upon exposure to core body temperature, the amount of expansion is predetermined by the heat expansion properties of the particular alloy utilized in the manufacture of the intraluminal stent. Consequently, once the foregoing types of intraluminal stents were expanded at the desired location within a body passageway, the expanded size of the stent could not be increased. If the proposed expanded diameter of the narrow body passageway was not determined correctly, the stent might not expand enough to contact the interior surface of the body passageway so as to be secured thereto and/or not expand the body passageway to the desired diameter. The stent disclosed in the '665 patent overcame the problems associated with these past stent designs.
- The stent based upon the '665 patent is currently being used in angioplasty procedures. Stents, including the stent of the '665 patent, are presently used in approximately 30-60 percent of all angioplasty procedures. However, these stents have several shortcomings which contribute to procedural failure rates. The currently used stents are not readily visible under fluoroscopic guidance procedures. Stent placement is hindered as a result of poor visibility. As a result, precise positioning of the stent during the insertion procedure was difficult to achieve. Consequently, the stent could be inadvertently positioned in the wrong or non-optimal location in the body passageway. These stents also shorten longitudinally after radial expansion, which is not desirable for their intended use. The shortening of the stent resulted in longitudinal movement of the stent during expansion, which sometimes resulted in the stent being fully expanded in the wrong or non-optimal position. One stent design was proposed in U.S. Pat. No. 5,853,419. The stent included a hexagon in the side wall of the stent which theoretically resulted in the stent retaining its longitudinal length during expansion. The stent also included ends that flared outwardly. However, in practice, the stent does not expand as described in the '419 patent. Due to the hexagonal configuration of the openings in the stent, the struts that form the hexagonal configuration cause the ribs of the hexagonal configuration to bend, buckle or twist when the struts are being expanded, thus resulting in a reduction in the longitudinal length of the stent. The bending, buckling or twisting of the ribs can only be avoided if the struts are made of a very flexible or bendable material; however, the use of such material compromises the strength of the stent. Not only does the stent not retain its longitudinal length, the complex stent design is both difficult to manufacture and to uniformly expand in a body passageway.
- The improved stent disclosed in U.S. patent application Ser. No. 09/273,736 filed Mar. 22, 1999, which is incorporated herein by reference, overcomes these past problems with stents. The patent application discloses an improved stent that can be coated with one or more substances in various regions of the stent to improve the visibility of the stent by various techniques (e.g. fluoroscopy) during the insertion procedure, thereby improving the positional accuracy of the stent in the body passageway. The improved stent also incorporates a unique design which enables the stent to retain its original longitudinal length during expansion. The improved stent also is easier to manufacture and substantially uniformly expands in the body passageway.
- Although the improved stent overcomes the deficiencies of prior art stents with respect to accurate stent positioning, problems can still exist with respect to tissue damage by the stent during insertion and/or expansion of the stent. The two ends of prior art stents typically include one or more rough, sharp and/or pointed surfaces. These surfaces can cause irritation and/or damage to surrounding tissue as the stent is moved within the body passageways. Such irritation or damage to the surrounding tissue can create various types of complications during the surgical procedure. These surfaces can also cause damage to surrounding tissue during the expansion of the stent. During stent expansion, the middle of the stent is first expanded by the angioplasty balloon. As the middle of the stent expands, the ends of the stent move toward one another. This movement of the ends can result in the stent ends digging into and/or penetrating the surrounding tissue. Furthermore, tissue damage can result when the end portions of the stent are eventually expanded by the angioplasty balloon. Stent designs that have flared out ends can also cause damage to tissue during insertion of the stent and expansion of the stent. U.S. patent application Ser. No. 09/771,073 filed Jan. 29, 2001, which is incorporated herein by reference, includes a stent design that overcomes or minimizes tissue damage by the stent during stent insertion and stent expansion. The stent includes rounded and/or smooth edges for the end portions of the stent.
- Several problems can develop after the stent is inserted into a body passageway. One problem is known as in-stent restenosis wherein the body passageway, which has been previously treated with a stent, renarrows or closes within the stented segment. The renarrowing or closure of the body passageway can be caused by a structural failure of the stent due to contractive forces by the body passageway on the stent and/or by the body passageway growing into the openings in the stent. Other problems can include vascular narrowing and restenosis. Vascular narrowing is defined as a vascular segment that has not been previously treated by any interventional means and eventually closes, thereby preventing a fluid body passageway. Restenosis is the renarrowing of a previously treated vascular segment not involving a stent. Both of these problems are the result of a body passageway that was not treated with an invasive angioplasty, narrowing or closing, and from the insertion of a stent in one portion of the body passageway causing vascular narrowing or restenosis in another part of the body passageway. Vascular narrowing, restenosis and in-stent restenosis are caused by biological factors causing the premature closing of the body passageways. One such biological factor is platelet derived growth factor, referred to as PDGF. PDGF is an intercellular messenger capable of stimulating proliferation of smooth muscle cells. Smooth muscle cells are known to migrate within body passageways such as arteries and cause a restenotic reaction.
- The problems with vascular narrowing, restenosis and in-stent restenosis are significantly overcome by the use of one or more drugs. U.S. Pat. No. 6,206,916 entitled “Coated Intraluminal Graft,” which is incorporated herein by reference, discloses the use of a drug coated on at least a portion of the stent to inhibit or prevent the occurrence of in-stent restenosis, vascular narrowing and/or restenosis. Although the intravenous use of drugs and/or the coating of the stent with drugs can inhibit or prevent the occurrence of in-stent restenosis, vascular narrowing and/or restenosis, the continued need for the drugs after the stent has been inserted can require the patient to be retained in the hospital for extended periods of time. Furthermore, in-stent restenosis, vascular narrowing and/or restenosis may occur days or weeks after the stent insertion procedure and after intravenous use of drugs has terminated and/or the drug coating on the stent has been dissolved off the stent. Several other United States patents disclose the use of various drugs coated on stents. For example, U.S. Pat. No. 5,716,981, which is incorporated herein by reference, discloses the use of paclitaxel or an analog or derivative thereof for use on a stent. U.S. Pat. Nos. 5,733,925 and 5,981,568, which are incorporated herein by reference, disclose the use of taxol or a water soluble taxol derivative; cytochalasin or analog thereof; or other type of cytoskeletal inhibitor for use on a stent. Several United States patents also disclose the use of polymers to bind the various drugs to the surface of the stent. Several of these polymers are disclosed in U.S. Pat. Nos. 5,578,075 and 5,679,400, which are incorporated herein by reference. U.S. Pat. No. 5,464,650, which is incorporated herein by reference, discloses the method of applying several coatings of a polymer that has been mixed with a drug so as to control the delivery of the drug in a body over a period of time. The method of coating the stent involves a series of steps that significantly increases the cost, complexity and time for the manufacture of the stent.
- In view of the present stent technology, there is a need and demand for a stent that has improved procedural success rates, has higher visibility under fluoroscopy in vivo, retains its longitudinal dimensions from its original pre-expanded configuration to its expanded configuration, minimizes damage to tissue during insertion and expansion of the stent, inhibits or prevents the occurrence of in-stent restenosis, vascular narrowing and/or restenosis long after the stent has been inserted into a body passageway, and is simple and cost effective to manufacture.
- This invention pertains to an improved expandable stent designed to meet the present day needs and demands relating to stents. The present invention is directed to a stent and will be particularly described with respect thereto; however, the present invention has much broader scope and can be applied in part to a wide variety of implants (e.g., prosthetic implants, heart pacers, organ implants, and/or other electronic and/or mechanical implants). The stent has a body member that includes first and second ends and a wall surface disposed between the first and second ends. The wall surface is typically formed by a plurality of intersecting elongated members, and at least some of the elongated members typically intersect with one another at a point intermediate to the first and second ends of the body member. Alternatively, or in addition, the wall surface includes one or more slots. The body member has a first cross-sectional area which permits delivery of the body member into a body passageway, and a second, expanded cross-sectional area. As defined herein, the term “body passageway” means any passageway or cavity in a living organism, including humans, animals and plants. A “body passageway” in an animal or human includes, but is not limited to, the bile duct, bronchiole tubes, nasal cavity, blood vessels, heart, esophagus, trachea, stomach, fallopian tube, uterus, ureter, urethra, the intestines, lymphatic vessels, nasal passageways, eustachian tube, acoustic meatus, and/or the like. The invention when used in association with stents is particularly applicable for use in blood vessels, and will hereinafter be particularly described with reference thereto. The expansion of the stent body member can be accomplished in a variety of manners. Typically, the body member is expanded to its second cross-sectional area by a radially, outwardly extending force applied at least partially from the interior region of the body member. Alternatively or additionally, the body member can include heat sensitive materials that expand upon exposure to heat. The second cross-sectional area of the stent can be fixed or variable. When the second cross-sectional area is variable, the second cross-sectional area is typically dependent upon the amount of radially outward force applied to the body member. Generally, the body member is expanded so as to expand at least a portion of the body passageway while retaining the original length of the body member. In one particular body member design, the first cross-sectional shape of the body member is substantially uniformly circular so as to form a substantially tubular body member; however, the body member can have other cross-sectional shapes such as, but not limited to, elliptical, oval, polygonal, trapezoidal, and the like. As can be appreciated, the cross-sectional shape of the body member can be uniform or non-uniform in the first and/or second cross-sectional shape. In addition, if more than one body member is included in a stent, all the body members can have substantially the same size and shape, or one or more of the body members can have a different size and/or shape from one or more other body members.
- Another and/or alternative feature of the present invention is that the stent includes a plurality of elongated members wherein one or more elongated members is a wire. In one embodiment of the present invention, the elongated members include a plurality of wires wherein the two or more of the wires are secured to one another where a plurality of wires intersect with one another. Two or more of the wires can be connected together by a variety of techniques such as, but not limited to, welding, soldering, brazing, adhesives, lock and groove configurations, snap configurations, melting together the wires, and the like. In another and/or alternative embodiment of the present invention, the body member is at least partially in the form of a wire mesh arrangement. In one aspect of this embodiment, the wire mesh arrangement is utilized as the stent. In another and/or alternative aspect of this embodiment, the wire mesh arrangement is designed to be expanded to a second diameter within the body passageway. In one non-limiting design, the second expanded diameter is variable and determined by the desired expanded internal diameter of the body passageway. In another and/or alternative design, the second expanded diameter is selected so that the expanded wire mesh arrangement will not or substantially not migrate from the desired location within the body passageway. In still another and/or alternative non-limiting design, the expansion of the stent does not or substantially does not cause a rupture of the body passageway. In still another and/or alternative embodiment of the present invention, the plurality of wires forms a plurality of polygonal shaped regions on the body of the stent. In one aspect of this embodiment, the polygonal regions are aligned along the longitudinal axis of the body of the stent. In another and/or alternative aspect of this embodiment, the body of the stent includes a plurality of polygonal regions that are aligned along the longitudinal axis and lateral axis of the stent body. In one non-limiting design, the plurality of polygonal regions aligned along the longitudinal axis of the stent body are oriented substantially the same with respect to one another, and the plurality of polygonal regions aligned along the lateral axis are oriented differently from one another. In another and/or alternative non-limiting design, the polygonal regions that are aligned along the same longitudinal axis have a top that lies in the same longitudinal axis and have a bottom that lies in the same longitudinal axis, and the polygonal regions that are aligned along the same latitudinal axis have sides that do not lie in the same latitudinal axis; however, alternating polygonal regions have sides that are substantially parallel to one another. In still another and/or alternative non-limiting design, the side wall of at least one body member includes an even number of polygonal regions about the peripheral surface of the body member. In yet another and/or alternative embodiment of the present invention, the polygonal shape, upon expansion, retains the original longitudinal length of the body of the stent. In one aspect of this embodiment, a plurality of polygonal shapes have a substantially parallelogram shape. In another and/or alternative aspect of this embodiment, the body member includes about 2-15 polygonal shapes along the longitudinal length of the body member, typically about 2-10 polygonal shapes, and more typically about 2-8 polygonal shapes; however, more polygonal shapes can be used depending on the shape and/or size of the body member.
- Yet another and/or alternative feature of the present invention is that the stent includes a plurality of elongated members wherein one or more elongated members is a thin bar. In one embodiment of the present invention, the elongated members include a plurality of thin bars wherein two or more of the thin bars are secured to one another where a plurality of bars intersect with one another. Two or more of the thin bars can be connected together by a variety of techniques such as, but not limited to, welding, soldering, brazing, adhesives, lock and groove configurations, snap configurations, melting together the thin bars, and the like. In still another and/or alternative embodiment of the present invention, the plurality of thin bars forms a plurality of polygonal shaped regions on the body of the stent. In one aspect of this embodiment, the polygonal regions are aligned along the longitudinal axis of the body of the stent. In another and/or alternative aspect of this embodiment, the body of the stent includes a plurality of polygonal regions that are aligned along the longitudinal axis and lateral axis of the stent body. In one non-limiting design, the plurality of polygonal regions aligned along the longitudinal axis of the stent body are oriented substantially the same with respect to one another, and the plurality of polygonal regions aligned along the lateral axis are oriented differently from one another. In another and/or alternative non-limiting design, the polygonal regions that are aligned along the same longitudinal axis have a top that lies in the same longitudinal axis and have a bottom that lies in the same longitudinal axis, and the polygonal regions that are aligned along the same latitudinal axis have sides that do not lie in the same latitudinal axis; however, alternating polygonal regions have sides that are substantially parallel to one another. In still another and/or alternative aspect of this embodiment, the side wall of at least one body member includes an even number of polygonal regions about the peripheral surface of the body member. In yet another and/or alternative embodiment of the present invention, the polygonal shape, upon expansion, substantially retains the original longitudinal length of the body of the stent. In one aspect of this embodiment, a plurality of polygonal shapes have a substantially parallelogram shape. In another and/or alternative aspect of this embodiment, the body member includes about 2-15 polygonal shapes along the longitudinal length of the body member, typically about 2-10 polygonal shapes, and more typically about 2-8 polygonal shapes; however, more polygonal shapes can be used depending on the shape and/or size of the body member.
- Still yet another and/or alternative feature of the present invention is that the side wall of at least one body member of the stent includes a plurality of elongated members that are arranged to form at least one polygonal shape. In one embodiment of the present invention, the polygonal shape, upon expansion, retains the original longitudinal length of the body of the stent. In one aspect of this embodiment, a plurality of polygonal shapes have a substantially parallelogram shape. In another and/or alternative aspect of this embodiment, the body member of the stent is formed from a flat piece of material. On the surface of the flat material there are formed a plurality of polygonal shaped regions. The flat material is rolled or otherwise formed and the side edges of the flat material are connected together to form the stent. The side edges of the flat material can be connected together by a variety of techniques such as, but not limited to, welding, soldering, brazing, adhesives, lock and groove configurations, snap configurations, melting together the edges, and the like. The polygonal regions in the flat material can also be formed by a variety of techniques such as, but not limited to, mechanical cutting, laser cutting, etching, molding, stamping, and/or the like. In one non-limiting design, the polygonal regions are aligned along the longitudinal axis of the flat material. In another and/or alternative non-limiting design, the flat material includes a plurality of polygonal regions aligned along the longitudinal axis and lateral axis of the flat material. In still another and/or alternative non-limiting design, the plurality of polygonal regions aligned along the longitudinal axis of the flat material are oriented substantially the same with respect to one another, and the plurality of polygonal regions aligned along the lateral axis are oriented differently from one another. In yet another and/or alternative non-limiting design, the polygonal regions that are aligned along the same longitudinal axis have a top that lies in the same longitudinal axis and have a bottom that lies in the same longitudinal axis, and the polygonal regions that are aligned along the same latitudinal axis have sides that do not lie in the same latitudinal axis; however, alternating polygonal regions have sides that are substantially parallel to one another. In still yet another and/or alternative non-limiting design, the side wall of at least one body member includes an even number of polygonal regions about the peripheral surface of the body member. In a further and/or alternative non-limiting design, the body member includes about 2-15 polygonal shapes along the longitudinal length of the body member, typically about 2-10 polygonal shapes, and more typically about 2-8 polygonal shapes; however, more polygonal shapes can be used depending on the shape and/or size of the body member.
- Another and/or alternative feature of the present invention is that the side wall of at least one body member of the stent includes at least one set of slots. In one embodiment of the present invention, the one or more sets of slots are arranged to substantially maintain the original longitudinal length of the body member when the body member is expanded. In one aspect of this embodiment, the body member of the stent is formed from a substantially flat single piece of material. On the surface of the flat material there is formed a plurality of slots. The flat material is rolled or otherwise formed and the side edges of the flat material are connected together to form the stent. The side edges of the flat material can be connected together by a variety of techniques such as, but not limited to, welding, soldering, brazing, adhesives, lock and groove configurations, snap configurations, melting together the edges, and the like. The slots in the flat material can also be formed by a variety of techniques such as, but not limited to, mechanical cutting, laser cutting, etching, molding, stamping, and/or the like. In another and/or alternative embodiment of the present invention, at least one set of slots forms substantially a V-shape when the body member is unexpanded. In one aspect of this embodiment, body portion includes a plurality of V-shapes. In one non-limiting design of this aspect, a plurality of V-shapes are aligned along the longitudinal axis of the side wall of the body member and are positioned in a partial stacked position with respect to one another to form a set of V-shapes. Generally, the body member includes about 2-20 V-shapes in each set of V-shapes, typically about 2-10 V-shapes, and more typically about 2-5 V-shapes; however, more V-shapes per set can be used depending on the shape and/or size of the body member. In another and/or alternative non-limiting design, a plurality of V-shapes are aligned along the latitudinal axis of the side wall of the body member. In still another and/or alternative non-limiting design, at least a plurality of the V-shapes are substantially equally spaced from one another. In yet another and/or alternative non-limiting design, an even number of V-shapes are aligned along the latitudinal axis of the side wall of the body member. In still yet another and/or alternative non-limiting design, at least a plurality of V-shapes have substantially the same angle when the body member is unexpanded. In a further and/or alternative non-limiting design, the angle formed by the V-shapes is between 0-90° when the body member is unexpanded, typically about 10-75°, and more typically about 15-60°, and even more typically about 15-45°. In still a further and/or alternative non-limiting design, a plurality of slots have a length dimension that is at least about twice as great as the width dimension of the slot when the body member is unexpanded, and typically at least about 3 times as great, and more typically at least about 5 times as great, and even more typically at least about 10 times as great, and still even more typically at least about 15 times as great. In yet a further and/or alternative non-limiting design, a plurality of V-shapes in a set of V-shapes are oriented in the same direction with respect to one another and oriented such that the base of one V-shape is positioned from the base of an adjacent V-shape a distance that is at least about 15% of the length of the legs of the V-shaped slot, typically about 15-80% of the length of the slots forming a leg of the V-shape, typically about 20-60% of the length of the leg of the V-shape, and even more typically about 30-50% of the length of the leg of the V-shape. In still yet a further and/or alternative non-limiting design, a plurality of slots have a substantially oval shape. In another and/or alternative non-limiting design, at least a plurality of slots that form the V-shape do not intersect with one another. In one particular design, none of the slots that form the V-shape intersect with one another.
- Still another and/or alternative feature of the present invention is that the body member has a biocompatible coating that is coated and/or impregnated on at least a portion of its wall surface. The biocompatible coating can be used to reduce inflammation, infection, irritation and/or rejection of the stent. In one embodiment of the present invention, the biocompatible coating includes, but is not limited to, a metal coating. In one aspect of this embodiment, the metal coating is plated on at least a portion of the stent. In another and/or alternative aspect of this embodiment, the metal coating includes, but is not limited to, gold, platinum, titanium, nickel, tin, or combinations thereof. In another and/or alternative embodiment of the present invention, the biocompatible coating includes, but is not limited to, a polymer and/or a copolymer coating. In one aspect of this embodiment, the polymer and/or a copolymer coating includes, but is not limited to, polytetrafluoroethylene, polyethylene, poly(hydroxyethly methacrylate), poly(vinyl alcohol), polycaprolactone, poly(D, L-lactic acid), poly(L-lactic acid), poly(lactide-co-glycolide), poly(hydroxybutyrate), poly(hydroxybutyrate-co-valerate), polydioxanone, polyorthoester, polyanhydride, poly(glycolic acid), poly(glycolic acid-cotrimethylene cabonate), polyphosphoester, polyphosphoester urethane, poly(amino acids), cyanoacrylates, poly(trimethylene carbonate), poly(iminocarbonate), copoly(ether-esters), polyalkylene oxalates, polyphosphazenes, polyiminocarbonates, aliphatic polycarbonates, polyethylene oxide, polyethylene gylcol, poly(propylene oxide), polyacrylamides, polyacrylic acid (30-60% solution), polymethacrylic acid, poly(N-vinyl-2-pyrollidone), polyurethanes, poly(aminoacid), cellulosic polymers (e.g. sodium carboxymethyl cellulose, hydroxyethyl celluslose), collagens, carrageenan, alginate, starch, dextrin, gelatins, poly(lactide), poly(glycolide), polydioxanone, polycaprolactone, polyhydroxybutyrate, poly(phospazazene), poly(phosphate ester), poly(lactide-co-glycolide), poly(glycolide-co-trimethylene carbonate), poly(glycolide-co-caprolactone), polyanhydrides, polyamides, polyesters, polyethers, polyketones, polyether elastomers, parylene, polyether amide elastomers, polyacrylate-based elastomers, polyethylene, polypropylene, and/or and derivatives thereof. In one aspect of this embodiment, the polymer and/or copolymer is substantially non-biodegradable so as to substantially maintain its fluction throughout most or all of the useful life of the stent. In another and/or alternative aspect of this embodiment, one or more polymers are at least partially coated onto the surface of the stent by a process disclosed in U.S. Pat. Nos. 5,355,832 and 5,447,799, which are incorporated herein by reference. In still another and/or alternative embodiment of the present invention, the biocompatible coating includes, but is not limited to, living cells. In yet another and/or alternative embodiment of the invention, the coating layer has a thickness in a range from about 50 to 500,000 Angstroms (Å), and typically in the range from about 100,000 to 500,000 Å.
- Still yet another and/or alternative feature of the present invention is that the stent, upon expansion, substantially maintains its original longitudinal length. In one embodiment of the present invention, the stent, upon expansion, substantially maintains its original longitudinal length throughout the expansion of the stent.
- Another and/or alternative feature of the present invention is that the stent includes at least two body members that are connected together by at least one connector member that allows transverse bending and flexibility invariant to the plane of bending. In one embodiment of the present invention, the connector member includes a non-linear portion. In one aspect of this embodiment, the connector member is at least partially V-shaped member (e.g., V-shaped, N-shaped, and/or M-shaped, W-shaped, X-shaped, Y-shaped, Z-shaped, etc.) and/or U-shaped (e.g., U-shaped, S-shaped, etc.) member. In another and/or alternative embodiment of the present invention, the two body members are connected together by a plurality of connectors. In one aspect of this embodiment, two or more of the connectors are spaced at substantially equal distances from one another. In another and/or alternative aspect of this embodiment, two or more of the connectors are substantially symmetrically oriented from one another. In still another and/or alternative aspect of this embodiment, at least three connectors connect together two body members, and typically about 3-20 connectors connect together two body members, and even more typically about 3-10 connectors connect together two body members. In still another and/or alternative embodiment of the present invention, the size of the connector is limited so as not to interfere with the proper expansion of the stent. In one aspect of this embodiment, the substantially V-shaped or U-shaped member has a height that is less than about five times the maximum height of a polygonal shape in the unexpanded stent, and typically less than about three times the maximum height of a polygonal shape in the unexpanded stent, and more typically less than about two times the maximum height of a polygonal shape in the unexpanded stent, and even more typically less than about 1.75 times the maximum height of a polygonal shape in the unexpanded stent, and yet even more typically less than about 1.5 times the maximum height of a polygonal shape in the unexpanded stent, and still yet even more typically less than about 1.3 times the maximum height of a polygonal shape in the unexpanded stent. In another and/or alternative aspect of this embodiment, the substantially V-shaped or U-shaped member has a height that is less than about 1.5 times the maximum width of the V-shape in the unexpanded stent, and typically less than about 1.0 times the maximum width of the V-shape in the unexpanded stent, and more typically less than about 0.75 times the maximum width of the V-shape in the unexpanded stent, and even more typically less than about 0.65 times the maximum width of the V-shape in the unexpanded stent, and yet typically less than about 0.5 times the maximum width of the V-shape in the unexpanded stent, and still yet more typically less than about 0.4 times the maximum width of the V-shape in the unexpanded stent.
- Yet another and/or alternative feature of the present invention is that the body member is made of and/or includes a material that is visible under fluoroscopy in vivo. The material to increase visibility includes, but is not limited to, metals, polymers and/or copolymers. In one embodiment of the present invention, the material to increase visibility is adhered to the surface of at least a portion of the stent by coating, plating, mounting, welding and/or braising. In another and/or alternative embodiment of the present invention, the material to increase visibility is secured to the stent so as to principally come in contact with the inner luminal surface of the body passageway. For instance, when the stent is inserted into a blood vessel, the material to increase visibility primarily contacts the inner luminal surface of the blood vessel and not any blood-borne components that could accelerate stent failure rates. In one aspect of this embodiment, the material to increase visibility is at least partially located on at least one end, and typically both ends, of at least one body member. This positioning of the material on the body member helps to identify the location of the ends of the body member and the stent as a whole, thus enhancing the critical placement of the stent so as to reduce the failure rate. In another and/or alternative aspect of this embodiment, the material to increase visibility is at least partially located on the outer surface of the body member at one or more connector members of the stent. This location of the material at one or more connector members enhances the critical placement of the stent around areas of high tortuosity so as to reduce the failure rate. In still another and/or alternative embodiment of the present invention, the material to increase visibility includes gold, gold alloy, and/or tantalum, etc. In one aspect of this embodiment, the gold and/or gold alloy is plated on at least a portion of the stent.
- Still another and/or alternative feature of the present invention is that the stent material is treated with gamma, beta and/or e-beam radiation to reduce the vascular narrowing of the stented section. The radiation treatment can inactivate the cell migration and properties thereof within a 3 mm depth of the arterial wall. The radiation treatment can further and/or alternatively sterilize the stent to reduce infection when the stent is inserted into a body passageway.
- Another and/or alternative feature of the present invention is that the stent can be inserted and expanded by standard procedures. The stent is designed so it can be inserted into a body passageway until it is disposed at the desired location within the body passageway. The stent can then be radially expanded outwardly into contact with the body passageway until the body passageway, at the desired location, has been expanded, whereby the stent inhibits or prevents the body passageway from collapsing. In one embodiment of the present invention, the stent is at least partially expanded by an angioplasty balloon.
- Still another and/or alternative feature of the present invention is a stent that includes rounded, smooth and/or blunt surfaces that minimize and/or prevent damage to body passageways as the stent is inserted into a body passageway and/or expanded in a body passageway. The modified end surfaces are designed to reduce the cutting and/or piercing of tissue as the stent is positioned in and/or expanded in a body passageway. Typically, the path from the point of entry into a body passageway, and the final position of the stent in the body passageway, are not straight. As a result, the stent is caused to be weaved through the body passageway to reach the final position in the body passageway. This weaving of the stent can result in the front ends, back ends, and/or side walls of the stent to cut, scrape or otherwise damage tissue in the body passageway as the stent is moved in the body passageway. The rounding, smoothing and/or blunting of the surfaces significantly reduces possible damage to the tissue. Damage to the tissue in the body passageway can also occur during the expansion of the stent. The rounding, smoothing and/or blunting of the surfaces likewise significantly reduces possible damage to the tissue during the expansion of the stent. In one embodiment of the present invention, the rounding, smoothing and/or blunting of the surfaces can be accomplished by a number of different procedures. Some of these procedures include, but are not limited to, buffing, grinding, and/or sanding the surfaces. In another and/or alternative embodiment of the present invention, the surfaces of the stent are smoothed by coating and/or impregnating the stent with one or more metals or compounds. In one aspect of this embodiment, at least a portion of the stent is coated and/or impregnated with a polymer and/or copolymer so as to reduce or eliminate the sharp, rough, and/or pointed surfaces on the stent.
- A further and/or alternative feature of the present invention is that the stent is at least partially coated and/or impregnated with one or more vascular active agents that inhibit and/or reduce restenosis, vascular narrowing and/or in-stent restenosis. In one embodiment of the present invention, at least one of the vascular active agents affects and/or alters tissue contraction and/or expansion to inhibit and/or reduce restenosis, vascular narrowing and/or in-stent restenosis. Prior substances have been coated onto stents to address one or more problems associated with the use of stents. These substances include aspirin, heparin, colchicine and dexamethazone, among others. These substances are used to inactivate platelets, stop cell division and prevent cell adhesion. The problems associated with the use of these substances have varied effects. Heparin is not potent enough to extend a clinical effect. Colchicine has been shown to kill the cells in the surrounding area and actually propagate the problem. Dexamethazone has not provided the desired restenosis prevention. As defined herein, the term “vascular active agent” is defined as a substance other than aspirin, colchicine, dexamethazone, or heparin. The vascular active agent is formulated to inhibit, reduce, and/or prevent restenosis, vascular narrowing and/or in-stent restenosis in a body passageway. As can be appreciated, the vascular active agent can be used independent of or in combination with a “secondary vascular active agent.” In another and/or alternative embodiment of the present invention, the secondary vascular active agent includes, but is not limited to, an agent that inhibits, reduces, and/or prevents thrombosis. Such agent can include, but is not limited to, antithrombotic compounds, anti-platelet compounds, and/or anti-coagulant compounds. In addition, the “secondary vascular active agent” can include compounds that include, but are not limited to, metabolic inhibitors, antineoplastics, proliferation inhibitors, cytotoxic compounds, antiplatelets, anti-coagulants, fribrinolytics, thrombin inhibitors, antimitotics, anti-inflammatory compounds, radioactive isotopes, and/or anti-tumor compounds. Furthermore, the “secondary vascular active agent” can include, but is not limited to, DNA, plasmid DNA, RNA, plasmid RNA, ACE inhibitors, growth factors, cholesterol-lowering agents, vasodilating agents, oligonucleotides, and/or anti-sense oligonucleotides. Specific secondary vascular active agents that can be used include, but are not limited to, aspirin, colchicine, heparin, glucocorticoids (e.g. dexamethazone, betamethazone), hirudin, tocopherol, angiopeptin, D-Phe-ProArg chloromethyl ketone, and/or derivatives of these compounds. Heretofore, Applicant is unaware of stents being coated and/or impregnated with a combination of at least one vascular active agent and at least one secondary vascular active agent. In addition, Applicant is unaware of stents being coated and/or impregnated with a combination of two or more secondary vascular active agents. Although the prior use of a single secondary vascular active agent has not resolved problems associated with in-stent restenosis, vascular narrowing and/or restenosis, the combination of two or more of these compounds coated and/or impregnated on the stent can provide better results. The scope of this invention encompasses the concept of at least partially coating and/or impregnating the stent with two or more secondary vascular active agents by themselves or in combination with one or more vascular active agents. In one aspect of this embodiment, the vascular active agent includes a compound that at least partially inhibits PDGF activity in the body passageway. After a stent is inserted into a body passageway, the stent may induce some irritation in the body passageway. The biological factor, PDGF, is turned on due to such irritation and activates the components of clotting. These components can cause clotting in the stent area or in adjacent areas. This clotting can cause the body passageway to narrow or ultimately close. At least one or more substances coated and/or impregnated onto the stent are formulated to deactivate and/or inhibit the activity of the PDGF, thereby reducing the occurrence of in-stent restenosis, vascular narrowing and/or restenosis. In another and/or alternative aspect of this embodiment, at least one of the vascular active agents that is at least partially coated and/or impregnated onto the stent to inhibit PDGF activity in the body passageway includes triazolopyrimidime (Trapidil), prostacyclin, and/or derivatives thereof. When the stent is inserted into a body passageway, some damage to the tissue of the body passageway can occur. For instance, a damaged endothelium exposes the connective tissue to platelet aggregation and to local release of PDGF. Numerous animal models have shown that platelet adhesion to the vascular wall of this damaged endothelium soon triggers the proliferation and migration of smooth muscle cells. If platelets are a source of PDGF, it has now been demonstrated that endothelial cells, macrophages and smooth muscle cells are also a source of PDGF following vascular trauma. The influence of Trapidil on platelet aggregation is linked to inhibition of the synthesis of thromboxane A2 and the partial blocking of thromboxane A2 receptors. Trapidil is able to normalize an incorrect balance between thromboxane A2 and prostacycline. Thromboxane A2 is a powerful inducer of platelet aggregation. Thromboxane A2 is also responsible for the contraction of smooth muscles or vessels and stimulates the proliferation of the arterial intimal cells. Prostacyclin also inhibits platelet aggregation and has vasodilator properties. Trapidil also has antithrombotic properties and can significantly reduce thrombosis induced by creation of an arteriovenous conduit, as compared to aspirin and dipyridamoles, which only had a modest effect. Trapidil has other desirable properties such as vasodilation, a decrease in angina and an increase in HDL levels in patients with ischemic heart disease. Trapidil also effectively inhibits restenosis. Trapidil has an affinity to exert clinical effects starting in the second hour of treatment. The platelet inhibition in the first day of treatment with Trapidil continues through the thirtieth day. The philosophy of a multifactorial approach, including but not limited to the increasing success of angioplasty and stent associated with a considerable reduction in complications, promotes the use of this technique in a large scale in the treatment of patients with coronary heart disease. Restenosis is one of the most important limitations to the long term benefits of angioplasty and a stent combination. A pharmacological approach aiming to intervene in the mechanism of restenosis is needed to supplement the mechanical approach of the revascularization procedure. Various approaches have been proposed for the prevention of restenosis. The use of drugs such as, but not limited to, Trapidil, delivered by a stent locally to the affected area satisfies this need. As can be appreciated, Trapidil can be used in combination with one or more other vascular active agents and/or in combination with one or more secondary vascular active agents. The amount of Trapidil coated and/or impregnated into the stent can be varied depending on the intended use of the stent and/or size of the stent. In still another and/or alternative embodiment of the present invention, the stent includes up to about 200 mg of Trapidil. In one aspect of this embodiment, the stent includes at least about 1 μg of Trapidil. In another and/or alternative aspect of this embodiment, the stent includes about 10 μg to about 50 mg of Trapidil. In still another and/or alternative aspect of this embodiment, the stent includes about 20 μg to about 10 mg of Trapidil.
- Still a further and/or alternative feature of the present invention is that the stent is at least partially coated and/or impregnated with one or more vascular active agents that promote blood vessel growth. The fully or partially blocked blood vessel and tissue about the fully or partially blocked blood vessel become oxygen starved due to the impaired flow of blood through the fully or partially blocked blood vessels. When a stent in inserted into the blood vessel to reestablish a more normal blood flow rate through the blood vessel, the region around the formerly fully or partially blocked blood vessel once again begins to receive a proper oxygen supply. However, prolonged oxygen starvation can damage the blood vessels and surrounding tissue to an extent that a substantial time period is required to naturally repair such damaged tissue. Furthermore, the formerly blocked or partially blocked blood vessel may be weaker resulting in further damage to the blood vessel once normal blood flow rates are reestablished. Many of these problems can be addressed by at least partially coating and/or impregnating the stent with one or more vascular active agents that promote blood vessel growth. One non-limiting blood vessel growth promoter that can be coated and/or, impregnated on the stent is granulo-cyte-macrophage colony-stimulating-factor (GM-CSF). GM-CSF has been found to simulate blood vessel growth even in oxygen starved environments. As can be appreciated, GM-CSF can be used in combination with one or more other vascular active agents and/or in combination with one or more secondary vascular active agents. The amount of GM-CSF coated and/or impregnated into the stent can be varied depending on the intended use of the stent and/or size of the stent. In one embodiment of the present invention, the stent includes up to about 200 mg of GM-CSF. In one aspect of this embodiment, the stent includes at least about 1 μg of GM-CSF. In another and/or alternative aspect of this embodiment, the stent includes about 10 μg to about 50 mg of GM-CSF. In still another and/or alternative aspect of this embodiment, the stent includes about 20 μg to about 10 mg of GM-CSF.
- Yet another and/or alternative feature of this invention corresponds to the local delivery of one or more vascular active agents to inhibit and/or prevent restenosis, vascular narrowing and/or in-stent restenosis including, but not limited to, Trapidil, and/or GM-CSF, through an angioplasty balloon with the physical capability to transfer solute of the vascular active agent through the angioplasty balloon membrane to the affected sight. As can be appreciated, a vascular active agent such as, but not limited to, Trapidil and/or GM-CSF, can be delivered alone and/or in combination with another vascular active agent and/or a secondary vascular active agent. This delivery can be in the form of a stream, a slow oozing delivery or a bolus injection. The delivery can be made through magnetic, electrical or physical arrangements. In one embodiment of the present invention, the delivery of a vascular active agent and/or secondary vascular active agent is accomplished through a separate passageway capable of channeling the solute of the vascular active agent and/or secondary vascular agent to the affected area. This delivery through an angioplasty balloon also delivers the vascular active agent and/or secondary vascular active agent to the sight of restenosis, vascular narrowing, in-stent restenosis, thrombosis and the like, and/or to the site to promote growth of blood vessels. In one aspect of this embodiment, the angioplasty balloon includes one or more slits or openings wherein the vascular active agent and/or secondary vascular active agent can stream, ooze or otherwise flow out of the angioplasty balloon and into the body passageway. The one or more slits and/or openings can be designed so as to allow the vascular active agent and/or secondary vascular active agent to exit the angioplasty balloon when the angioplasty balloon is in an expanded and unexpanded state. In one non-limiting design, the one or more slits and/or openings in the angioplasty balloon inhibit or prevent the vascular active agent and/or secondary vascular active agent from entering the body passageway when the angioplasty balloon is in the unexpanded state.
- Another and/or alternative feature of the present invention is that one or more vascular active agents and/or secondary vascular active agents are at least partially coated and/or impregnated totally on or partially on the stent. In one embodiment of the present invention, the thickness of the coating on the stent can be uniform or varied. Generally, the thickness of the coating is not as important as the concentration of the vascular active agent and/or secondary vascular active agent needed to acquire the desired affect. High concentrations of vascular active agents and/or secondary vascular active agents can be coated with thinner coatings, and lower concentrations of vascular active agents and/or secondary vascular active agents can be coated with thicker coatings. In one aspect of this embodiment, the coating thickness is less than or equal to the material that forms the stent. In another and/or alternative embodiment of the invention, the stent includes a single coating on specific regions of the stent or on the total surface of the stent. In one aspect of this embodiment, the composition of the coating on different regions of the stent is substantially the same. In another and/or alternative aspect of this embodiment, the composition of the coating on different regions of the stent is different. In still another and/or alternative embodiment of the present invention, the stent includes a multiple coatings on specific regions of the stent or on the total surface of the stent. In one aspect of this embodiment, the coating thicknesses are of the multiple coatings are substantially the same. In another and/or alternative aspect of this embodiment, the coating thickness of the two or more coatings is different. In still another and/or alternative aspect of this embodiment, the composition of the coatings is substantially the same. In yet another and/or alternative aspect of this embodiment, the composition of two or more coatings is different. In yet another and/or alternative embodiment of the present invention, one or more coatings are applied to the stent by vaporization, plasma deposition, ionization, dipping, brushing, and/or spraying. In still yet another and/or alternative embodiment of the invention, the vascular active agent and/or secondary vascular active agent is at least partially impregnated into the stent. The impregnation can be the result of a porous surface of the stent and/or the stent including one or more internal cavities. In one aspect of this embodiment, the stent is impregnated on specific regions of the stent or on the total surface of the stent. In another and/or alternative aspect of this embodiment, the stent is impregnated with the same compound. In still another and/or alternative aspect of this embodiment, the stent is impregnated with different compounds at different regions of the stent. In yet another and/or alternative aspect of this embodiment, the stent is impregnated with multiple compounds. In a further and/or alternative embodiment of the present invention, one or more compounds are impregnated in the stent by vaporization, ionization, dipping, brushing, and/or spraying.
- Still another and/or alternative feature of the present invention is that one or more vascular active agents and/or secondary vascular active agents are at least partially coated and/or impregnated onto the stent by the use of an intermediate compound. Typically, the intermediate compound is a synthetic biocompatible material that does not adversely affect the vascular active agent and/or secondary vascular active agent or cause problems or adverse reactions in the body passageway. In one embodiment of the present invention, the intermediate compound is biodegradable. In another and/or alternative embodiment of the present invention, the intermediate compound is non-biodegradable. In still another and/or alternative embodiment of the invention, the intermediate compound is at least partially coated and/or impregnated on specific regions of the stent or totally coats the stent. In one aspect of this embodiment, the thickness of the coating on the stent can be uniform or varied. The coating thickness can be used to control the amount of vascular active agent and/or secondary vascular active agent that is coated on the stent and/or to control the release rate of the vascular active agent from the stent. Thicker coating can hold more vascular active agent and/or secondary vascular active agent. Thicker coating can also increase the time of full release of the vascular active agent and/or secondary vascular active agent from the stent. In one particular non-limiting design, the coating thickness is less than or equal to the material that forms the stent. In another and/or alternative embodiment of the invention, the stent includes a single coating of intermediate compound on specific regions of the stent or on the total surface of the stent. In one aspect of this embodiment, the composition of the intermediate compound on different regions of the stent is substantially the same. In another and/or alternative aspect of this embodiment, the composition of the intermediate compound on different regions of the stent is different. In still another and/or alternative embodiment of the present invention, the stent includes a multiple coatings of intermediate compound on specific regions of the stent or on the total surface of the stent. In one aspect of this embodiment, the coating thicknesses of the intermediate compound are substantially the same. In another and/or alternative aspect of this embodiment, the coating thickness of two or more coatings of intermediate compound is different. In still another and/or alternative aspect of this embodiment, the composition of the coatings of intermediate compound is substantially the same. In yet another and/or alternative aspect of this embodiment, the composition of two or more coatings of intermediate compound are different. In yet another and/or alternative embodiment of the present invention, one or more coatings of intermediate compound are applied to the stent by vaporization, ionization, dipping, brushing, and/or spraying. In yet another and/or alternative embodiment of the invention, the intermediate compound is at least partially impregnated into the stent. The impregnation can be the result of a porous surface of the stent and/or the stent including one or more internal cavities. In one aspect of this embodiment, the stent is impregnated with the intermediate compound on specific regions of the stent or on the total surface of the stent. In another and/or alternative aspect of this embodiment, the stent is impregnated with the same intermediate compound. In still another and/or alternative aspect of this embodiment, the stent is impregnated with different intermediate compounds at different regions of the stent. In yet another and/or alternative aspect of this embodiment, the stent is impregnated with multiple intermediate compounds. In a further and/or alternative embodiment of the present invention, one or more intermediate compounds are impregnated in the stent by vaporization, ionization, dipping, brushing, and/or spraying. In still a further and/or alternative embodiment of the present invention, the one or more vascular active agents and/or secondary vascular active agents are coated and/or impregnated onto the stent prior to coating and/or impregnating the stent with one or more intermediate compounds. In yet a further and/or alternative embodiment of the present invention, the one or more intermediate compounds are coated and/or impregnated onto the stent prior to coating and/or impregnating the stent with one or more vascular active agents and/or secondary vascular active agents.
- Still yet another and/or alternative feature of the present invention is that the stent is at least partially coated and/or impregnated with, and/or at least partially includes one or more biological agents. The biological agent can be directly coated and/or impregnated on to the stent, and/or coated with the assistance of one or more intermediate compounds. In one embodiment of the present invention, the thickness of the coating of the biological agent on the stent can be uniform or varied. Generally, the thickness of the coating is not as important as the concentration of the vascular active agent and/or secondary vascular active agent needed to acquire the desired affect. High concentrations of biological agent can be coated with thinner coatings, and lower concentrations of biological agent can be coated with thicker coatings. In one aspect of this embodiment, the coating thickness is less than or equal to the material that forms the stent. In another and/or alternative embodiment of the invention, the stent includes a single coating on specific regions of the stent or on the total surface of the stent. In one aspect of this embodiment, the composition of the coating on different regions of the stent is substantially the same. In another and/or alternative aspect of this embodiment, the composition of the coating on different regions of the stent is different. In still another and/or alternative embodiment of the present invention, the stent includes multiple coatings on specific regions of the stent or on the total surface of the stent. In one aspect of this embodiment, the coating thicknesses of the multiple coatings are substantially the same. In another and/or alternative aspect of this embodiment, the coating thickness of the two or more coatings is different. In still another and/or alternative aspect of this embodiment, the composition of the coatings is substantially the same. In yet another and/or alternative aspect of this embodiment, the composition of two or more coatings is different. In yet another and/or alternative embodiment of the present invention, one or more coatings of biological agent are applied to the stent by vaporization, ionization, dipping, brushing, and/or spraying. In still yet another and/or alternative embodiment of the invention, the biological agent is at least partially impregnated into the stent. The impregnation can be the result of a porous surface of the stent and/or the stent including one or more internal cavities. In one aspect of this embodiment, the stent is impregnated on specific regions of the stent or on the total surface of the stent. In another and/or alternative aspect of this embodiment, the stent is impregnated with the same compound. In still another and/or alternative aspect of this embodiment, the stent is impregnated with different compounds at different regions of the stent. In yet another and/or alternative aspect of this embodiment, the stent is impregnated with multiple compounds. In a further and/or alternative embodiment of the present invention, one or more compounds are impregnated in the stent by vaporization, ionization, dipping, brushing, and/or spraying. As defined herein, the term “biological agent” is defined as any substance, drug or otherwise, that is formulated or designed to prevent, inhibit and/or treat one or more biological problems, such as, but not limited to, viral, fungus and/or bacteria infection; vascular disorders; digestive disorders; reproductive disorders; lymphatic disorders; cancer; implant rejection; pain; nausea; swelling; arthritis; bone disease; organ failure; immunity diseases; cholesterol problems; blood diseases; lung diseases and/or disorders; heart diseases and/or disorders; brain diseases and/or disorders; neuroglial diseases and/or disorders; kidney diseases and/or disorders; ulcers; liver diseases and/or disorders; intestinal diseases and/or disorders; gallbladder diseases and/or disorders; pancreatic diseases and/or disorders; psychological disorders; respiratory disorders; gland disorders; skin diseases; hearing disorders; oral disorders; nasal disorders; eye disorders; fatigue; genetic disorders; bums; scars; trauma; weight disorders; addiction disorders; hair loss; cramps; muscle spasms; tissue repair; and/or the like. As such, the term “biological agent” includes vascular active agents and secondary vascular active agents.
- Still another and/or alternative feature of the present invention is that the biological agent is at least partially coated and/or impregnated onto the stent by the use of an intermediate compound. Typically, the intermediate compound is a synthetic biocompatible material that does not adversely affect the biological agent or cause problems or adverse reactions in the body passageway. In one embodiment of the present invention, the intermediate compound is biodegradable. In another and/or alternative embodiment of the present invention, the intermediate compound is non-biodegradable. In still another and/or alternative embodiment of the invention, the intermediate compound is at least partially coated and/or impregnated on specific regions of the stent or totally coats the stent. In one aspect of this embodiment, the thickness of the coating on the stent can be uniform or varied. The coating thickness can be used to control the amount of biological agent that is coated on the stent and/or to control the release rate of the biological agent from the stent. Thicker coating can hold more biological agent. Thicker coating can also increase the time of full release of the biological agent from the stent. In one particular non-limiting design, the coating thickness is less than or equal to the material that forms the stent. In another and/or alternative embodiment of the invention, the stent includes a single coating of intermediate compound on specific regions of the stent or on the total surface of the stent. In one aspect of this embodiment, the composition of the intermediate compound on different regions of the stent is substantially the same. In another and/or alternative aspect of this embodiment, the composition of the intermediate compound on different regions of the stent is different. In still another and/or alternative embodiment of the present invention, the stent includes a multiple coatings of intermediate compound on specific regions of the stent or on the total surface of the stent. In one aspect of this embodiment, the coating thicknesses of the intermediate compound are substantially the same. In another and/or alternative aspect of this embodiment, the coating thickness of two or more coatings of intermediate compound is different. In still another and/or alternative aspect of this embodiment, the composition of the coatings of intermediate compound is substantially the same. In yet another and/or alternative aspect of this embodiment, the composition of two or more coatings of intermediate compound are different. In yet another and/or alternative embodiment of the present invention, one or more coatings of intermediate compound are applied to the stent by vaporization, ionization, dipping, brushing, and/or spraying. In yet another and/or alternative embodiment of the invention, the intermediate compound is at least partially impregnated into the stent. The impregnation can be the result of a porous surface of the stent and/or the stent including one or more internal cavities. In one aspect of this embodiment, the stent is impregnated with the intermediate compound on specific regions of the stent or on the total surface of the stent. In another and/or alternative aspect of this embodiment, the stent is impregnated with the same intermediate compound. In still another and/or alternative aspect of this embodiment, the stent is impregnated with different intermediate compounds at different regions of the stent. In yet another and/or alternative aspect of this embodiment, the stent is impregnated with multiple intermediate compounds. In a further and/or alternative embodiment of the present invention, one or more intermediate compounds are impregnated in the stent by vaporization, ionization, dipping, brushing, and/or spraying. In still a further and/or alternative embodiment of the present invention, the one or more biological agents are coated and/or impregnated onto the stent prior to coating and/or impregnating the stent with one or more intermediate compounds. In yet a further and/or alternative embodiment of the present invention, the one or more intermediate compounds are coated and/or impregnated onto the stent prior to coating and/or impregnating the stent with one or more biological agents.
- A further another and/or alternative feature of the present invention is that the biological agent is at least partially encapsulated by a material. In one embodiment of the present invention, the biological agent includes one or more vascular active agents and/or one or more secondary vascular active agents to inhibit and/or reduce restenosis, vascular narrowing and/or in-stent restenosis. In another and/or alternative embodiment of the present invention, the biological agent is at least partially encapsulated in biodegradable polymer and/or copolymer. In one aspect of this embodiment, the polymer and/or copolymer is at least partially formulated from aliphatic polyester compounds such as, but not limited to, PLA (i.e. poly(D, L-lactic acid), poly(L-lactic acid)) and/or PLGA (i.e. poly(lactide-co-glycoside)). In still another and/or alternative embodiment of the present invention, the rate of degradation of the polymer and/or copolymer is principally a function of 1) the water permeability and solubility of the polymer and/or copolymer, 2) chemical composition of the polymer and/or copolymer, 3) mechanism of hydrolysis of the polymer and/or copolymer, 4) the biological agent encapsulated in the polymer and/or copolymer, 5) the size, shape and surface volume of the polymer and/or copolymer, 6) porosity of the polymer and/or copolymer, and/or 7) the molecular weight of the polymer and/or copolymer. As can be appreciated, other factors may also affect the rate of degradation of the polymer and/or copolymer. The rate of degradation of the polymer and/or copolymer controls the amount of biological agent released during a specific time period into the body passageway or other parts of the body. As can be appreciated, the biological agent can be formed into a pill, capsule or the like for oral ingestion by a human or animal. The rate of degradation of the polymer and/or copolymer that is at least partially encapsulating the biological agent controls the amount of biological agent that is released into a body passageway or other part of the body over time. The biological agent can be at least partially encapsulated with different polymer and/or copolymer coating thickness, different numbers of coating layers, and/or with different polymers or copolymers to alter the time period one at least partially encapsulated biological agent is released in a body passageway or other part of the body over time as compared to another at least partially encapsulated biological agent. Alternatively or in addition, one or more at least partially encapsulated biological agents can be at least partially encapsulated in a biodegradable capsule and/or coating, which biodegradable capsule and/or coating delays the exposure of one or more of the at least partially encapsulated biological agents to fluids in a body passageway or other part of the body. As can further be appreciated, the at least partially encapsulated biological agent can be introduced into a human or animal by means other than by oral introduction, such as, but not limited to, injection, topical applications, intravenously, eye drops, nasal spray, surgical insertion, suppositories, intrarticularly, intraocularly, intranasally, intradermally, sublingually, intravesically, intrathecally, intraperitoneally, intracranially, intramuscularly, subcutaneously, directly at a particular site, and the like. In another aspect of this embodiment, the polymer and/or copolymer is formed into one or more shapes such as, but not limited to, spherical, cubical, cylindrical, pyramidal, and the like.
- Yet a further another and/or alternative feature of the present invention is that the stent is at least partially coated and/or impregnated with one or more polymers or copolymers that include one or more biological agents. In one embodiment of the present invention, the coating thickness of each intermediate compound on the stent is less than about 0.08 inch, and typically less than about 0.01 inch, and even more typically less than about 0.005 inch. The particular coating sequence on a stent will generally depend on 1) the amount of a particular biological agent to be released over time, 2) the sequence of biological agents to be released over time, 3) the time period the release of the biological agent is to begin, 4) the time period the release of the biological agent is to end, and/or 5) the location in the body the biological agent is to be released. As can be appreciated, other factors may dictate the particular coating sequence on a stent. In another and/or alternative embodiment of the present invention, the intermediate compound is formulated to delay and/or regulate the time and/or amount of one or more biological agents being released into the body passageway, and/or to facilitate in the bonding of one or more biological agents to the stent. The intermediate compound can be formulated so as to form one or more bonds with one or more biological agents or be chemically inert with respect to one or more biological agents.
- Still a further another and/or alternative feature of the present invention is that the stent is at least partially formed by a material that includes one or more biological agents. In one embodiment of the present invention, one or more biological agents are at least partially embedded in the stent so as to inhibit the release, control the release, and/or delay the release of one or more biological agents into the body passageway. The material forming at least a portion of the stent in which one or more biological agents are imbedded can be a biodegradable material and/or a non-biodegradable material. The material can be formulated so as to form one or more bonds with one or more biological agents or be chemically inert with respect to one or more biological agents. Typically, the material is a substantially non-biodegradable material so that the structural integrity of the stent or other implant is maintained throughout the life of the stent or other implant. However, there may be instances wherein the stent or other implant advantageously becomes fully or partially degraded over time. In one aspect of this embodiment, the material includes a metal and/or polymer and/or copolymer.
- Still a further another and/or alternative feature of the present invention is that one or more biological agents at least partially forms a chemical bond with an intermediate compound that at least partially encapsulates one or more of the biological agents; that at least partially coats and/or impregnates the stent or other implant; and/or that at least partially forms the stent or other implant. In one embodiment of the present invention, one or more of the biological agents forms a polymer and/or copolymer salt complex with one or more intermediate compounds that at least partially encapsulates one or more of the biological agents; that at least partially coats and/or impregnates the stent or other implant; and/or that at least partially forms the stent or other implant. In one aspect of this embodiment, the biological agent includes, but is not limited to, Trapidil and/or derivatives thereof; GM-CSF and/or derivatives thereof; taxol and/or derivatives thereof (e.g. taxotere, baccatin,10-deacetyltaxol, 7-xylosyl-10-deacetyltaxol, cephalomannine, 10-deacetyl-7-epitaxol, 7 epitaxol, 10-deacetylbaccatin III, 10-deacetylcephaolmannine); 5-Fluorouracil and/or derivatives thereof; Beta-Estradiol and/or derivatives thereof; Tranilast and/or derivatives thereof; Probucol and/or derivatives thereof; Angiopeptin and/or derivatives thereof; paclitaxel and/or derivatives thereof; cytochalasin and/or derivatives thereof (e.g. cytochalasin A, cytochalasin B, cytochalasin C, cytochalasin D, cytochalasin E, cytochalasin F, cytochalasin G, cytochalasin H, cytochalasin J, cytochalasin K, cytochalasin L, cytochalasin M, cytochalasin N, cytochalasin O, cytochalasin P, cytochalasin Q, cytochalasin R, cytochalasin S, chaetoglobosin A, chaetoglobosin B, chaetoglobosin C, chaetoglobosin D, chaetoglobosin E, chaetoglobosin F, chaetoglobosin G, chaetoglobosin J, chaetoglobosin K, deoxaphomin, proxiphomin, protophomin, zygosporin D, zygosporin E, zygosporin F, zygosporin G, aspochalasin B, aspochalasin C, aspochalasin D); aspirin and/or derivatives thereof; dipyridamoles and/or derivatives thereof; argatroban and/or derivatives thereof; forskolin and/or derivatives thereof; vapiprost and/or derivatives thereof; prostacyclin and prostacyclin and/or derivatives thereof; glycoprotein Ilb/Illa platelet membrane receptor antibody; colchicine and/or derivatives thereof; dexamethazone and/or derivatives thereof; dipyridamoles and/or derivatives thereof; and/or heparin and/or derivatives thereof; glucocorticoids (e.g. dexamethasone, betamethasone)and/or derivatives thereof; hirudin and/or derivatives thereof; coumadin and/or derivatives thereof; prostacyclenes and/or derivatives thereof; antithrombogenic agents; steroids; seramin and/or derivatives thereof; thioprotese inhibitors; nitric oxide; ibuprofen; antimicrobials; antibiotics; tissue plasma activators; rifamycin and/or derivatives thereof; monoclonal antibodies; antifibrosis compounds; cyclosporine; hyaluronate; protamine and/or derivatives thereof; tocopherol and/or derivatives thereof; angiopeptin and/or derivatives thereof; tick anticoagulant protein and/or derivatives thereof; methotrexate and/or derivatives thereof; azathioprine and/or derivatives thereof; vincristine and/or derivatives thereof; vinblastine and/or derivatives thereof; fluorouracil and/or derivatives thereof; adriamycin and/or derivatives thereof; mutamycin and/or derivatives thereof; Anti-Invasive Factor; Cartilage-Derived Inhibitor; retinoic acids and/or derivatives thereof, Suramin; Tissue Inhibitor of Metalloproteinase-1 and/or derivatives thereof; Tissue Inhibitor of Metalloproteinase-2 and/or derivatives thereof; Plasminogen Activator Inhibitor-1 and/or derivatives thereof; Plasminogen Activator Inhibitor-2 and/or derivatives thereof; estramustine and/or derivatives thereof; methotrexate and/or derivatives thereof, curacin-A and/or derivatives thereof; epothilone and/or derivatives thereof; vinblastine and/or derivatives thereof; tBCEV and/or derivatives thereof; lighter “d group” transition metals (e.g ammonium metavanadate, sodium metavanadate, sodium orthovanadate, vanadyl acetylacetonate, vanadyl sulfate mono- and trihydrates, ammonium tungstate, calcium tungstate, sodium tungstate dihydrate, tungstic acid, tungsten (IV) oxide, tungsten (VI) oxide, ammonium molybdate and its hydrates, sodium molybdate and its hydrates, potassium molybdate and its hydrates, molybdenum (VI) oxide, molybdenum (VI) oxide, molybdic acid, molybdenyl acetylacetonate); Platelet Factor 4; growth factors (e.g. VEGF; TGF; IGF; PDGF; FGF); Protamine Sulphate (Clupeine); Sulphated Chitin Derivatives; Sulphated Polysaccharide Peptidoglycan Complex; Staurosporine; proline analogs (L-azetidine-2-carboxylic acid (LACA); cishydroxyproine; d,L-3,4-dehydroproline; Thiaproline; alpha-dipyridyl; beta aminopropionitrile fumarate; 4-propyl-5-(4-pyridinyl)-2(3H)-oxazolone; Methotrexate Mitoxantrone; Interferons; alpha 2 Macroglobulin; ChIMP-3; Chymostatin; beta-Cyclodextrin Tetradecasulfate; Eponemycin; Camptothecin; Fumagillin; Gold Sodium Thiomalate; D-Penicillamine; beta-1-anticollagenase; alpha 2-antiplasmin; Bisantrene; Lobenzarit disodium (N-(2)-carboxyphenyl-4-chloroanthronilic acid disodium; Thalidomide; Angiostatic steroid; AGM-1470; carboxynaminolmidazole; penicillins; cephalosporins (e.g. cefadroxil, cefazolin, cefaclor); aminoglycosides (e.g. gentamycin, tobramycin; sulfonamides (e.g. sulfamethoxazole); rapamycin, metronidazole; prednisone; prednisolone;hydrocortisone; adrenocorticotropic hormone; sulfasalazine; naproxen; fenoprofen; indomethacin; phenylbutazone; acyclovir; ganciclovir; zidovudine; nystatin; ketoconazole; griseofulvin; flucytosine; miconazole; clotrimazole; pentamidine isethionate; quinine; chloroquine; mefloquine; thyroid hormone; estrogen; progesterone; cortisone; growth hormone; insulin; T.sub.H 1 (e.g., Interleukins-2, -12, and -15, gamma interferon); T.sub.H 2 (e.g. Interleukins-4 and -10) cytokines); estramustine; epothilone; curacin-A; colchicine; methotrexate; vinblastine; 4-tert-butyl->3-(2-chloroethyl)ureido!benzene (“tBCEU”); alpha-adrenergic blocking agents; angiotensin II receptor antagonists; receptor antagonists for histamine; serotonin; serotonin blockers; endothelin; inhibitors of the sodium/hydrogen antiporter (e.g., amiloride and derivatives thereof); agents that modulate intracellular Ca.sup.2+ transport such as L-type (e.g., diltiazem, nifedipine, verapamil) or T-type Ca.sup.2+ channel blockers (e.g. amiloride); calmodulin antagonists (e.g., H.sub.7); inhibitors of the sodium/calcium antiporter (e.g. amiloride); ap-1 inhibitors (for tyrosine kinases, protein kinase C, myosin light chain kinase, Ca.sup.2+/calmodulin kinase II, casein kinase II); anti-depressants (e.g. amytriptyline, fluoxetine, LUVOX.RTM. and PAXIL.RTM.); cytokine and/or growth factors as well as their respective receptors, (e.g., the interleukins, alpha, beta or gamma-IFN (interferons), GM-CSF, G-CSF, epidermal growth factor, transforming growth factors alpha and beta, TNF, and antagonists of vascular epithelial growth factor, endothelial growth factor, acidic or basic fibroblast growth factors, and platelet derived growth factor); inhibitors of the IP3 receptor; protease; collagenase inhibitors; nitrovasodilators (e.g. isosorbide dinitrate); anti-mitotic agents (e.g. colchicine, anthracyclines and other antibiotics, folate antagonists and other anti-metabolites, vinca alkaloids, nitrosoureas, DNA alkylating agents, topoisomerase inhibitots, purine antagonists and analogs, pyrimidine antagonists and analogs, alkyl sulfonates); immunosuppressive agents (e.g. adrenocorticosteroids, cyclosporine); sense or antisense oligonucleotides (e.g. DNA, RNA, plasmid DNA, plasmid RNA, nucleic acid analogues (e.g. peptide nucleic acids); inhibitors of transcription factor activity (e.g. lighter d group transition metals); anti-neoplastic compounds; chemotherapeutic compounds (e.g. 5-fluorouracil, vincristine, vinblastine, cisplatin, doxyrubicin, adriamycin, or tamocifen), radioactive agents (e.g. Cu-64, Ca-67, Cs-131, Ga-68, Zr-89, Ku-97, Tc-99m, Rh-105, Pd-103, Pd-109, In-111, I-123, I-125, I-131, Re-186, Re-188, Au-198, Au-199, Pb-203, At-211, Pb-212, Bi-212, H3P32O4); 7E-3B; CAPTOPRIL; CILAZAPRIL; LISINOPRIL; LOVASTATIN; nitroprusside; phosphodiesterase inhibitors; prostaglandin inhibitors; thioprotesase inhibitors; triazolopyrimidine and/or derivatives thereof; calcium channel blockers; toxins (e.g. ricin, abrin, diphtheria toxin, cholera toxin, gelonin, pokeweed antiviral protein, tritin, Shigella toxin, and Pseudomonas exotoxin A); metalloproteinase inhibitors; ACE inhibitors; growth factors; oligonucleotides; antiplatlet compounds; antitabolite compounds; anti-inflammatory compounds; anticoagulent compounds; antimitotic compounds; antioxidants; antimetabolite compounds (e.g staurosporin, trichothecenes, and modified diphtheria and ricin toxins, Pseudomonas exotoxin); anti-migratory agents (e.g. caffeic acid derivatives, nilvadipine); anti-matrix compounds (e.g. colchicine, tamoxifen); protein kinase inhibitors (e.g staurosporin); anti-vital compounds, anti-proliferatives, anti-fungal compounds and/or anti-protozoal compounds. As can be appreciated, the biological agent can include other compounds. In one aspect of this embodiment, the Trapidil forms a salt complex with the intermediate compound such that the Trapidil forms the cationic component and the coating compound forms the anionic component.
- Still another and/or alternative feature of the present invention, the intermediate compound used to at least partially encapsulate one or more biological agents; at least partially coat and/or impregnate the stent or other implant; and/or at least partially form the stent or other implant is a polymer and/or copolymer. In one embodiment of the present invention, the polymer and/or copolymer includes one or more carboxylate groups, phosphate groups, sulfate groups, and/or other organic anion groups. In one aspect of this embodiment, the polymer and/or copolymer includes one or more groups which form one or more anionic bonding sites for cationic salts of the biological agent. In one aspect of this embodiment, the polymer and/or copolymer includes one or more groups that form one or more cationic bonding sites for anionic salts of the biological agent. In one specific example of this aspect, the polymer and/or copolymer includes one or more amine groups and the like. In still another and/or alternative embodiment of the present invention, the polymer and/or copolymer includes one or more hydrophobic and/or hydrophilic groups. As can be appreciated, the polymer and/or copolymer can include only hydrophobic groups, only hydrophilic groups, or include a combination hydrophobic groups and hydrophilic groups. Furthermore, it can be appreciated that the hydrophobic and/or hydrophilic groups in the polymer and/or copolymer can be the same or different. Non-limiting examples of hydrophilic groups include carboxylate groups (e.g. acrylate groups, methacrylate groups), alcohol groups, sulfate groups, and the like. Specific non-limiting examples include acrylic acid groups, methacrylic acid groups, and/or maleic acid groups. Non-limiting examples of hydrophobic groups include ethylene groups, vinyl groups, styrene groups, propylene groups, urethane groups, ester groups, and/or alkyl groups. Specific non-limiting examples include ethylene groups, propylene groups, acrylonitrile groups, and/or methyl methacrylate groups. In still another and/or alternative embodiment of the present invention, the general formula of the polymer and/or copolymer that can be used is set forth in the following formula:
- Hydrophobic GroupxHydrophilic Group)yn
- wherein x is the number of hydrophobic monomer units, y is the number of hydrophilic monomer units, and n is the total number of all monomer units in the polymer and/or copolymer chain. The x and y values can stay constant or vary throughout the polymer and/or copolymer chain. In addition, the type of hydrophobic monomer or hydrophilic monomer can stay constant or vary throughout the polymer and/or copolymer chain. Biological agents that form anionic or cationic salts generally bond with the hydrophilic groups in the polymer and/or copolymer chain. Consequently, the more hydrophilic groups in the polymer and/or copolymer chain, the higher the concentration of biological agents that can bond with the polymer and/or copolymer chain. As can be appreciated, one or more biological agents may bond with hydrophobic groups. Therefore, the more hydrophobic groups in the polymer and/or copolymer chain, the higher the concentration of biological agent that can bond with the polymer and/or copolymer chain. Irrespective of whether a biological agent bonds with a hydrophobic group or hydrophilic group, the ratio of the hydrophilic groups to the hydrophobic groups in the polymer and/or copolymer determines the amount of biological agent that bonds with the polymer and/or copolymer. The number of groups of hydrophilic groups (y) and hydrophobic groups (x) typically varies from about 50 to over 10,000. Non-limiting examples of polymer and/or copolymers that can be used include poly(ethylene terephthalate); polyacetal; poly(lactic acid); polyglycolic acid; polyesters; hydrogels; polytetrafluoroethylene; fluorosilicones hyaluronates; polymethylmethacrylate; poly(ethylene oxide)/poly(butylene terephthalate) copolymer; polycaprolactone; poly(lactide-co-glycolide); poly(hydroxybutyrate); poly(hydroxybutyrate-co-valerate); polydioxanone; polyorthoester; polyanhydride; poly(glycolic acid); copolymers of lactic acid and glycolic acid; poly (caprolactone); poly (valerolactone); poly (anhydrides); copolymers of poly (caprolactone) or poly (lactic acid) with polyethylene glycol; poly(glycolic acid-co-trimethylene carbonate); polyphosphoester; polyphosphoester urethane; poly(amino acids); cyanoacrylates; poly(trimethylene carbonate); polyvinyl alcohol; polyethylene; poly(iminocarbonate); polyorthoesters; polyacetals; polyorthocarbonates; copoly(ether-esters) (e.g. PEO/PLA); polyalkylene oxalates; polyphosphazenes; parylene; biomolecules such as fibrin, fibrinogen, cellulose, starch, collagen and hyaluronic acid; silicones; polyolefins; polyisobutylene and ethylene-alphaolefin copolymers; acrylic polymers and copolymers (e.g., n-butyl-acrylate, n-butyl methacrylate, 2-ethylhexyl acrylate, lauryl-acrylate, 2-hydroxy-propyl acrylate); vinyl halide polymers and copolymers (e.g. polyvinyl chloride); polyvinyl ethers (e.g. polyvinyl methyl ether); polyvinylidene halides (e.g. polyvinylidene fluoride, polyvinylidene chloride); polyacrylonitrile; polyvinyl ketones; polyvinyl aromatics (e.g. polystyrene); polyvinyl esters (e.g. polyvinyl acetate); copolymers of vinyl monomers; olefins (e.g. ethylene-methyl methacrylate copolymers); acrylonitrile-styrene copolymers; ABS resins; ethylene-vinyl acetate copolymers; polyamides (e.g. Nylon 66, polycaprolactam); alkyd resins; polycarbonates; polyoxymethylenes; polyimides; polyethers; epoxy resins; polyurethanes; rayon; rayon-triacetate; albumin; gelatin; starch; dextrans; polysaccharides; fibrinogen; poly (hydroxybutyrate); poly (alkylcarbonate); poly (orthoesters); EVA copolymers; silicone rubber; poly (methylmethacrylate); cellulose acetate; cellulose butyrate;
- cellulose acetate butyrate; cellophane; cellulose nitrate; cellulose propionate; cellulose ethers; and/or carboxymethyl cellulose. One particular non-limiting copolymer chain that can be used to form a polymer salt complex with a biological agent such as, but not limited to, Trapidil, is an ethylene-acrylic acid copolymer. In this copolymer, ethylene is the hydrophobic group and acrylic acid is the hydrophilic group. The mole ratio of the ethylene to the acrylic acid in the copolymer determines the hydrophobicity of the copolymer. Generally a mole ratio for hydrophobic groups/hydrophilic groups ranges from about 90:10-2:98; however, other mole ratios can be used. As can be appreciated, a mole ratio of 2:98 forms a hydrophilic copolymer and a mole ratio of 90:10 forms a hydrophobic copolymer. In still another and/or alternative embodiment of the present invention, the polymer and/or copolymer includes parylene and/or derivatives thereof. Parylene is substantially biologically inert, and forms a bond with many types of biological agents such as, but not limited to Trapidil. The bond between parylene is strong enough to retain the biological agent to the parylene during the insertion of the stent into a body passageway; however, the bond is weak enough to enable the bonded biological agent to disengage from the parylene while in the body passageway. The polyamide, parylene or parylene derivative can be applied by catalyst-free vapor deposition to a coating thickness of about 5,000 to 250,000 Å, which is adequate to provide a controlled release of the Trapidil, and/or other biological agent. “Parylene” is both a generic name for a known group of polymers based on p-xylylene and can made by vapor phase polymerization. More particularly, parylene or a parylene derivative can be created by first heating p-xylene or a suitable derivative at an appropriate temperature (e.g., about 950° C.) to produce the cyclic dimer di-p-xylylene (or a derivative thereof). The resultant solid can be separated in pure form, and then cracked and pyrolyzed at an appropriate temperature (e.g., about 680° C.) to produce a monomer vapor of p-xylylene (or derivative); the monomer vapor is cooled to a suitable temperature (e.g., below about 50° C.) and allowed to condense on the desired object (e.g., stent). The resultant polymer has the repeating structure (CH2C6H4CH2)n, with n equal to about 100-10,000, and a molecular weight in the range of about 100,000-1,000,000.
- The parylene or parylene derivative is thought to form a network resembling a fibrous mesh, with relatively large pores. As more is deposited, the porous layer not only becomes thicker, but it is believed that parylene or parylene derivative is also deposited in the previously formed pores, making the existing pores smaller. Careful and precise control over the deposition of the parylene or parylene derivative therefore permits close control over the release rate of the one or more biological agents. The biological agent can be dispersed in the parylene or parylene derivative, and/or the parylene or parylene derivative can be at least partially coated over one or more layers of biological agent. The porous layer also protects the biological agent during deployment of the stent or other device during insertion of the device through a catheter and into the vascular system or elsewhere in the patient. In a further and/or alternative embodiment of the invention, the polyamide, parylene or parylene derivative can be applied by plasma deposition. Plasma is an ionized gas maintained under vacuum and excited by electrical energy, typically in the radiofrequency range. Because the gas is maintained under vacuum, the plasma deposition process can occur at or near room temperature. Plasma can be used to deposit polymers such as poly(ethylene oxide), poly(ethylene glycol), and poly(propylene oxide), as well as polymers of silicone, methane, tetrafluoroethylene (including TEFLON brand polymers), tetramethyldisiloxane, and others.
- In still a further another and/or alternative feature of the present invention, the amount of biological agent that can be loaded on the polymer and/or copolymer is dependent on the structure of the polymer and/or copolymer. For biological agents that are cationic, the concentration of biological agent that can be loaded on the polymer and/or copolymer is a function of the concentration of anionic groups in the polymer and/or copolymer. Alternatively, for biological agents that are anionic, the concentration of biological agent that can be loaded on the polymer and/or copolymer is a function of the concentration of cationic groups (e.g. amine groups and the like) in the polymer and/or copolymer. For instance, when the biological agent is such as, but not limited to, Trapidil, the maximum concentration of Trapidil that can be loaded on to the polymer and/or copolymer is dependent on the concentration of anionic groups (i.e. carboxylate groups, phosphate groups, sulfate groups, and/or other organic anionic groups) in the polymer and/or copolymer, and the fraction of these anionic groups that can ionically bind the cationic form of Trapidil. As a result, the concentration of biological agent bound to the polymer and/or copolymer can be varied by controlling the amount of hydrophobic and hydrophilic monomer in the polymer and/or copolymer, by controlling the efficiency of salt formation between the biological agent, and/or the anionic/cationic groups in the polymer and/or copolymer. Loading levels of the biological agent in the polymer and/or copolymer can be from zero to about 90 percent on a weight by weight basis. Therefore, the chemical properties of the biological agent typically dictate the type of polymer and/or copolymer to be used so as to deliver the desired levels of biological agent into a body passageway to achieve a desired biological response.
- Yet a further another and/or alternative feature of the present invention is that the stent is at least partially coated and/or impregnated with one or more intermediate compounds that include one or more biological agents, wherein the one or more intermediate compounds are cross-linked to alter the rate of release of the one or more biological agents into the body passageway. It has been discovered that by causing the one or more intermediate compounds to cross-link after being at least partially coated and/or impregnated onto the stent, the rate at which the one or more biological agents disassociates from the stent and migrates into the body passageway can be controlled. As can be appreciated, the cross-linking of the intermediate compound can be used to alter the rate of release of the one or more biological agents into the body passageway or other body parts. The cross-linking can be instituted by a number to techniques including, but not limited to, using catalysts, using radiation, using heat, and/or the like. In one embodiment of the present invention, the intermediate compound is exposed to radiation to cause one or more cross-links to be formed. The radiation can include, but is not limited to, gamma radiation, beta radiation and/or e-beam radiation. When the intermediate compound is exposed to radiation, one or more hydrogen radicals are removed from the polymer and/or copolymer chain in the intermediate compound. The removal of the hydrogen radical causes the polymer and/or copolymer chain to cross-link with another portion of the polymer and/or copolymer chain or cross-link with a different polymer and/or copolymer. The cross-linking effect results in the one or more biological agents to become partially or fully entrapped within the cross-linked intermediate compound. The entrapped biological agent takes longer to release itself from the cross-linked intermediate compound and to pass into the body passageway. As a result, the amount of biological agent, and/or the rate at which the biological agent is released from the stent over time can be controlled by the amount of cross-linking in the intermediate compound. The amount of cross-linking in the intermediate compound is at least partially controlled by the type and amount of radiation applied to the intermediate compound. Gamma radiation is a higher intensity radiation and e-beam radiation is a lower intensity radiation. Increased radiation intensities and increased radiation exposure periods typically result in increased cross-linking of the intermediate compound. Each polymer composition has its unique threshold and capacity for cross-linking. The amount of cross-linking that is induced by radiation will be dependent on the chemical structure and composition of the polymer and/or copolymer. The extent or degree of cross-linking for each polymer and/or copolymer in combination with the biological agent will vary, depending on the type, strength and duration of radiation, the chemical structure of the biological agent, the type of polymer and/or copolymer, and the amount of loading (weight percent) of the biological agent in the polymer and/or copolymer. Reduced solubility of the copolymer/polymer in a body passageway can reduce the need for induced cross-linking of the polymer and/or copolymer. For instance, while the polymer and/or copolymer may be hydrophilic, salt formation with a hydrophobic biological agent can result in a reduction of solubility of the bound polymer and/or copolymer in physiological environments. The reduction in solubility of the bound polymer and/or copolymer may reduce the need or totally obviate the need for induced cross-linking by radiation or otherwise. The hydrophobic nature of the bound polymer and/or copolymer will control the rate of release of the biological agent from the polymer and/or copolymer. The amount of radiation exposure to the intermediate compound and the biological agent is limited so as to prevent degradation of the biological agent, and/or the intermediate compound during the irradiation procedure. Generally, less than about 2000 rads (irradiation absorbed doses) are applied to the intermediate compound, the biological agent, and typically less than about 1000 rads, and more typically less than about 500 rads, and even more typically less than about 400 rads. Generally, at least about 0.1 rad is applied to the intermediate compound, the biological agent, and typically at least about 1 rad, and more typically at least about 10 rads. Alternatively, up to 300 microvolt equivalents is used.
- A further another and/or alternative feature of the present invention is that the stent is at least partially coated and/or impregnated with one or more intermediate compounds that include one or more biological agents, wherein the one or more intermediate compounds are bonded with one or more biological agents to alter the rate of release of the one or more biological agents into the body passageway. It has been discovered that by causing the one or more intermediate compounds to form a bond with one or more biological agents after being at least partially coated and/or impregnated onto the stent, the rate at which the one or more biological agents disassociates from the stent and migrates into the body passageway can be controlled. As can be appreciated, the bonding of the one or more biological agents can be used to alter the rate of release of the one or more biological agents into the body passageway. The post bonding of the one or more biological agents to one or more intermediate compounds can be instituted by a number to techniques including, but not limited to, using catalysts, using radiation, using heat, and/or the like. In one embodiment of the present invention, the coating compound is exposed to radiation to cause one or more bonds to be formed. The radiation can include, but is not limited to, gamma radiation, beta radiation and/or e-beam radiation. When the intermediate compound is exposed to radiation, one or more hydrogen radicals are removed from the polymer and/or copolymer chain in the intermediate compound. The removal of the hydrogen radical causes the polymer and/or copolymer chain to bond to one or more surrounding biological agents. The hydrogen radical typically bonds with a salt of the biological agents. The bonded biological agent takes longer to release itself from the intermediate compound and to pass into the body passageway. As a result, the amount of biological agent, and/or the rate at which the biological agent is released from the stent over time can be controlled by the amount of bonding of the biological compound to the intermediate compound. The amount of bonding of the biological compound to the intermediate compound is at least partially controlled by the type and amount of radiation applied to the intermediate compound. Increased radiation intensities and increased radiation exposure periods typically result in increased amounts of bonding. Each polymer composition has its unique threshold and capacity for bonding with one or more biological agents. The amount of bonding that is induced by radiation will be dependent on the chemical structure and composition of the polymer and/or copolymer and the biological agents. The extent or degree of bonding for each polymer and/or copolymer in combination with the biological agent will vary, depending on the type, strength and duration of radiation, the chemical structure of the biological agent, the type of polymer and/or copolymer, and the amount of loading (weight percent) of the biological agent in the polymer and/or copolymer.
- Still yet a further another and/or alternative feature of the present invention is that the stent is at least partially sterilized by subjecting the stent to radiation. Prior to the stent-being inserted into a body passageway, the stent should be free or substantially free of foreign organisms so as to avoid infection in the body passageway. In the past, the stent was sterilized by ethylene oxide. Although this compound effectively sterilized the stent, the FDA has imposed various restrictions on this compound making it less desirable to use. Stent sterilization by radiation overcomes the problems and limitations associated with the use of ethylene oxide. The radiation destroys most, if not all, of the foreign organisms on the stent. As a result, sterilization by radiation reduces the occurrence of infection by foreign organisms as compared to past sterilization techniques. Generally, less than about 5000 rads (irradiation absorbed doses) are applied to the stent to at least partially sterilize the stent, and typically less than about 1000 rads, and more typically less than about 500 rads. Generally, at least about 0.1 rad is applied to the stent, and typically at least about 1 rad, and more typically at least about 5 rads.
- The primary object of the present invention is the provision of a stent having improved procedural success rates.
- Another and/or alternative object of the present invention is the provision of a stent having higher visibility under fluoroscopy in vivo.
- Still another and/or alternative object of the present invention is the provision of a stent retaining its longitudinal dimensions from its original pre-expanded configuration to its expanded configuration.
- Yet another and/or alternative object of the present invention is the provision of a stent that minimizes damage to tissue during insertion and expansion of the stent.
- Still yet another and/or alternative object of the present invention is the provision of a stent that inhibits or prevents the occurrence of in-stent restenosis, vascular narrowing and/or restenosis long after the stent has been inserted into a body passageway.
- A further and/or alternative object of the present invention is the provision of a stent that is simple and cost effective to manufacture.
- Still a further and/or alternative object of the present invention is the provision of a stent that is at least partially coated and/or impregnated with a biocompatible coating.
- Yet a further and/or alternative object of the present invention is the provision of a stent that includes two or more body members connected by one or more connectors to allow transverse bending and flexibility of the stent invariant to the plane of bend.
- Still yet a further and/or alternative object of the present invention is the provision of a stent that is at least partially visible under fluoroscopy in vivo.
- Another and/or alternative object of the present invention is the provision of a stent that is coated and/or impregnated with one or more vascular active agents and/or secondary vascular agents.
- Still another and/or alternative object of the present invention is the provision of a stent having one or more intermediate compounds used with one or more vascular active agents and/or secondary vascular agents to coat and/or impregnate one or more vascular active agents and/or secondary vascular agents on the stent.
- Yet another and/or alternative object of the present invention is the provision of a stent that is coated and/or impregnated with one or more biological agents.
- Still yet another and/or alternative object of the present invention is the provision of a stent having one or more intermediate compounds used with one or more biological agents to coat and/or impregnate one or more biological agents on the stent.
- A further and/or alternative object of the present invention is the provision of a stent having one or more intermediate compounds to at least partially regulate or control the release of one or more biological agents from the stent.
- Still a further and/or alternative object of the present invention is the provision of a stent having one or more intermediate compounds that bond with one or more biological agents.
- Yet a further and/or alternative object of the present invention is the provision of a stent having one or more intermediate compounds that include polymers and/or copolymers which include hydrophobic groups and hydrophilic groups.
- Still yet a further and/or alternative object of the present invention is the provision of a stent having one or more intermediate compounds having post induced cross-linking to at least partially regulate or control the release of one or more biological agents from the stent.
- Another and/or alternative object of the present invention is the provision of a stent having one or more intermediate compounds having post bonding with one or more biological agents to at least partially regulate or control the release of one or more biological agents from the stent.
- Still another and/or alternative object of the present invention is the provision of a stent having one or more intermediate compounds that are subjected to radiation to cause post induced cross-linking between the one or more intermediate compounds and/or to cause post induced bonding with one or more biological agents.
- Yet another and/or alternative object of the present invention is the provision of a stent that is sterilized prior to insertion into a body passageway.
- These and other advantages will become apparent to those skilled in the art upon the reading and following of this description taken together with the accompanying drawings.
- Reference may now be made to the drawings, which illustrate various embodiments that the invention may take in physical form and in certain parts and arrangements of parts wherein:
- FIG. 1 is a perspective view of a section of an unexpanded stent which permits delivery of the stent into a body passageway;
- FIG. 1A is an enlarged perspective view of one end of the stent of FIG. 1;
- FIG. 2 is a perspective view of a section of the unexpanded stent of FIG. 1 in a non-tubular state;
- FIG. 3 is a sectional view of the unexpanded stent of FIG. 2 showing a connector used to connect the ends of two tubular body members of the stent;
- FIG. 3B is a perspective view of the stent of FIG. 1 in a non-tubular state wherein the stent has rounded edges;
- FIG. 4 is a sectional view of the stent of FIG. 2 showing the polygonal structure of the stent before and after expansion;
- FIG. 5 is a perspective view of an additional embodiment of the present invention showing an unexpanded section of the stent having a series of slots of FIG. 4;
- FIG. 6 is a sectional view of the stent of FIG. 5 showing a connector used to connect the ends of two body members of the stent together;
- FIG. 7 is a sectional view of the stent of FIG. 5 showing a part of the structure of the stent before and after expansion;
- FIG. 8 is a perspective view of a stent of FIG. 1 showing a coating that includes a biological agent on the stent;
- FIG. 9 is a perspective view of an angioplasty balloon delivering fluid materials to a local site;
- FIG. 10 is a graphical representation of the steps for coating the stent with a biological agent and coating compound;
- FIG. 10A is a graphical representation of the biological agent entrapped in a cross-linked polymer and/or copolymer; and, FIG. 11 is a graphical representation of the steps to form cross-linking of a polymer and/or copolymer that includes a biological agent.
- Referring now to the drawings wherein the showing is for the purpose of illustrating preferred embodiments of the invention only and not for the purpose of limiting the same, FIGS.1-8 disclose a stent for a body passageway. The apparatus and structures of the present invention may be utilized not only in connection with an expandable stent for at least partially expanding occluded segments of a body passageway, but also for additional uses. For example, the expandable stent may be used for, but not limited to, such purposes as 1) a supportive stent placement within a blocked vasculature opened by transluminal recanalization, which are likely to collapse in the absence of an internal support; 2) forming a catheter passage through mediastinal and/or other veins occluded by inoperable cancers; 3) reinforcement of catheter created intrahepatic communications between portal and/or hepatic veins in patients suffering from portal hypertension; 4) supportive stent placement of narrowing of the esophagus, the intestine, the ureter and/or the urethra; and/or 5) supportive stent reinforcement of reopened and previously obstructed bile ducts. Accordingly, use of the term “stent” encompasses the foregoing usages within various types of body passageways, and also encompasses use for expanding a body passageway.
- The
expandable stent 20, as shown in FIGS. 1, 1A, 2, 3, 3B, and 4, generally comprises two tubularshaped body members first end second end 34, 44, and awall surface elongated members 50, with at least some of the elongated members intersecting with one another intermediate the first and second ends of each body member. As can be appreciated, the stent can be formed of only one body member or be formed by more than two body members.Body members Body members -
Elongated members 50, which formwall surface body members -
Elongated members 50 are generally small diameter wires or bars that have a maximum cross-sectional length or diameter of up to about 0.02 inches, and generally about 0.0005 to 0.008 inch, and typically about 0.002 to 0.004 inch; however, other cross-sectional lengths or diameters can be used. The cross-sectional length or diameter of the elongated members is designated by “a” in FIG. 2. It should, of course, be understood that each elongated member can have a variety of different cross-sectional configurations along part, or the complete length of, each elongated member. Such configurations include circular, oval, elliptical, diamond, triangular, trapezoidal, polygonal (e.g. square, rectangular, hexagonal, etc.). In addition, the cross-sectional length or diameter of the elongated members can be the same or different. - Referring to FIGS. 1, 2,3B, and 4, the elongated members on
body members parallelogram 80, 90 is formed by foursides body member 30 which are defined by sides 82 a-d, sides 82 a of each parallelogram ofbody member 30 substantially lie in a single longitudinal axis. Likewise, sides 82 c of each parallelogram ofbody member 30 substantially lie in a single longitudinal axis. In addition, sides 82 a and 82 c of each parallelogram are substantially parallel to each other.Sides 82 b and 82 d of each parallelogram are substantially parallel to one another.Sides 82 b and 82 d are shown to slope from left to right. The slope angle between sides 82 b and 82 c and sides 82 a and 82 d ranges between 0-90°, and typically about 10-60°. The parallelogram shape has a height “b.” Height b will vary depending or the size of the unexpanded body member. The maximum of height b is about 1 inch, and generally about 0.005 to 0.5 inch, and typically about 0.01 to 0.1 inch; however, other heights can be used.Sides 82 a and 82 c can have the same or different length fromsides 82 b and 82 d . The length of the sides can be up to 2 inches, and generally ranges from 0.005 to 1 inch, and typically 0.01 to 0.5 inch. As shown in FIG. 2, all the sides have substantially the same length. Each of the parallelograms has substantially the same dimensions. - Referring now to a set of parallelogram shapes aligned along a longitudinal axis of
body member 30 which are defined bysides 82 a′-d′, sides 82 a′ of each parallelogram ofbody member 30 substantially lie in a single longitudinal axis. Likewise, sides 82 c′ of each parallelogram ofbody member 30 substantially lie in a single longitudinal axis. In addition, sides 82 a′ and 82 c′ of each parallelogram are substantially parallel to each other. Sides 82 b′ and 82 d′ of each parallelogram are substantially parallel to one another. Sides 82 b′ and 82 d′ are shown to slope from right to left. The slope angle between sides 82 b′ and 82 c′ and sides 82 a′ and 82 d′ ranges between 0-90°, and typically about 10-60°. The parallelogram shape has a height “b′.” Height b′ will vary depending or the size of the unexpanded body member. The height ranges of b′ are generally the same as b. The length ranges of sides 82 a-d are also generally the same as 82 a′-d′. - As shown in FIG. 2, all the sides have substantially the same length. Each of the parallelograms has substantially the same dimensions. In addition, the shape and size of the parallelograms is substantially the same as the parallelogram defined by sides82 a-d. Referring again to FIG. 2, the orientation of the parallelograms alternates along the latitudinal axis from
parallelograms having sides 82 b and 82 d sloping from left to right and parallelograms having sides 82 b′ and 82 d′ sloping from right to left. A similar parallelogram pattern exists onbody member 40. Referring now to FIGS. 2 and 3B, the orientation of the parallelograms that are aligned along the same longitudinal axis forbody members body members - To provide flexibility to the stent,
body members several connector members 70. One such connector member is a connector member having a “U” shapedmember 72 as shown in FIGS. 1, 2 and 3. As best shown in FIGS. 1 and 2,connector member 70 joinsend 34 ofbody member 30 to end 42 ofbody member 40. Four connector members are shown to connect the two body members together.Connector member 70 also includes a bar member 74. The bar member spans between the second end of “U” shapedmember 72 and end 42 ofbody member 40. The first end of “U” shapedmember 72 is connected to end 34 ofbody member 30. As best shown in FIG. 2,connectors 70 do not connect to all of theends 34 ofbody member 30 or all of theends 42 ofbody member 40. - Referring to FIG. 3, the connector member has certain dimensions that enhance the flexibility of the stent. The cross-sectional length or diameter of the “U” shaped member is generally the same as the cross-sectional length or diameter “a” of the elongated members; however, other cross-sectional lengths or diameters of the “U” shaped member can be used. The height of the legs of the “U” shaped member is generally equal to2 a+(b or b′) wherein “a” is the cross-sectional length or diameter of the elongated members and b or b′ is the height of the parallelograms in the unexpanded state. As can be appreciated, other heights of the legs of the “U” shaped member can be used. The width “c” of the “U” shaped member also affects the flexibility of the connector member and the stent. The width generally is about 1-4 times the cross-sectional length or diameter “a” of the “U” shaped member, and typically about 1.2-2 times the cross-sectional length or diameter “a” of the “U” shaped member; however, other widths can be used. In addition, the spacing of the “U” shaped member from ends 34 of
body member 30 and end 42 ofbody member 40 also affects the flexibility of the connector member and the stent. As shown in FIG. 2, the “U” shaped portion of the connector member is spaced a distance from the ends of the body members that is substantially equal to cross-sectional length or diameter “a” of the elongated members. Bar member 74 has a sufficient length to form the desired spacing of the “U” shaped portion of the connector member from ends ofbody member 40. The connector member allows the body members to transverse, bend and improve flexibility invariant to the plane of bending. As can be appreciated, other shaped connectors which include an arcuate portion and/or V-shaped portion can be used. - Referring now to FIG. 1A, ends32, 34, 42, and 44 are treated so as to have generally smooth surfaces 60. Generally, the ends are treated by filing, buffing, polishing, grinding, and/or the like the end surfaces. As a result, sharp edges, pointed surfaces and the like are substantially eliminated from the end section. Typically all the ends of the body members are treated to have smooth surfaces. The smooth surfaces of the ends reduce damage to surrounding tissue as the body member is positioned in and/or expanded in a body passageway. In addition to the ends having generally smooth surfaces, the
elongated members 50 and/or joints between the elongated members are formed, filed, buffed, ground, polished, and/or the like to also have generally smooth surfaces. Furthermore,connector members 70 and/or the connection points between the connector members and the elongated members are formed, filed, buffed, ground, polished, and/or the like to have generally smooth surfaces. The substantial removal of sharp edges, pointed surfaces and the like from the entire stent reduces damage to surrounding tissue as the stent is positioned in and/or expanded in a body passageway. As can be appreciated, the ends of the body members, the elongated members, the joints between the elongated members, the connector members, and/or the connection points between the elongated members and the connector members can additionally or alternatively be coated with a material that reduces or eliminates any sharp and/or rough surfaces. The coating, if used, is generally a polymer and/or copolymer material. The coating can be nonbiodegradable, biodegradable or semi-biodegradable. Typically the coating thickness is less than the cross-sectional thickness of the elongated members. One non-limiting example of a coating thickness is about 0.00005 to 0.0005 inches. -
Elongated members 50 and/orconnector members 70 can be formed by a variety of processes. Typically, the elongated members and connector members are formed by etching, laser cutting and/or punching a single piece of material so that the individual intersections of the elongated members and/or the connections between the elongated members and the connector members need not be welded, soldered, glued or otherwise connected together. For example, the stent can be formed from a thin-walled metal tube, and the openings between the elongated members and the connector members are formed by an etching process, such as electromechanical or laser etching, whereby the resultant structure is a stent having a plurality of intersecting elongated members and connector members as shown in FIG. 1. This technique enhances the structural integrity of the structure and reduces the number of rough surfaces at the intersection points. An alternative method or process to form the stent is to use a flat piece of material and form the openings between the elongated members and the connector members by an etching process, such as electromechanical or laser etching, stamping, laser cutting, drilling, and/or the like. Such a flat piece of material is illustrated in FIGS. 3 and 3B. - Referring specifically to FIG. 3B, the complete stent with the cut out regions is shown prior to the stent being formed into a tubular shape or some other cross-sectional shape. The flat sheet includes seven (7) formed parallelograms along the latitudinal axis of the sheet and one partially formed parallelogram. The flat sheet also includes ten (10) parallelograms along the longitudinal axis of the sheet. Four “U” shaped connector members are formed along the latitudinal axis of the sheet. The connector members divide the parallelograms along the longitudinal axis of the sheet into two sets of five (5), thus each body member has five (5) parallelograms along the longitudinal axis and seven (7) fully formed parallelograms and one partially formed parallelogram along the latitudinal axis. As shown in FIG. 3B,
body members top bar 38, 48. In addition,body members ends top bar 38, 48 thereby resulting in a fully formed parallelogram, thereby resulting in eight (8) fully formed parallelograms about the outer surface ofbody members body members top bar 38, 48 can be formed by welding, soldering, brazing, adhesives, lock and groove configurations, snap configurations, melting together the ends and the top bars, and the like. Typically, after the connection has been made, the surfaces around the connection are smoothed to remove sharp and/or rough surfaces. FIG. 3B illustrates ends 32,34,42, and 44 as being smooth surfaces. Ends 39 are also shown as being relatively smooth surfaces. - Referring now to FIG. 4, there is shown a
single parallelogram shape 80. The left parallelogram shape is representative of the parallelogram shapes inbody members - Referring now to FIGS. 5, 6, and7, a second embodiment of the present invention is illustrated. As shown in FIG. 5, a
stent 100 includes twobody members stent 100 can include more than two body members.Body members body member 110 and ends 144, 146 ofbody member 112. The two body members are connected together byseveral connector members 120. Generally,connector members 120 include an arcuate shapedmember 122, and typically is “U” shaped, similar to shape and size ofconnector members 70 as shown in FIG. 3B.Connector member 120 also includes abar member 124. The connector members provide flexibility to thestent body members member 122 and end. As best shown in FIGS. 5 and 6, the “U” shaped member alternates between being connected to end 142 and end 144 and similarly, the bar member alternates between being connected to end 144 and end 142. The “U” shaped members are typically spaced apart a sufficient distance so as to avoid contacting one another in the unexpanded state. In addition, the “U” shaped members are typically spaced apart a sufficient distance so as to avoid contacting one another in the expanded state. The connector members allow the body members to transverse, bend and improve flexibility invariant to the plane of bending. As can be appreciated, other shaped connectors which include an arcuate portion can be used. - Referring to FIG. 5,
body members slots Slots slot 130 includes two ends 130a, 130b and eachslot 132 includes two ends 132 a, 132 b. Each series ofslots 130 along a longitudinal axis of the stent are arranged substantially parallel to one another. Similarly, each series ofslots 132 along a longitudinal axis of the stent are arranged substantially parallel to one another.Slots slots slots slots - The slots in the body members can be formed in a variety of manners. In one method or process, the stent is formed from a flat piece of material and the slots and connector members are formed by an etching process, such as electromechanical or laser etching, stamping, laser cutting, drilling, and/or the like. After the slots are formed, the stent is generally treated so as to have generally smooth surfaces60. Generally, the ends, slots and connector members are treated by filing, buffing, polishing, grinding, and/or the like. As a result, sharp edges, pointed surfaces and the like are substantially eliminated. The smooth surfaces reduce damage to surrounding tissue as the body member is positioned in and/or expanded in a body passageway. As can be appreciated, the ends of the body members, the slots, and/or the connector members can additionally or alternatively be coated and/or impregnated with a material that reduces or eliminates any sharp and/or rough surfaces. The coating, if used, is generally a polymer and/or copolymer material. The coating can be non-biodegradable, biodegradable or semi-biodegradable. Typically the coating thickness is less than the half the width of the slots. One non-limiting example of a coating thickness is about 0.00005 to 0.0005 inches.
- After the flat material has the slots and connector members inserted therein, the flat material is rolled or otherwise formed and the side edges of the flat material are connected together form the stent. The side edges of the flat material can be connected together by a variety of techniques such as, but not limited to, welding, soldering, brazing, adhesives, lock and groove configurations, snap configurations, melting together the edges, and the like. The cross-sectional shape of the stent is typically circular; however, other cross-sectional shapes can be formed such as, but not limited to, oval, elliptical, diamond, triangular, trapezoidal, polygonal (e.g. square, rectangular, hexagonal, etc.). The connection between the edges is generally treated to reduce or eliminate the rough or sharp surfaces.
- Referring now to FIG. 8, a
stent 200 is shown to include acompound 210 on theelongated members 220 andconnector 230 of the body member.Compound 210 is or includes a vascular active agent that inhibits and/or prevents restenosis, vascular narrowing and/or in-stent restenosis. As can be appreciated, compound can alternatively or also be a secondary vascular active agent and/or a biological agent. As can be appreciated, compound 2 1 0 can represent one or more different compounds. One preferable compound that is or is included in the vascular active agent is a PDGF inhibitor. One type of PDGF inhibitor that is used is Trapidil and/or derivative thereof; however, other PDGF inhibitors can be used. Another preferable compound that is or is included in the vascular active agent is GM-CSF and/or derivative thereof. - The amount of vascular active agent and/or secondary vascular active agent and/or other biological agent delivered to a certain region of a body passageway can be controlled by varying the coating thickness, drug concentration of the vascular active agent and/or secondary vascular active agent and/or other biological agent, the solubility of the vascular active agent and/or secondary vascular active agent and/or other biological agent in a particular body passageway, the amount of surface area of the
body member 200 that is coated and/or impregnated with the vascular active agent and/or secondary vascular active agent and/or other biological agent, the location of the vascular active agent and/or secondary vascular active agent and/or other biological agent on the stent, and/or the size of cavity openings in the stent. As can be appreciated, the vascular active agent and/or secondary vascular active agent and/or other biological agent can be combined with, or at least partially coated with, another compound that affects the rate at which the vascular active agent and/or secondary vascular active agent and/or other biological agent is released from the surface of the stent. An intermediate compound can be used in conjunction withcompound 210 to assist in bindingcompound 210 tobody member 200. In addition, or alternatively, the intermediate compound can be used to control the release ofcompound 210 into the body passageways. In one particular application, the intermediate compound is biodegradable and dissolves over the course of time, and the intermediate compound is coated at one or more thicknesses overcompound 210 to delay delivery ofcompound 210 into a body passageway. - Referring now to FIGS. 10, 10A and11, the vascular active agent and/or secondary vascular active agent and/or other biological agent is combined with a polymer and/or copolymer prior to being at least partially coated onto the stent. The polymer and/or copolymer can be formulated to bond the vascular active agent and/or secondary vascular active agent and/or other biological agent to the stent; however, the polymer and/or copolymer can be used in combination with other compounds to facilitate in the bonding of the vascular active agent, secondary vascular active agent and/or other biological agent and/or polymer and/or copolymer to the stent. Referring now to FIG. 10, there is illustrated a typical process whereby one or more vascular active agents, one or more secondary vascular active agents, one or more other biological agents, and/or other compounds are coated to the stent. As shown in FIG. 10, the vascular active agent and/or secondary vascular active agent and/or other biological agent is mixed with a polymer and/or copolymer prior to coating the stent. The polymer and/or copolymer is formulated to delay and/or regulate the time and/or amount of vascular active agent and/or secondary vascular active agent and/or other biological agent being released into the body passageway. The polymer and/or copolymer can be a biodegradable compound, a non-biodegradable compound, or a partially biodegradable compound. The polymer and/or copolymer can be formulated so as to form one or more bonds with the vascular active agent and/or secondary vascular active agent and/or other biological agent, or be chemically inert with respect to the vascular active agent and/or secondary vascular active agent and/or other biological agent. Generally, the polymer and/or copolymer form at least one bond with one or more vascular active agents and/or secondary vascular active agents and/or other biological agents. The bond is generally formed in a polymer and/or copolymer salt complex. For example, when the vascular active agent is or includes Trapidil, the Trapidil forms a salt complex with the polymer and/or copolymer. The Trapidil forms the cationic component of the salt complex and the polymer and/or copolymer forms the anionic component of the salt complex. Typically, the carboxylate groups, phosphate groups, and/or sulfate groups in the polymer and/or copolymer form the bond with this vascular active agent.
- After the vascular active agent and/or secondary vascular active agent and/or other biological agent has been mixed with the polymer and/or copolymer, the mixture is coated onto the stent. After the stent or a portion of the stent has been coated with the mixture, the coated stent can be subjected to radiation. The radiation causes the polymer and/or copolymer to form cross-linking between the polymer and/or copolymer chains and/or causes one or more bonds to form between the polymer and/or copolymer and the vascular active agent and/or secondary vascular active agent and/or other biological agent. The cross-linking and/or bond formation alters the rate of release of the one or more vascular active agents and/or secondary vascular active agents and/or other biological agents into the body passageway. The radiation typically includes, but is not limited to, gamma radiation, beta radiation, and/or e-beam radiation; however, other types of radiation (e.g. inferred, ultraviolet) can be used in conjunction with or as an alternative to gamma radiation, beta radiation, and/or e-beam radiation. When the polymer and/or copolymer is exposed to radiation, one or more hydrogen radicals are typically removed from the polymer and/or copolymer chain. This process is illustrated in FIG. 11. As can be appreciated, other elements in the polymer and/or copolymer can be removed and/or disassociated from the polymer and/or copolymer when the polymer and/or copolymer is exposed to radiation.
- As illustrated in FIG. 11, a polymer and/or copolymer chain includes a carboxyl group that has formed a salt complex with Trapidil. Radiation is applied to the polymer and/or copolymer salt complex resulting in removal of one or more hydrogen atoms from the polymer and/or copolymer chain. The removal of the hydrogen radical causes the polymer and/or copolymer chain to cross-link with another portion of the polymer and/or copolymer chain or cross-link with a different polymer and/or copolymer as shown in FIG. 11. FIG. 10A illustrates the vascular active agent and/or secondary vascular active agent and/or other biological agent being entrapped or partially entrapped within the cross-linking of the polymer and/or copolymer. The entrapped vascular active agent and/or secondary vascular active agent and/or other biological agent takes longer to release itself from the cross-linked coating compound and to pass into the body passageway. As a result, the amount of vascular active agent and/or secondary vascular active agent and/or other biological agent, and/or rate at which the vascular active agent and/or secondary vascular active agent and/or other biological agent released from the stent over time can be controlled by the amount of cross-linking in the coating compound and/or the amount of bonding in the coating compound. The amount of cross-linking and/or bonding in the coating compound is controlled by the type and amount of radiation applied to the coating compound. The amount of radiation exposure to the polymer and/or copolymer salt complex is controlled so as to prevent degradation of the vascular active agent, secondary vascular active agent, other biological agent, and/or polymer and/or copolymer during the irradiation procedure. In addition to the radiation causing cross-linking and/or bonding, the radiation at least partially sterilizes the stent. The radiation destroys most if not all of the foreign organisms on the stent and/or on any coating on the stent. As a result, sterilization by radiation reduces the occurrence of infection by foreign organisms.
- Referring now to FIG. 9, a vascular active agent and/or secondary vascular active agent and/or other
biological agent 240 is delivered into a body passageway A viaangioplasty balloon 250.Balloon 250 includes one ormore slots 260 to allow delivery of vascular active agent and/or secondary vascular active agent and/or otherbiological agent 240 into bodypassageway A. Balloon 250 can be used to both delivercompound 210 and expand thestent 200, or be used in conjunction with another balloon or stent expanding device. When the vascular active agent includes one or more PDGF inhibitors, local delivery of the inhibitor by a stent and/or via a balloon is highly advantageous. - The present invention has been described with reference to a number of different embodiments. It is to be understood that the invention is not limited to the exact details of construction, operation, exact materials or embodiments shown and described, as obvious modifications and equivalents will be apparent to one skilled in the art. It is believed that many modifications and alterations to the embodiments disclosed will readily suggest themselves to those skilled in the art upon reading and understanding the detailed description of the invention. It is intended to include all such modifications and alterations insofar as they come within the scope of the present invention.
Claims (67)
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/209,591 US20030040790A1 (en) | 1998-04-15 | 2002-07-31 | Stent coating |
JP2003539737A JP2005507711A (en) | 2001-10-26 | 2002-08-15 | Improved stent coating |
PCT/US2002/026195 WO2003037398A2 (en) | 2001-10-26 | 2002-08-15 | Improved stent coating |
EP02775716A EP1453557A4 (en) | 2001-10-26 | 2002-08-15 | Improved stent coating |
AU2002341567A AU2002341567A1 (en) | 2001-10-26 | 2002-08-15 | Improved stent coating |
US10/935,516 US8016881B2 (en) | 2002-07-31 | 2004-09-07 | Sutures and surgical staples for anastamoses, wound closures, and surgical closures |
US11/283,330 US7967855B2 (en) | 1998-07-27 | 2005-11-18 | Coated medical device |
US11/283,434 US8070796B2 (en) | 1998-07-27 | 2005-11-18 | Thrombosis inhibiting graft |
US11/337,225 US8740973B2 (en) | 2001-10-26 | 2006-01-20 | Polymer biodegradable medical device |
US11/646,890 US8100963B2 (en) | 2001-10-26 | 2006-12-28 | Biodegradable device |
US12/267,651 US8114152B2 (en) | 1998-04-15 | 2008-11-10 | Stent coating |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8182498P | 1998-04-15 | 1998-04-15 | |
US9425098P | 1998-07-27 | 1998-07-27 | |
US09/273,736 US6436133B1 (en) | 1998-04-15 | 1999-03-22 | Expandable graft |
US77107301A | 2001-01-29 | 2001-01-29 | |
US10/039,816 US20020099438A1 (en) | 1998-04-15 | 2001-10-26 | Irradiated stent coating |
US10/209,591 US20030040790A1 (en) | 1998-04-15 | 2002-07-31 | Stent coating |
Related Parent Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/039,816 Continuation-In-Part US20020099438A1 (en) | 1998-04-15 | 2001-10-26 | Irradiated stent coating |
US10/039,816 Continuation US20020099438A1 (en) | 1998-04-15 | 2001-10-26 | Irradiated stent coating |
US11/337,225 Continuation-In-Part US8740973B2 (en) | 2001-10-26 | 2006-01-20 | Polymer biodegradable medical device |
US11/646,890 Continuation-In-Part US8100963B2 (en) | 2001-10-26 | 2006-12-28 | Biodegradable device |
Related Child Applications (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/810,356 Continuation-In-Part US8603158B2 (en) | 1998-04-15 | 2004-03-26 | Irradiated stent coating |
US10/935,516 Continuation-In-Part US8016881B2 (en) | 2002-07-31 | 2004-09-07 | Sutures and surgical staples for anastamoses, wound closures, and surgical closures |
US11/283,330 Continuation-In-Part US7967855B2 (en) | 1998-07-27 | 2005-11-18 | Coated medical device |
US11/337,225 Continuation-In-Part US8740973B2 (en) | 2001-10-26 | 2006-01-20 | Polymer biodegradable medical device |
US11/646,890 Continuation-In-Part US8100963B2 (en) | 2001-10-26 | 2006-12-28 | Biodegradable device |
US12/267,651 Continuation US8114152B2 (en) | 1998-04-15 | 2008-11-10 | Stent coating |
Publications (1)
Publication Number | Publication Date |
---|---|
US20030040790A1 true US20030040790A1 (en) | 2003-02-27 |
Family
ID=26716476
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/209,591 Abandoned US20030040790A1 (en) | 1998-04-15 | 2002-07-31 | Stent coating |
US12/267,651 Expired - Fee Related US8114152B2 (en) | 1998-04-15 | 2008-11-10 | Stent coating |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/267,651 Expired - Fee Related US8114152B2 (en) | 1998-04-15 | 2008-11-10 | Stent coating |
Country Status (5)
Country | Link |
---|---|
US (2) | US20030040790A1 (en) |
EP (1) | EP1453557A4 (en) |
JP (1) | JP2005507711A (en) |
AU (1) | AU2002341567A1 (en) |
WO (1) | WO2003037398A2 (en) |
Cited By (178)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020198344A1 (en) * | 2001-04-10 | 2002-12-26 | Wolfgang Voigt | Stabilized medium and high voltage cable insulation composition |
US6629994B2 (en) | 2001-06-11 | 2003-10-07 | Advanced Cardiovascular Systems, Inc. | Intravascular stent |
US20040098118A1 (en) * | 2002-09-26 | 2004-05-20 | Endovascular Devices, Inc. | Apparatus and method for delivery of mitomycin through an eluting biocompatible implantable medical device |
US20040182312A1 (en) * | 2001-05-31 | 2004-09-23 | Pacetti Stephen D | Apparatus and method for coating implantable devices |
US20040234737A1 (en) * | 2001-09-27 | 2004-11-25 | Advanced Cardiovascular Systems Inc. | Rate-reducing membrane for release of an agent |
US20050038472A1 (en) * | 2002-07-31 | 2005-02-17 | Icon Interventional Systems, Inc. | Sutures and surgical staples for anastamoses, wound closures, and surgical closures |
US20050085898A1 (en) * | 2003-10-21 | 2005-04-21 | Cook Incorporated. | Natural tissue stent |
US20050100609A1 (en) * | 2001-03-30 | 2005-05-12 | Claude Charles D. | Phase-separated polymer coatings |
US20050106204A1 (en) * | 2003-11-19 | 2005-05-19 | Hossainy Syed F. | Biologically beneficial coatings for implantable devices containing fluorinated polymers and methods for fabricating the same |
US20050112171A1 (en) * | 2003-11-21 | 2005-05-26 | Yiwen Tang | Coatings for implantable devices including biologically erodable polyesters and methods for fabricating the same |
US20050131201A1 (en) * | 2003-12-16 | 2005-06-16 | Pacetti Stephen D. | Biologically absorbable coatings for implantable devices based on poly(ester amides) and methods for fabricating the same |
US20050137381A1 (en) * | 2003-12-19 | 2005-06-23 | Pacetti Stephen D. | Biobeneficial polyamide/polyethylene glycol polymers for use with drug eluting stents |
US20050147647A1 (en) * | 2003-12-24 | 2005-07-07 | Thierry Glauser | Coatings for implantable medical devices comprising hydrophilic substances and methods for fabricating the same |
US20050159802A1 (en) * | 2004-01-15 | 2005-07-21 | Icon Interventional Systems, Inc., An Ohio Corporation | Method for verifying position on an angioplasty balloon |
US20050165476A1 (en) * | 2004-01-23 | 2005-07-28 | Furst Joseph G. | Vascular grafts with amphiphilic block copolymer coatings |
US20050171596A1 (en) * | 2004-02-03 | 2005-08-04 | Furst Joseph G. | Stents with amphiphilic copolymer coatings |
US20050186248A1 (en) * | 2003-02-26 | 2005-08-25 | Hossainy Syed F. | Stent coating |
US20050191332A1 (en) * | 2002-11-12 | 2005-09-01 | Hossainy Syed F. | Method of forming rate limiting barriers for implantable devices |
US20050208091A1 (en) * | 2004-03-16 | 2005-09-22 | Pacetti Stephen D | Biologically absorbable coatings for implantable devices based on copolymers having ester bonds and methods for fabricating the same |
US20050233062A1 (en) * | 1999-09-03 | 2005-10-20 | Hossainy Syed F | Thermal treatment of an implantable medical device |
US20050238686A1 (en) * | 1999-12-23 | 2005-10-27 | Advanced Cardiovascular Systems, Inc. | Coating for implantable devices and a method of forming the same |
US20050244363A1 (en) * | 2004-04-30 | 2005-11-03 | Hossainy Syed F A | Hyaluronic acid based copolymers |
US20050266038A1 (en) * | 2004-05-27 | 2005-12-01 | Thierry Glauser | Antifouling heparin coatings |
US20050287184A1 (en) * | 2004-06-29 | 2005-12-29 | Hossainy Syed F A | Drug-delivery stent formulations for restenosis and vulnerable plaque |
US20060002977A1 (en) * | 2004-06-30 | 2006-01-05 | Stephen Dugan | Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders with an implantable medical device |
US20060002968A1 (en) * | 2004-06-30 | 2006-01-05 | Gordon Stewart | Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders |
US20060002974A1 (en) * | 2002-06-21 | 2006-01-05 | Advanced Cardiovascular Systems, Inc. | Polycationic peptide coatings and methods of coating implantable medical devices |
US20060013853A1 (en) * | 2004-07-19 | 2006-01-19 | Richard Robert E | Medical devices having conductive substrate and covalently bonded coating layer |
US20060034888A1 (en) * | 2004-07-30 | 2006-02-16 | Advanced Cardiovascular Systems, Inc. | Coatings for implantable devices comprising poly (hydroxy-alkanoates) and diacid linkages |
US20060035012A1 (en) * | 2001-06-27 | 2006-02-16 | Advanced Cardiovascular Systems, Inc. | Method of using a mandrel to coat a stent |
US20060047095A1 (en) * | 2004-08-31 | 2006-03-02 | Pacetti Stephen D | Polymers of fluorinated monomers and hydrophilic monomers |
US20060045901A1 (en) * | 2004-08-26 | 2006-03-02 | Jan Weber | Stents with drug eluting coatings |
US20060062824A1 (en) * | 2004-09-22 | 2006-03-23 | Advanced Cardiovascular Systems, Inc. | Medicated coatings for implantable medical devices including polyacrylates |
US20060062821A1 (en) * | 2002-06-21 | 2006-03-23 | Simhambhatla Murthy V | Polycationic peptide coatings and methods of making the same |
US20060067908A1 (en) * | 2004-09-30 | 2006-03-30 | Ni Ding | Methacrylate copolymers for medical devices |
US20060070626A1 (en) * | 2004-10-04 | 2006-04-06 | Andrew Frazier | System and method for airway manipulation |
US20060074191A1 (en) * | 2004-10-06 | 2006-04-06 | Desnoyer Jessica R | Blends of poly(ester amide) polymers |
US20060089485A1 (en) * | 2004-10-27 | 2006-04-27 | Desnoyer Jessica R | End-capped poly(ester amide) copolymers |
US20060095122A1 (en) * | 2004-10-29 | 2006-05-04 | Advanced Cardiovascular Systems, Inc. | Implantable devices comprising biologically absorbable star polymers and methods for fabricating the same |
US20060093842A1 (en) * | 2004-10-29 | 2006-05-04 | Desnoyer Jessica R | Poly(ester amide) filler blends for modulation of coating properties |
US20060115513A1 (en) * | 2004-11-29 | 2006-06-01 | Hossainy Syed F A | Derivatized poly(ester amide) as a biobeneficial coating |
US20060115449A1 (en) * | 2004-11-30 | 2006-06-01 | Advanced Cardiovascular Systems, Inc. | Bioabsorbable, biobeneficial, tyrosine-based polymers for use in drug eluting stent coatings |
US20060136051A1 (en) * | 1998-07-27 | 2006-06-22 | Icon Interventional Systems, Inc. | Coated medical device |
US20060134165A1 (en) * | 2004-12-22 | 2006-06-22 | Pacetti Stephen D | Polymers of fluorinated monomers and hydrocarbon monomers |
US20060147412A1 (en) * | 2004-12-30 | 2006-07-06 | Hossainy Syed F | Polymers containing poly(hydroxyalkanoates) and agents for use with medical articles and methods of fabricating the same |
US20060160985A1 (en) * | 2005-01-14 | 2006-07-20 | Pacetti Stephen D | Poly(hydroxyalkanoate-co-ester amides) and agents for use with medical articles |
US20060193892A1 (en) * | 2001-10-26 | 2006-08-31 | Icon Medical Corp. | Polymer biodegradable medical device |
US20060200226A1 (en) * | 2005-03-03 | 2006-09-07 | Icon Medical Corp. | Metal alloys for medical devices |
US20060200225A1 (en) * | 2005-03-03 | 2006-09-07 | Icon Interventional Systems, Inc. | Metal alloy for a stent |
US20060201601A1 (en) * | 2005-03-03 | 2006-09-14 | Icon Interventional Systems, Inc. | Flexible markers |
US20060207501A1 (en) * | 2002-12-12 | 2006-09-21 | Advanced Cardiovascular Systems, Inc. | Clamp mandrel fixture and a method of using the same to minimize coating defects |
US20060224237A1 (en) * | 2005-03-03 | 2006-10-05 | Icon Medical Corp. | Fragile structure protective coating |
US20060264914A1 (en) * | 2005-03-03 | 2006-11-23 | Icon Medical Corp. | Metal alloys for medical devices |
US20070016284A1 (en) * | 2001-09-07 | 2007-01-18 | Advanced Cardiovascular Systems, Inc. | Polymeric coating for reducing the rate of release of a therapeutic substance from a stent |
US20070016280A1 (en) * | 2005-07-14 | 2007-01-18 | Cappella, Inc. | Delivery System And Method Of Use For Deployment Of Self-Expandable Vascular Device |
US20070020381A1 (en) * | 2002-03-27 | 2007-01-25 | Advanced Cardiovascular Systems, Inc. | 40-O-(2-hydroxy)ethyl-rapamycin coated stent |
US20070020380A1 (en) * | 2005-07-25 | 2007-01-25 | Ni Ding | Methods of providing antioxidants to a drug containing product |
US20070037891A1 (en) * | 2005-04-15 | 2007-02-15 | Roseita Esfand | Methods and compositions for the delivery of biologically active agents |
US20070043381A1 (en) * | 2005-08-19 | 2007-02-22 | Icon Medical Corp. | Medical device deployment instrument |
WO2007022201A2 (en) * | 2005-08-16 | 2007-02-22 | Poly-Med, Inc. | Absorbable endo-urological devices and applications therefor |
US20070043422A1 (en) * | 2005-08-18 | 2007-02-22 | Cappella, Inc. | Delivery system and method of use for accurate positioning of a device in a bifurcation |
US20070061003A1 (en) * | 2005-09-15 | 2007-03-15 | Cappella, Inc. | Segmented ostial protection device |
US20070065480A1 (en) * | 2003-11-14 | 2007-03-22 | Advanced Cardiovascular Systems, Inc. | Block copolymers of acrylates and methacrylates with fluoroalkenes |
US20070077347A1 (en) * | 1996-12-26 | 2007-04-05 | Jacob Richter | Flat process of drug coating for stents |
US20070088428A1 (en) * | 2005-09-15 | 2007-04-19 | Cappella, Inc. | Intraluminal device with asymmetric cap portion |
US20070123973A1 (en) * | 2001-10-26 | 2007-05-31 | Roth Noah M | Biodegradable device |
WO2007065016A2 (en) * | 2005-12-02 | 2007-06-07 | Au Jessie L S | Methods and compositions to improve activity and reduce toxicity of stents |
US20070128246A1 (en) * | 2005-12-06 | 2007-06-07 | Hossainy Syed F A | Solventless method for forming a coating |
US20070135909A1 (en) * | 2005-12-08 | 2007-06-14 | Desnoyer Jessica R | Adhesion polymers to improve stent retention |
US20070167602A1 (en) * | 2004-11-24 | 2007-07-19 | Advanced Cardiovascular Systems | Biologically absorbable coatings for implantable devices based on polyesters and methods for fabricating the same |
US20070191926A1 (en) * | 2006-02-14 | 2007-08-16 | Advanced Cardiovascular Systems, Inc. | Stent pattern for high stent retention |
US20070191708A1 (en) * | 2003-12-24 | 2007-08-16 | Bodo Gerold | Radio-opaque marker for medical implants |
US20070196424A1 (en) * | 2006-02-17 | 2007-08-23 | Advanced Cardiovascular Systems, Inc. | Nitric oxide generating medical devices |
US20070198081A1 (en) * | 2000-09-28 | 2007-08-23 | Daniel Castro | Poly(butylmethacrylate) and rapamycin coated stent |
US20070202323A1 (en) * | 2006-02-28 | 2007-08-30 | Kleiner Lothar W | Coating construct containing poly (vinyl alcohol) |
US20070207181A1 (en) * | 2006-03-03 | 2007-09-06 | Kleiner Lothar W | Coating containing PEGylated hyaluronic acid and a PEGylated non-hyaluronic acid polymer |
US20070231363A1 (en) * | 2006-03-29 | 2007-10-04 | Yung-Ming Chen | Coatings formed from stimulus-sensitive material |
US20070259102A1 (en) * | 2006-05-04 | 2007-11-08 | Mcniven Andrew | Methods and devices for coating stents |
US20070259101A1 (en) * | 2006-05-02 | 2007-11-08 | Kleiner Lothar W | Microporous coating on medical devices |
WO2005120549A3 (en) * | 2004-06-07 | 2007-11-15 | Conor Medsystems Inc | Local delivery of growth factors for stem cell transplantation |
US20070286882A1 (en) * | 2006-06-09 | 2007-12-13 | Yiwen Tang | Solvent systems for coating medical devices |
US20080003253A1 (en) * | 2006-06-29 | 2008-01-03 | Thierry Glauser | Block copolymers including a methoxyethyl methacrylate midblock |
US20080008739A1 (en) * | 2006-07-07 | 2008-01-10 | Hossainy Syed F A | Phase-separated block copolymer coatings for implantable medical devices |
US20080008736A1 (en) * | 2006-07-06 | 2008-01-10 | Thierry Glauser | Random copolymers of methacrylates and acrylates |
US20080021008A1 (en) * | 2003-05-08 | 2008-01-24 | Advanced Cardiovascular Systems, Inc. | Stent coatings comprising hydrophilic additives |
US20080021307A1 (en) * | 2006-07-13 | 2008-01-24 | Abigail Freeman | Radio frequency identification monitoring of stents |
US20080038310A1 (en) * | 2006-06-09 | 2008-02-14 | Hossainy Syed F A | Coating comprising an elastin-based copolymer |
WO2008022258A2 (en) * | 2006-08-16 | 2008-02-21 | Surmodics, Inc. | Methods and materials for increasing the adhesion of elution control matrices to substrates |
US20080075753A1 (en) * | 2006-09-25 | 2008-03-27 | Chappa Ralph A | Multi-layered coatings and methods for controlling elution of active agents |
US20080086194A1 (en) * | 2006-10-06 | 2008-04-10 | Advanced Cardiovascular Systems, | Intravascular stent |
US20080095815A1 (en) * | 2004-10-22 | 2008-04-24 | The Board Of Trustees Of The University Of Illinois | Hollow and Porous Orthopaedic or Dental Implant that Delivers a Biological Agent |
US20080095918A1 (en) * | 2006-06-14 | 2008-04-24 | Kleiner Lothar W | Coating construct with enhanced interfacial compatibility |
US20080118541A1 (en) * | 2006-11-21 | 2008-05-22 | Abbott Laboratories | Use of a terpolymer of tetrafluoroethylene, hexafluoropropylene, and vinylidene fluoride in drug eluting coatings on medical devices |
US20080125560A1 (en) * | 2006-11-21 | 2008-05-29 | Abbott Laboratories | Copolymers having 1-methyl-2-methoxyethyl moieties |
US20080124372A1 (en) * | 2006-06-06 | 2008-05-29 | Hossainy Syed F A | Morphology profiles for control of agent release rates from polymer matrices |
US20080125857A1 (en) * | 2000-10-31 | 2008-05-29 | Advanced Cardiovascular Systems, Inc. | Hemocompatible polymers on hydrophobic porous polymers |
US20080146992A1 (en) * | 2006-12-15 | 2008-06-19 | Hossainy Syed F A | Coatings of acrylamide-based copolymers |
US20080145393A1 (en) * | 2006-12-13 | 2008-06-19 | Trollsas Mikael O | Coating of fast absorption or dissolution |
US20080206306A1 (en) * | 2004-12-27 | 2008-08-28 | Syed Faiyaz Ahmed Hossainy | Poly(ester amide) block copolymers |
US20080226812A1 (en) * | 2006-05-26 | 2008-09-18 | Yung Ming Chen | Stent coating apparatus and method |
US20080262606A1 (en) * | 2004-07-30 | 2008-10-23 | Ni Ding | Polymers containing siloxane monomers |
US20090041845A1 (en) * | 2007-08-08 | 2009-02-12 | Lothar Walter Kleiner | Implantable medical devices having thin absorbable coatings |
US20090062904A1 (en) * | 1998-04-15 | 2009-03-05 | Icon Interventional Systems, Inc. | Stent coating |
US20090200177A1 (en) * | 2005-03-03 | 2009-08-13 | Icon Medical Corp. | Process for forming an improved metal alloy stent |
US20090232865A1 (en) * | 2004-10-27 | 2009-09-17 | Abbott Cardiovascular Systems Inc. | End-Capped Poly(Ester Amide) Copolymers |
US20090286761A1 (en) * | 2002-12-16 | 2009-11-19 | Jin Cheng | Anti-Proliferative and Anti-Inflammatory Agent Combination for Treatment of Vascular Disorders with an Implantable Medical Device |
US20090286864A1 (en) * | 2007-06-01 | 2009-11-19 | Taewoong Medical Co., Ltd. | Coating agent for drug releasing stent, preparation method thereof and drug releasing stent coated therewith |
US7648727B2 (en) | 2004-08-26 | 2010-01-19 | Advanced Cardiovascular Systems, Inc. | Methods for manufacturing a coated stent-balloon assembly |
US7700659B2 (en) | 2005-03-24 | 2010-04-20 | Advanced Cardiovascular Systems, Inc. | Implantable devices formed of non-fouling methacrylate or acrylate polymers |
US20100100171A1 (en) * | 2005-06-20 | 2010-04-22 | Advanced Cardiovascular Systems, Inc. | Method Of Manufacturing An Implantable Polymeric Medical Device |
US7713541B1 (en) | 2006-11-21 | 2010-05-11 | Abbott Cardiovascular Systems Inc. | Zwitterionic terpolymers, method of making and use on medical devices |
US20100131044A1 (en) * | 2006-07-13 | 2010-05-27 | Udayan Patel | Stent |
US20100143332A1 (en) * | 2006-11-17 | 2010-06-10 | Schering Corporation | Combination therapy for proliferative disorders |
US7735449B1 (en) | 2005-07-28 | 2010-06-15 | Advanced Cardiovascular Systems, Inc. | Stent fixture having rounded support structures and method for use thereof |
US7758880B2 (en) | 2002-12-11 | 2010-07-20 | Advanced Cardiovascular Systems, Inc. | Biocompatible polyacrylate compositions for medical applications |
US20100196438A1 (en) * | 2004-05-27 | 2010-08-05 | Medtronic, Inc. | Methods including medical devices having a surface including a biologically active agent therein |
US7776926B1 (en) | 2002-12-11 | 2010-08-17 | Advanced Cardiovascular Systems, Inc. | Biocompatible coating for implantable medical devices |
US7785512B1 (en) | 2003-07-31 | 2010-08-31 | Advanced Cardiovascular Systems, Inc. | Method and system of controlled temperature mixing and molding of polymers with active agents for implantable medical devices |
US7795467B1 (en) | 2005-04-26 | 2010-09-14 | Advanced Cardiovascular Systems, Inc. | Bioabsorbable, biobeneficial polyurethanes for use in medical devices |
US7803394B2 (en) | 2002-06-21 | 2010-09-28 | Advanced Cardiovascular Systems, Inc. | Polycationic peptide hydrogel coatings for cardiovascular therapy |
US7820732B2 (en) | 2004-04-30 | 2010-10-26 | Advanced Cardiovascular Systems, Inc. | Methods for modulating thermal and mechanical properties of coatings on implantable devices |
US7823533B2 (en) | 2005-06-30 | 2010-11-02 | Advanced Cardiovascular Systems, Inc. | Stent fixture and method for reducing coating defects |
US20100275431A1 (en) * | 2001-01-11 | 2010-11-04 | Abbott Laboratories | Drug delivery from stents |
US7867547B2 (en) | 2005-12-19 | 2011-01-11 | Advanced Cardiovascular Systems, Inc. | Selectively coating luminal surfaces of stents |
US7892592B1 (en) | 2004-11-30 | 2011-02-22 | Advanced Cardiovascular Systems, Inc. | Coating abluminal surfaces of stents and other implantable medical devices |
US7976891B1 (en) | 2005-12-16 | 2011-07-12 | Advanced Cardiovascular Systems, Inc. | Abluminal stent coating apparatus and method of using focused acoustic energy |
US7985441B1 (en) | 2006-05-04 | 2011-07-26 | Yiwen Tang | Purification of polymers for coating applications |
US8003156B2 (en) | 2006-05-04 | 2011-08-23 | Advanced Cardiovascular Systems, Inc. | Rotatable support elements for stents |
US20110214785A1 (en) * | 2010-03-04 | 2011-09-08 | Icon Medical Corp. | method for forming a tubular medical device |
US8017237B2 (en) | 2006-06-23 | 2011-09-13 | Abbott Cardiovascular Systems, Inc. | Nanoshells on polymers |
US8021676B2 (en) | 2005-07-08 | 2011-09-20 | Advanced Cardiovascular Systems, Inc. | Functionalized chemically inert polymers for coatings |
US20110238152A1 (en) * | 2006-03-15 | 2011-09-29 | Medinol Ltd. | Flat process of preparing drug eluting stents |
US20110238163A1 (en) * | 2008-09-08 | 2011-09-29 | Laboratorios Farmaceuticos Rovi S.A. | Multi-layered Device |
US8048441B2 (en) | 2007-06-25 | 2011-11-01 | Abbott Cardiovascular Systems, Inc. | Nanobead releasing medical devices |
US8048448B2 (en) | 2006-06-15 | 2011-11-01 | Abbott Cardiovascular Systems Inc. | Nanoshells for drug delivery |
US8052912B2 (en) | 2003-12-01 | 2011-11-08 | Advanced Cardiovascular Systems, Inc. | Temperature controlled crimping |
US8057841B2 (en) | 2004-02-12 | 2011-11-15 | University Of Akron | Mechanically attached medical device coatings |
US20110282430A1 (en) * | 2010-05-14 | 2011-11-17 | Boston Scientific Scimed, Inc. | Endoprosthesis |
US8062350B2 (en) | 2006-06-14 | 2011-11-22 | Abbott Cardiovascular Systems Inc. | RGD peptide attached to bioabsorbable stents |
US8067023B2 (en) | 2002-06-21 | 2011-11-29 | Advanced Cardiovascular Systems, Inc. | Implantable medical devices incorporating plasma polymerized film layers and charged amino acids |
US8070796B2 (en) | 1998-07-27 | 2011-12-06 | Icon Interventional Systems, Inc. | Thrombosis inhibiting graft |
US8109904B1 (en) | 2007-06-25 | 2012-02-07 | Abbott Cardiovascular Systems Inc. | Drug delivery medical devices |
US8147769B1 (en) | 2007-05-16 | 2012-04-03 | Abbott Cardiovascular Systems Inc. | Stent and delivery system with reduced chemical degradation |
US8197879B2 (en) | 2003-09-30 | 2012-06-12 | Advanced Cardiovascular Systems, Inc. | Method for selectively coating surfaces of a stent |
WO2012164294A1 (en) * | 2011-06-03 | 2012-12-06 | Vascutek Limited | Stent element |
US8506617B1 (en) | 2002-06-21 | 2013-08-13 | Advanced Cardiovascular Systems, Inc. | Micronized peptide coated stent |
US20130218181A1 (en) * | 2012-02-08 | 2013-08-22 | Quattro Vascular PE Ltd. | Constraining structure with non-linear axial struts |
US8568764B2 (en) | 2006-05-31 | 2013-10-29 | Advanced Cardiovascular Systems, Inc. | Methods of forming coating layers for medical devices utilizing flash vaporization |
WO2013172938A1 (en) * | 2012-05-14 | 2013-11-21 | C.R. Bard, Inc. | Uniformly expandable stent |
US8603158B2 (en) | 1998-04-15 | 2013-12-10 | Icon Interventional Systems, Inc | Irradiated stent coating |
US8603530B2 (en) | 2006-06-14 | 2013-12-10 | Abbott Cardiovascular Systems Inc. | Nanoshell therapy |
US20140066960A1 (en) * | 2012-02-08 | 2014-03-06 | Quattro Vascular Pte Ltd. | System and method for treating biological vessels |
US8703167B2 (en) | 2006-06-05 | 2014-04-22 | Advanced Cardiovascular Systems, Inc. | Coatings for implantable medical devices for controlled release of a hydrophilic drug and a hydrophobic drug |
US8703169B1 (en) | 2006-08-15 | 2014-04-22 | Abbott Cardiovascular Systems Inc. | Implantable device having a coating comprising carrageenan and a biostable polymer |
US8741378B1 (en) | 2001-06-27 | 2014-06-03 | Advanced Cardiovascular Systems, Inc. | Methods of coating an implantable device |
US20140163586A1 (en) * | 2012-12-11 | 2014-06-12 | Dolly Jeanne Holt | Tissue repair devices and methods |
US8778014B1 (en) | 2004-03-31 | 2014-07-15 | Advanced Cardiovascular Systems, Inc. | Coatings for preventing balloon damage to polymer coated stents |
US8778375B2 (en) | 2005-04-29 | 2014-07-15 | Advanced Cardiovascular Systems, Inc. | Amorphous poly(D,L-lactide) coating |
EP2796112A1 (en) * | 2005-04-05 | 2014-10-29 | Elixir Medical Corporation | Degradable implantable medical devices |
USD723165S1 (en) | 2013-03-12 | 2015-02-24 | C. R. Bard, Inc. | Stent |
US9056155B1 (en) | 2007-05-29 | 2015-06-16 | Abbott Cardiovascular Systems Inc. | Coatings having an elastic primer layer |
US9107899B2 (en) | 2005-03-03 | 2015-08-18 | Icon Medical Corporation | Metal alloys for medical devices |
US9180225B2 (en) | 2007-05-14 | 2015-11-10 | Abbott Laboratories | Implantable medical devices with a topcoat layer of phosphoryl choline acrylate polymer for reduced thrombosis, and improved mechanical properties |
US9364498B2 (en) | 2004-06-18 | 2016-06-14 | Abbott Cardiovascular Systems Inc. | Heparin prodrugs and drug delivery stents formed therefrom |
US9381279B2 (en) | 2005-03-24 | 2016-07-05 | Abbott Cardiovascular Systems Inc. | Implantable devices formed on non-fouling methacrylate or acrylate polymers |
US9561351B2 (en) | 2006-05-31 | 2017-02-07 | Advanced Cardiovascular Systems, Inc. | Drug delivery spiral coil construct |
US10076591B2 (en) | 2010-03-31 | 2018-09-18 | Abbott Cardiovascular Systems Inc. | Absorbable coating for implantable device |
US10220193B2 (en) | 2012-02-01 | 2019-03-05 | TriReme Medical, LLC | Device for compartmental dilatation of blood vessels |
US10232148B2 (en) | 2014-11-17 | 2019-03-19 | TriReme Medical, LLC | Balloon catheter system and method of using same |
US10238513B2 (en) | 2017-07-19 | 2019-03-26 | Abbott Cardiovascular Systems Inc. | Intravascular stent |
US20190125935A1 (en) * | 2007-12-18 | 2019-05-02 | Intersect Ent, Inc. | Self-expanding devices and methods therefor |
US10549077B2 (en) | 2010-03-12 | 2020-02-04 | TriReme Medical, LLC | Device and method for compartmental vessel treatment |
US11123091B2 (en) | 2005-04-04 | 2021-09-21 | Intersect Ent, Inc. | Device and methods for treating paranasal sinus conditions |
US11291812B2 (en) | 2003-03-14 | 2022-04-05 | Intersect Ent, Inc. | Sinus delivery of sustained release therapeutics |
US11484693B2 (en) | 2009-05-15 | 2022-11-01 | Intersect Ent, Inc. | Expandable devices and methods for treating a nasal or sinus condition |
US11672960B2 (en) | 2013-03-14 | 2023-06-13 | Intersect Ent, Inc. | Systems, devices, and method for treating a sinus condition |
US11766506B2 (en) | 2016-03-04 | 2023-09-26 | Mirus Llc | Stent device for spinal fusion |
US11779685B2 (en) | 2014-06-24 | 2023-10-10 | Mirus Llc | Metal alloys for medical devices |
Families Citing this family (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7713297B2 (en) | 1998-04-11 | 2010-05-11 | Boston Scientific Scimed, Inc. | Drug-releasing stent with ceramic-containing layer |
US8137397B2 (en) * | 2004-02-26 | 2012-03-20 | Boston Scientific Scimed, Inc. | Medical devices |
US9000040B2 (en) | 2004-09-28 | 2015-04-07 | Atrium Medical Corporation | Cross-linked fatty acid-based biomaterials |
US20060088596A1 (en) | 2004-09-28 | 2006-04-27 | Atrium Medical Corporation | Solubilizing a drug for use in a coating |
US9012506B2 (en) | 2004-09-28 | 2015-04-21 | Atrium Medical Corporation | Cross-linked fatty acid-based biomaterials |
EP1811933B1 (en) | 2004-09-28 | 2016-03-23 | Atrium Medical Corporation | Barrier layer |
US9801982B2 (en) | 2004-09-28 | 2017-10-31 | Atrium Medical Corporation | Implantable barrier device |
AU2012202903B2 (en) * | 2005-02-18 | 2014-12-11 | Abraxis Bioscience, Inc. | Drugs with improved hydrophobicity for incorporation in medical devices |
US20090130163A1 (en) | 2005-02-18 | 2009-05-21 | Abraxis Bio Scoence, Inc. | Drugs With Improved Hydrophobicity For Incorporation in Medical Devices |
DE102005031868A1 (en) * | 2005-07-04 | 2007-01-18 | Biotronik Vi Patent Ag | Drug depot for parenteral, especially intravascular drug release |
US9278161B2 (en) | 2005-09-28 | 2016-03-08 | Atrium Medical Corporation | Tissue-separating fatty acid adhesion barrier |
US9427423B2 (en) | 2009-03-10 | 2016-08-30 | Atrium Medical Corporation | Fatty-acid based particles |
CA2626030A1 (en) | 2005-10-15 | 2007-04-26 | Atrium Medical Corporation | Hydrophobic cross-linked gels for bioabsorbable drug carrier coatings |
US20070224235A1 (en) | 2006-03-24 | 2007-09-27 | Barron Tenney | Medical devices having nanoporous coatings for controlled therapeutic agent delivery |
US8187620B2 (en) | 2006-03-27 | 2012-05-29 | Boston Scientific Scimed, Inc. | Medical devices comprising a porous metal oxide or metal material and a polymer coating for delivering therapeutic agents |
US8815275B2 (en) | 2006-06-28 | 2014-08-26 | Boston Scientific Scimed, Inc. | Coatings for medical devices comprising a therapeutic agent and a metallic material |
US8771343B2 (en) | 2006-06-29 | 2014-07-08 | Boston Scientific Scimed, Inc. | Medical devices with selective titanium oxide coatings |
WO2008033711A2 (en) | 2006-09-14 | 2008-03-20 | Boston Scientific Limited | Medical devices with drug-eluting coating |
US9492596B2 (en) | 2006-11-06 | 2016-11-15 | Atrium Medical Corporation | Barrier layer with underlying medical device and one or more reinforcing support structures |
WO2008057328A2 (en) | 2006-11-06 | 2008-05-15 | Atrium Medical Corporation | Tissue separating device with reinforced support for anchoring mechanisms |
US7981150B2 (en) | 2006-11-09 | 2011-07-19 | Boston Scientific Scimed, Inc. | Endoprosthesis with coatings |
US8070797B2 (en) | 2007-03-01 | 2011-12-06 | Boston Scientific Scimed, Inc. | Medical device with a porous surface for delivery of a therapeutic agent |
US8431149B2 (en) | 2007-03-01 | 2013-04-30 | Boston Scientific Scimed, Inc. | Coated medical devices for abluminal drug delivery |
US8067054B2 (en) | 2007-04-05 | 2011-11-29 | Boston Scientific Scimed, Inc. | Stents with ceramic drug reservoir layer and methods of making and using the same |
US7976915B2 (en) | 2007-05-23 | 2011-07-12 | Boston Scientific Scimed, Inc. | Endoprosthesis with select ceramic morphology |
US7942926B2 (en) | 2007-07-11 | 2011-05-17 | Boston Scientific Scimed, Inc. | Endoprosthesis coating |
US8002823B2 (en) | 2007-07-11 | 2011-08-23 | Boston Scientific Scimed, Inc. | Endoprosthesis coating |
US9284409B2 (en) | 2007-07-19 | 2016-03-15 | Boston Scientific Scimed, Inc. | Endoprosthesis having a non-fouling surface |
US7931683B2 (en) | 2007-07-27 | 2011-04-26 | Boston Scientific Scimed, Inc. | Articles having ceramic coated surfaces |
US8815273B2 (en) | 2007-07-27 | 2014-08-26 | Boston Scientific Scimed, Inc. | Drug eluting medical devices having porous layers |
US8221822B2 (en) | 2007-07-31 | 2012-07-17 | Boston Scientific Scimed, Inc. | Medical device coating by laser cladding |
WO2009020520A1 (en) | 2007-08-03 | 2009-02-12 | Boston Scientific Scimed, Inc. | Coating for medical device having increased surface area |
US8216632B2 (en) | 2007-11-02 | 2012-07-10 | Boston Scientific Scimed, Inc. | Endoprosthesis coating |
US8029554B2 (en) | 2007-11-02 | 2011-10-04 | Boston Scientific Scimed, Inc. | Stent with embedded material |
US7938855B2 (en) | 2007-11-02 | 2011-05-10 | Boston Scientific Scimed, Inc. | Deformable underlayer for stent |
WO2009061389A2 (en) | 2007-11-05 | 2009-05-14 | St. Jude Medical, Inc. | Collapsible/expandable prosthetic heart valves with non-expanding stent posts and retrieval features |
JP5581311B2 (en) | 2008-04-22 | 2014-08-27 | ボストン サイエンティフィック サイムド,インコーポレイテッド | MEDICAL DEVICE HAVING INORGANIC MATERIAL COATING AND MANUFACTURING METHOD THEREOF |
US8932346B2 (en) | 2008-04-24 | 2015-01-13 | Boston Scientific Scimed, Inc. | Medical devices having inorganic particle layers |
WO2009155328A2 (en) | 2008-06-18 | 2009-12-23 | Boston Scientific Scimed, Inc. | Endoprosthesis coating |
US8231980B2 (en) | 2008-12-03 | 2012-07-31 | Boston Scientific Scimed, Inc. | Medical implants including iridium oxide |
US8071156B2 (en) | 2009-03-04 | 2011-12-06 | Boston Scientific Scimed, Inc. | Endoprostheses |
US8287937B2 (en) | 2009-04-24 | 2012-10-16 | Boston Scientific Scimed, Inc. | Endoprosthese |
JP5820370B2 (en) * | 2009-05-20 | 2015-11-24 | アーセナル メディカル, インコーポレイテッド | Medical implant |
US20110319987A1 (en) | 2009-05-20 | 2011-12-29 | Arsenal Medical | Medical implant |
US8992601B2 (en) | 2009-05-20 | 2015-03-31 | 480 Biomedical, Inc. | Medical implants |
US8888840B2 (en) * | 2009-05-20 | 2014-11-18 | Boston Scientific Scimed, Inc. | Drug eluting medical implant |
US9309347B2 (en) | 2009-05-20 | 2016-04-12 | Biomedical, Inc. | Bioresorbable thermoset polyester/urethane elastomers |
US9265633B2 (en) | 2009-05-20 | 2016-02-23 | 480 Biomedical, Inc. | Drug-eluting medical implants |
US20110038910A1 (en) | 2009-08-11 | 2011-02-17 | Atrium Medical Corporation | Anti-infective antimicrobial-containing biomaterials |
EP2593141B1 (en) | 2010-07-16 | 2018-07-04 | Atrium Medical Corporation | Composition and methods for altering the rate of hydrolysis of cured oil-based materials |
CN103781358A (en) * | 2010-12-10 | 2014-05-07 | 新泽西医科和牙科大学 | Implantable devices coated with insulin-mimetic agent composites and methods thereof |
US20120156128A1 (en) * | 2010-12-10 | 2012-06-21 | Yu-Li Chang | Controllable release composition and method for preparing same |
DE102011009372B3 (en) * | 2011-01-25 | 2012-07-12 | Acandis Gmbh & Co. Kg | Medical device with a grid structure and a treatment system with such a grid structure |
WO2013078422A2 (en) | 2011-11-23 | 2013-05-30 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US9718781B2 (en) | 2012-04-17 | 2017-08-01 | University College Dublin, National University Of Ireland, Dublin | Methods and compounds for treating proliferative disorders and viral infections |
US9388127B2 (en) | 2012-04-17 | 2016-07-12 | University College Dublin, National University Of Ireland, Dublin | Thromboxane receptor antagonists |
US9867880B2 (en) | 2012-06-13 | 2018-01-16 | Atrium Medical Corporation | Cured oil-hydrogel biomaterial compositions for controlled drug delivery |
US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US9763911B2 (en) * | 2013-12-12 | 2017-09-19 | Mayo Foundation For Medical Education And Research | Prostacyclin compositions for regulation of fracture repair and bone formation |
US10206932B2 (en) | 2014-05-22 | 2019-02-19 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
EP3310756B1 (en) | 2015-06-16 | 2020-12-09 | ATXA Therapeutics Limited | Thromboxane receptor antagonists |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
AU2017239645A1 (en) | 2016-04-01 | 2018-10-18 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
CN109925536B (en) * | 2017-12-15 | 2021-01-26 | 先健科技(深圳)有限公司 | Absorbable iron-based implantable device |
US11633405B2 (en) | 2020-02-07 | 2023-04-25 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical formulations |
Citations (92)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4733665A (en) * | 1985-11-07 | 1988-03-29 | Expandable Grafts Partnership | Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft |
US4942204A (en) * | 1988-08-15 | 1990-07-17 | The University Of Akron | Amphiphilic networks |
US5024671A (en) * | 1988-09-19 | 1991-06-18 | Baxter International Inc. | Microporous vascular graft |
US5102417A (en) * | 1985-11-07 | 1992-04-07 | Expandable Grafts Partnership | Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft |
US5108366A (en) * | 1990-09-28 | 1992-04-28 | Ovamed Corporation | Delivery catheter |
US5108424A (en) * | 1984-01-30 | 1992-04-28 | Meadox Medicals, Inc. | Collagen-impregnated dacron graft |
US5116318A (en) * | 1989-06-06 | 1992-05-26 | Cordis Corporation | Dilatation balloon within an elastic sleeve |
US5185408A (en) * | 1987-12-17 | 1993-02-09 | Allied-Signal Inc. | Medical devices fabricated totally or in part from copolymers of recurring units derived from cyclic carbonates and lactides |
US5195984A (en) * | 1988-10-04 | 1993-03-23 | Expandable Grafts Partnership | Expandable intraluminal graft |
US5197977A (en) * | 1984-01-30 | 1993-03-30 | Meadox Medicals, Inc. | Drug delivery collagen-impregnated synthetic vascular graft |
US5283257A (en) * | 1992-07-10 | 1994-02-01 | The Board Of Trustees Of The Leland Stanford Junior University | Method of treating hyperproliferative vascular disease |
US5304121A (en) * | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
US5306250A (en) * | 1992-04-02 | 1994-04-26 | Indiana University Foundation | Method and apparatus for intravascular drug delivery |
US5316023A (en) * | 1992-01-08 | 1994-05-31 | Expandable Grafts Partnership | Method for bilateral intra-aortic bypass |
US5383927A (en) * | 1992-05-07 | 1995-01-24 | Intervascular Inc. | Non-thromogenic vascular prosthesis |
US5383928A (en) * | 1992-06-10 | 1995-01-24 | Emory University | Stent sheath for local drug delivery |
US5417961A (en) * | 1993-04-30 | 1995-05-23 | Colgate-Palmolive Company | Sunscreen compositions |
US5500013A (en) * | 1991-10-04 | 1996-03-19 | Scimed Life Systems, Inc. | Biodegradable drug delivery vascular stent |
US5516781A (en) * | 1992-01-09 | 1996-05-14 | American Home Products Corporation | Method of treating restenosis with rapamycin |
US5605696A (en) * | 1995-03-30 | 1997-02-25 | Advanced Cardiovascular Systems, Inc. | Drug loaded polymeric material and method of manufacture |
US5608829A (en) * | 1995-03-10 | 1997-03-04 | The Whitaker Corporation | Optical connector having optical fiber protection member |
US5609629A (en) * | 1995-06-07 | 1997-03-11 | Med Institute, Inc. | Coated implantable medical device |
US5616608A (en) * | 1993-07-29 | 1997-04-01 | The United States Of America As Represented By The Department Of Health And Human Services | Method of treating atherosclerosis or restenosis using microtubule stabilizing agent |
US5624411A (en) * | 1993-04-26 | 1997-04-29 | Medtronic, Inc. | Intravascular stent and method |
US5716981A (en) * | 1993-07-19 | 1998-02-10 | Angiogenesis Technologies, Inc. | Anti-angiogenic compositions and methods of use |
US5725572A (en) * | 1994-04-25 | 1998-03-10 | Advanced Cardiovascular Systems, Inc. | Radiopaque stent |
US5733303A (en) * | 1994-03-17 | 1998-03-31 | Medinol Ltd. | Flexible expandable stent |
US5733925A (en) * | 1993-01-28 | 1998-03-31 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US5735871A (en) * | 1994-12-09 | 1998-04-07 | Sgro; Jean-Claude | Self-expanding endoprosthesis |
US5755781A (en) * | 1996-08-06 | 1998-05-26 | Iowa-India Investments Company Limited | Embodiments of multiple interconnected stents |
US5772864A (en) * | 1996-02-23 | 1998-06-30 | Meadox Medicals, Inc. | Method for manufacturing implantable medical devices |
US5861027A (en) * | 1996-04-10 | 1999-01-19 | Variomed Ag | Stent for the transluminal implantation in hollow organs |
US5873904A (en) * | 1995-06-07 | 1999-02-23 | Cook Incorporated | Silver implantable medical device |
US5879370A (en) * | 1994-02-25 | 1999-03-09 | Fischell; Robert E. | Stent having a multiplicity of undulating longitudinals |
US5911732A (en) * | 1997-03-10 | 1999-06-15 | Johnson & Johnson Interventional Systems, Co. | Articulated expandable intraluminal stent |
US5916585A (en) * | 1996-06-03 | 1999-06-29 | Gore Enterprise Holdings, Inc. | Materials and method for the immobilization of bioactive species onto biodegradable polymers |
US6059810A (en) * | 1995-05-10 | 2000-05-09 | Scimed Life Systems, Inc. | Endovascular stent and method |
US6066325A (en) * | 1996-08-27 | 2000-05-23 | Fusion Medical Technologies, Inc. | Fragmented polymeric compositions and methods for their use |
US6171609B1 (en) * | 1995-02-15 | 2001-01-09 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US6200960B1 (en) * | 1996-03-07 | 2001-03-13 | Unisearch Limited | Inhibition of proliferation of cells |
US6200337B1 (en) * | 1996-03-10 | 2001-03-13 | Terumo Kabushiki Kaisha | Implanting stent |
US6200589B1 (en) * | 1996-09-13 | 2001-03-13 | The University Of Akron | Biological implants of semipermeable amphiphilic membranes |
US6206916B1 (en) * | 1998-04-15 | 2001-03-27 | Joseph G. Furst | Coated intraluminal graft |
US6209604B1 (en) * | 1997-12-22 | 2001-04-03 | Bridgestone Corporation | Pneumatic tire for passenger cars with sidewall portions having a rubber reinforcing layer and a rubber-filament fiber composite |
US6221099B1 (en) * | 1992-05-20 | 2001-04-24 | Boston Scientific Corporation | Tubular medical prosthesis |
US6245537B1 (en) * | 1997-05-12 | 2001-06-12 | Metabolix, Inc. | Removing endotoxin with an oxdizing agent from polyhydroxyalkanoates produced by fermentation |
US6335029B1 (en) * | 1998-08-28 | 2002-01-01 | Scimed Life Systems, Inc. | Polymeric coatings for controlled delivery of active agents |
US6356600B1 (en) * | 1998-04-21 | 2002-03-12 | The United States Of America As Represented By The Secretary Of The Navy | Non-parametric adaptive power law detector |
US20020032414A1 (en) * | 1998-08-20 | 2002-03-14 | Ragheb Anthony O. | Coated implantable medical device |
US6358969B1 (en) * | 1991-02-19 | 2002-03-19 | Smithkline Beecham P.L.C. | 3-desmethylrapamycin or derivatives thereof, processes for their preparation and their use as antifungal agents and immunosuppressants |
US6358556B1 (en) * | 1995-04-19 | 2002-03-19 | Boston Scientific Corporation | Drug release stent coating |
US6365171B1 (en) * | 1999-11-04 | 2002-04-02 | The University Of Akron | Amphiphilic networks, implantable immunoisolatory devices and methods of preparation |
US6367658B1 (en) * | 2000-07-20 | 2002-04-09 | David Joseph Kenney | Windshield washer fluid dispensing system |
US6369065B1 (en) * | 2000-05-15 | 2002-04-09 | Ucb S.A. | CD40 signal blocking agent |
US6368658B1 (en) * | 1999-04-19 | 2002-04-09 | Scimed Life Systems, Inc. | Coating medical devices using air suspension |
US6379381B1 (en) * | 1999-09-03 | 2002-04-30 | Advanced Cardiovascular Systems, Inc. | Porous prosthesis and a method of depositing substances into the pores |
US6379379B1 (en) * | 1998-05-05 | 2002-04-30 | Scimed Life Systems, Inc. | Stent with smooth ends |
US6391052B2 (en) * | 1994-04-29 | 2002-05-21 | Scimed Life Systems, Inc. | Stent with collagen |
US6399144B2 (en) * | 1998-04-29 | 2002-06-04 | Medtronic Inc. | Medical device for delivering a therapeutic substance and method therefor |
US20020082679A1 (en) * | 2000-12-22 | 2002-06-27 | Avantec Vascular Corporation | Delivery or therapeutic capable agents |
US6506536B2 (en) * | 2000-12-29 | 2003-01-14 | Kodak Polychrome Graphics, Llc | Imageable element and composition comprising thermally reversible polymers |
US20030026840A1 (en) * | 1999-06-25 | 2003-02-06 | Christian Plank | Combinations for introducing nucleic acids into cells |
US20030028243A1 (en) * | 1995-06-07 | 2003-02-06 | Cook Incorporated | Coated implantable medical device |
US20030028244A1 (en) * | 1995-06-07 | 2003-02-06 | Cook Incorporated | Coated implantable medical device |
US6517571B1 (en) * | 1999-01-22 | 2003-02-11 | Gore Enterprise Holdings, Inc. | Vascular graft with improved flow surfaces |
US20030036794A1 (en) * | 1995-06-07 | 2003-02-20 | Cook Incorporated | Coated implantable medical device |
US6527802B1 (en) * | 1993-01-19 | 2003-03-04 | Scimed Life Systems, Inc. | Clad composite stent |
US6528584B2 (en) * | 2001-04-12 | 2003-03-04 | The University Of Akron | Multi-component polymeric networks containing poly(ethylene glycol) |
US6530951B1 (en) * | 1996-10-24 | 2003-03-11 | Cook Incorporated | Silver implantable medical device |
US20030064098A1 (en) * | 1999-12-08 | 2003-04-03 | Kararli Tugrul T. | Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect |
US6545097B2 (en) * | 2000-12-12 | 2003-04-08 | Scimed Life Systems, Inc. | Drug delivery compositions and medical devices containing block copolymer |
US6555619B1 (en) * | 2000-06-29 | 2003-04-29 | The University Of Akron | Physically crosslinked amphiphilic networks, methods of preparation, and uses thereof |
US6555157B1 (en) * | 2000-07-25 | 2003-04-29 | Advanced Cardiovascular Systems, Inc. | Method for coating an implantable device and system for performing the method |
US20030083646A1 (en) * | 2000-12-22 | 2003-05-01 | Avantec Vascular Corporation | Apparatus and methods for variably controlled substance delivery from implanted prostheses |
US20030093141A1 (en) * | 2001-11-02 | 2003-05-15 | Boston Scientific Corporation/Scimed Life Systems, Inc. | Vapor deposition process for producing a stent-graft and a stent-graft produced therefrom |
US6569195B2 (en) * | 1999-07-02 | 2003-05-27 | Scimed Life Systems, Inc. | Stent coating |
US6569441B2 (en) * | 1993-01-28 | 2003-05-27 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US20030099712A1 (en) * | 2001-11-26 | 2003-05-29 | Swaminathan Jayaraman | Therapeutic coating for an intravascular implant |
US6583251B1 (en) * | 1997-09-08 | 2003-06-24 | Emory University | Modular cytomimetic biomaterials, transport studies, preparation and utilization thereof |
US6676937B1 (en) * | 1998-03-09 | 2004-01-13 | Caritas St. Elizabeth's Medical Center Of Boston Inc. | Compositions and methods for modulating vascularization |
US6695833B1 (en) * | 2000-09-27 | 2004-02-24 | Nellix, Inc. | Vascular stent-graft apparatus and forming method |
US6709379B1 (en) * | 1998-11-02 | 2004-03-23 | Alcove Surfaces Gmbh | Implant with cavities containing therapeutic agents |
US6720350B2 (en) * | 1997-03-31 | 2004-04-13 | Scimed Life Systems, Inc. | Therapeutic inhibitor of vascular smooth muscle cells |
US6723120B2 (en) * | 1997-04-15 | 2004-04-20 | Advanced Cardiovascular Systems, Inc. | Medicated porous metal prosthesis |
US6726923B2 (en) * | 2001-01-16 | 2004-04-27 | Vascular Therapies, Llc | Apparatus and methods for preventing or treating failure of hemodialysis vascular access and other vascular grafts |
US6730699B2 (en) * | 1998-03-30 | 2004-05-04 | Pg-Txl Company, L.P. | Water soluble paclitaxel derivatives |
US6730349B2 (en) * | 1999-04-19 | 2004-05-04 | Scimed Life Systems, Inc. | Mechanical and acoustical suspension coating of medical implants |
US6734194B2 (en) * | 1997-06-02 | 2004-05-11 | Janssen Pharmaceutica N.V. | Method of use of (imidazol-5-yl)methyl-2-quinolinone derivatives to inhibit smooth muscle cell proliferation |
US20040093077A1 (en) * | 2002-08-06 | 2004-05-13 | Jason White | Stent with micro-latching hinge joints |
US20040093076A1 (en) * | 2002-08-06 | 2004-05-13 | Jason White | Helical stent with micro-latches |
US6749554B1 (en) * | 1999-02-25 | 2004-06-15 | Amersham Plc | Medical tools and devices with improved ultrasound visibility |
US6753071B1 (en) * | 2001-09-27 | 2004-06-22 | Advanced Cardiovascular Systems, Inc. | Rate-reducing membrane for release of an agent |
Family Cites Families (82)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4888389A (en) | 1985-02-05 | 1989-12-19 | University Of Akron | Amphiphilic polymers and method of making said polymers |
US6018030A (en) * | 1986-11-04 | 2000-01-25 | Protein Polymer Technologies, Inc. | Peptides comprising repetitive units of amino acids and DNA sequences encoding the same |
US4766337A (en) | 1987-05-21 | 1988-08-23 | Magnetek, Inc. | Open drip-proof machinery cooling system using totally enclosed type bearing brackets |
US5051272A (en) | 1988-07-19 | 1991-09-24 | United States Surgical Corporation | Method for improving the storage stability of a polymeric article susceptible to hydrolytic degradation and resulting article |
US5073381A (en) | 1988-08-15 | 1991-12-17 | University Of Akron | Amphiphilic networks |
US6146358A (en) | 1989-03-14 | 2000-11-14 | Cordis Corporation | Method and apparatus for delivery of therapeutic agent |
US5037392A (en) | 1989-06-06 | 1991-08-06 | Cordis Corporation | Stent-implanting balloon assembly |
US5067491A (en) | 1989-12-08 | 1991-11-26 | Becton, Dickinson And Company | Barrier coating on blood contacting devices |
US5059166A (en) | 1989-12-11 | 1991-10-22 | Medical Innovative Technologies R & D Limited Partnership | Intra-arterial stent with the capability to inhibit intimal hyperplasia |
US5545208A (en) | 1990-02-28 | 1996-08-13 | Medtronic, Inc. | Intralumenal drug eluting prosthesis |
US5344426A (en) | 1990-04-25 | 1994-09-06 | Advanced Cardiovascular Systems, Inc. | Method and system for stent delivery |
US5180366A (en) | 1990-10-10 | 1993-01-19 | Woods W T | Apparatus and method for angioplasty and for preventing re-stenosis |
US5370681A (en) | 1991-09-16 | 1994-12-06 | Atrium Medical Corporation | Polyumenal implantable organ |
US5443498A (en) | 1991-10-01 | 1995-08-22 | Cook Incorporated | Vascular stent and method of making and implanting a vacsular stent |
DE69328523T2 (en) * | 1992-02-13 | 2000-09-21 | Surmodics Inc | IMMOBILIZATION OF A CHEMICAL SPECIES IN A NETWORKED MATRIX |
JPH07505316A (en) | 1992-03-31 | 1995-06-15 | ボストン サイエンティフィック コーポレーション | medical wire |
US5246452A (en) | 1992-04-13 | 1993-09-21 | Impra, Inc. | Vascular graft with removable sheath |
DE69325845T2 (en) * | 1992-04-28 | 2000-01-05 | Terumo Corp | Thermoplastic polymer composition and medical devices made therefrom |
US5263349A (en) | 1992-09-22 | 1993-11-23 | E. I. Du Pont De Nemours And Company | Extrusion of seamless molybdenum rhenium alloy pipes |
US6306421B1 (en) | 1992-09-25 | 2001-10-23 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US5449382A (en) | 1992-11-04 | 1995-09-12 | Dayton; Michael P. | Minimally invasive bioactivated endoprosthesis for vessel repair |
US5578075B1 (en) | 1992-11-04 | 2000-02-08 | Daynke Res Inc | Minimally invasive bioactivated endoprosthesis for vessel repair |
CA2152594C (en) | 1993-01-19 | 1998-12-01 | David W. Mayer | Clad composite stent |
US6663881B2 (en) | 1993-01-28 | 2003-12-16 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US5437744A (en) | 1993-01-28 | 1995-08-01 | Rhenium Alloys, Inc. | Molybdenum-rhenium alloy |
US5649977A (en) * | 1994-09-22 | 1997-07-22 | Advanced Cardiovascular Systems, Inc. | Metal reinforced polymer stent |
JP3359640B2 (en) | 1995-02-01 | 2002-12-24 | シュナイダー(ユーエスエー)インク | Method for hydrophilizing hydrophobic polymers |
US20030083733A1 (en) | 1997-10-10 | 2003-05-01 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US20020091433A1 (en) | 1995-04-19 | 2002-07-11 | Ni Ding | Drug release coated stent |
US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
US6120536A (en) | 1995-04-19 | 2000-09-19 | Schneider (Usa) Inc. | Medical devices with long term non-thrombogenic coatings |
WO1998017331A1 (en) * | 1995-06-07 | 1998-04-30 | Cook Incorporated | Silver implantable medical device |
US6068325A (en) * | 1995-09-21 | 2000-05-30 | Hughes; Charles A. | Golf club cover for golf carts |
US5695516A (en) | 1996-02-21 | 1997-12-09 | Iso Stent, Inc. | Longitudinally elongating balloon expandable stent |
US6440460B1 (en) | 1996-03-05 | 2002-08-27 | Allergan Sales, Inc. | Pharmaceutical compositions containing buffered ortho ester polymers |
CA2199890C (en) | 1996-03-26 | 2002-02-05 | Leonard Pinchuk | Stents and stent-grafts having enhanced hoop strength and methods of making the same |
DK0914102T3 (en) | 1996-05-24 | 2006-01-09 | Angiotech Pharm Inc | Preparations and methods for treating or preventing diseases of the body canals |
DK0906129T3 (en) | 1996-06-04 | 2002-12-02 | Cook Inc | Implantable medical device |
US5807944A (en) | 1996-06-27 | 1998-09-15 | Ciba Vision Corporation | Amphiphilic, segmented copolymer of controlled morphology and ophthalmic devices including contact lenses made therefrom |
US5776183A (en) * | 1996-08-23 | 1998-07-07 | Kanesaka; Nozomu | Expandable stent |
US5962620A (en) | 1996-08-26 | 1999-10-05 | Tyndale Plains-Hunter, Ltd. | Hydrophicic and hydrophobic polyether polyurethanes and uses therefor |
US5993972A (en) | 1996-08-26 | 1999-11-30 | Tyndale Plains-Hunter, Ltd. | Hydrophilic and hydrophobic polyether polyurethanes and uses therefor |
US6007573A (en) | 1996-09-18 | 1999-12-28 | Microtherapeutics, Inc. | Intracranial stent and method of use |
US6099561A (en) | 1996-10-21 | 2000-08-08 | Inflow Dynamics, Inc. | Vascular and endoluminal stents with improved coatings |
US5824045A (en) | 1996-10-21 | 1998-10-20 | Inflow Dynamics Inc. | Vascular and endoluminal stents |
US6624138B1 (en) | 2001-09-27 | 2003-09-23 | Gp Medical | Drug-loaded biological material chemically treated with genipin |
IL131063A (en) | 1997-01-24 | 2005-07-25 | Kentucky Oil N V | Bistable spring construction for a stent and other medical apparatus |
US5853419A (en) | 1997-03-17 | 1998-12-29 | Surface Genesis, Inc. | Stent |
US5843172A (en) | 1997-04-15 | 1998-12-01 | Advanced Cardiovascular Systems, Inc. | Porous medicated stent |
US6273913B1 (en) | 1997-04-18 | 2001-08-14 | Cordis Corporation | Modified stent useful for delivery of drugs along stent strut |
JP4147604B2 (en) | 1997-04-23 | 2008-09-10 | 神鋼電機株式会社 | Induction heating melting furnace and bottom tapping mechanism |
US6273908B1 (en) | 1997-10-24 | 2001-08-14 | Robert Ndondo-Lay | Stents |
US6156062A (en) | 1997-12-03 | 2000-12-05 | Ave Connaught | Helically wrapped interlocking stent |
US5964798A (en) | 1997-12-16 | 1999-10-12 | Cardiovasc, Inc. | Stent having high radial strength |
US6623521B2 (en) | 1998-02-17 | 2003-09-23 | Md3, Inc. | Expandable stent with sliding and locking radial elements |
US6126247A (en) | 1998-03-10 | 2000-10-03 | Westinghouse Air Brake Company | Computer control of railroad train brake system operation |
US6436133B1 (en) * | 1998-04-15 | 2002-08-20 | Joseph G. Furst | Expandable graft |
US20030040790A1 (en) * | 1998-04-15 | 2003-02-27 | Furst Joseph G. | Stent coating |
US6120847A (en) | 1999-01-08 | 2000-09-19 | Scimed Life Systems, Inc. | Surface treatment method for stent coating |
US6419692B1 (en) * | 1999-02-03 | 2002-07-16 | Scimed Life Systems, Inc. | Surface protection method for stents and balloon catheters for drug delivery |
US6156373A (en) | 1999-05-03 | 2000-12-05 | Scimed Life Systems, Inc. | Medical device coating methods and devices |
US6872225B1 (en) | 1999-05-27 | 2005-03-29 | Biocompatibles Uk Limited | Local drug delivery |
US6368315B1 (en) | 1999-06-23 | 2002-04-09 | Durect Corporation | Composite drug delivery catheter |
US6287628B1 (en) | 1999-09-03 | 2001-09-11 | Advanced Cardiovascular Systems, Inc. | Porous prosthesis and a method of depositing substances into the pores |
US6790228B2 (en) | 1999-12-23 | 2004-09-14 | Advanced Cardiovascular Systems, Inc. | Coating for implantable devices and a method of forming the same |
AU1723201A (en) | 1999-11-18 | 2001-05-30 | Petrus Besselink | Method for placing bifurcated stents |
US6790218B2 (en) | 1999-12-23 | 2004-09-14 | Swaminathan Jayaraman | Occlusive coil manufacture and delivery |
ES2282246T3 (en) | 2000-03-10 | 2007-10-16 | Anthony T. Don Michael | VASCULAR EMBOLIA PREVENTION DEVICE USING FILTERS. |
US20030229393A1 (en) | 2001-03-15 | 2003-12-11 | Kutryk Michael J. B. | Medical device with coating that promotes cell adherence and differentiation |
JP2004501143A (en) | 2000-06-22 | 2004-01-15 | ニトロメド インコーポレーテッド | Nitrosated and nitrosylated taxanes, compositions and methods of use |
US20020051730A1 (en) | 2000-09-29 | 2002-05-02 | Stanko Bodnar | Coated medical devices and sterilization thereof |
US6783793B1 (en) | 2000-10-26 | 2004-08-31 | Advanced Cardiovascular Systems, Inc. | Selective coating of medical devices |
KR20030045847A (en) | 2000-10-31 | 2003-06-11 | 쿡 인코포레이티드 | Coated implantable medical device |
US6780849B2 (en) | 2000-12-21 | 2004-08-24 | Scimed Life Systems, Inc. | Lipid-based nitric oxide donors |
US6764505B1 (en) | 2001-04-12 | 2004-07-20 | Advanced Cardiovascular Systems, Inc. | Variable surface area stent |
US6656506B1 (en) | 2001-05-09 | 2003-12-02 | Advanced Cardiovascular Systems, Inc. | Microparticle coated medical device |
US20030229390A1 (en) | 2001-09-17 | 2003-12-11 | Control Delivery Systems, Inc. | On-stent delivery of pyrimidines and purine analogs |
US6669502B1 (en) | 2002-09-19 | 2003-12-30 | Tyco Electronics Corporation | High-speed axial connector |
US20030181973A1 (en) * | 2002-03-20 | 2003-09-25 | Harvinder Sahota | Reduced restenosis drug containing stents |
US20030229392A1 (en) | 2002-06-03 | 2003-12-11 | Wong Samuel J. | Drug eluted vascular graft |
US7368125B2 (en) | 2002-06-05 | 2008-05-06 | Ethicon, Inc. | Amphiphilic polymers for medical applications |
US6770729B2 (en) | 2002-09-30 | 2004-08-03 | Medtronic Minimed, Inc. | Polymer compositions containing bioactive agents and methods for their use |
-
2002
- 2002-07-31 US US10/209,591 patent/US20030040790A1/en not_active Abandoned
- 2002-08-15 EP EP02775716A patent/EP1453557A4/en not_active Withdrawn
- 2002-08-15 JP JP2003539737A patent/JP2005507711A/en active Pending
- 2002-08-15 WO PCT/US2002/026195 patent/WO2003037398A2/en active Application Filing
- 2002-08-15 AU AU2002341567A patent/AU2002341567A1/en not_active Abandoned
-
2008
- 2008-11-10 US US12/267,651 patent/US8114152B2/en not_active Expired - Fee Related
Patent Citations (101)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5108424A (en) * | 1984-01-30 | 1992-04-28 | Meadox Medicals, Inc. | Collagen-impregnated dacron graft |
US5197977A (en) * | 1984-01-30 | 1993-03-30 | Meadox Medicals, Inc. | Drug delivery collagen-impregnated synthetic vascular graft |
US4733665C2 (en) * | 1985-11-07 | 2002-01-29 | Expandable Grafts Partnership | Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft |
US4733665B1 (en) * | 1985-11-07 | 1994-01-11 | Expandable Grafts Partnership | Expandable intraluminal graft,and method and apparatus for implanting an expandable intraluminal graft |
US5102417A (en) * | 1985-11-07 | 1992-04-07 | Expandable Grafts Partnership | Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft |
US4733665A (en) * | 1985-11-07 | 1988-03-29 | Expandable Grafts Partnership | Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft |
US4739762B1 (en) * | 1985-11-07 | 1998-10-27 | Expandable Grafts Partnership | Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft |
US4739762A (en) * | 1985-11-07 | 1988-04-26 | Expandable Grafts Partnership | Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft |
US5185408A (en) * | 1987-12-17 | 1993-02-09 | Allied-Signal Inc. | Medical devices fabricated totally or in part from copolymers of recurring units derived from cyclic carbonates and lactides |
US4942204A (en) * | 1988-08-15 | 1990-07-17 | The University Of Akron | Amphiphilic networks |
US5024671A (en) * | 1988-09-19 | 1991-06-18 | Baxter International Inc. | Microporous vascular graft |
US5195984A (en) * | 1988-10-04 | 1993-03-23 | Expandable Grafts Partnership | Expandable intraluminal graft |
US5116318A (en) * | 1989-06-06 | 1992-05-26 | Cordis Corporation | Dilatation balloon within an elastic sleeve |
US5108366A (en) * | 1990-09-28 | 1992-04-28 | Ovamed Corporation | Delivery catheter |
US5304121A (en) * | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
US6358969B1 (en) * | 1991-02-19 | 2002-03-19 | Smithkline Beecham P.L.C. | 3-desmethylrapamycin or derivatives thereof, processes for their preparation and their use as antifungal agents and immunosuppressants |
US6515009B1 (en) * | 1991-09-27 | 2003-02-04 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US6074659A (en) * | 1991-09-27 | 2000-06-13 | Noerx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US5500013A (en) * | 1991-10-04 | 1996-03-19 | Scimed Life Systems, Inc. | Biodegradable drug delivery vascular stent |
US5316023A (en) * | 1992-01-08 | 1994-05-31 | Expandable Grafts Partnership | Method for bilateral intra-aortic bypass |
US5516781A (en) * | 1992-01-09 | 1996-05-14 | American Home Products Corporation | Method of treating restenosis with rapamycin |
US5306250A (en) * | 1992-04-02 | 1994-04-26 | Indiana University Foundation | Method and apparatus for intravascular drug delivery |
US5383927A (en) * | 1992-05-07 | 1995-01-24 | Intervascular Inc. | Non-thromogenic vascular prosthesis |
US6221099B1 (en) * | 1992-05-20 | 2001-04-24 | Boston Scientific Corporation | Tubular medical prosthesis |
US5383928A (en) * | 1992-06-10 | 1995-01-24 | Emory University | Stent sheath for local drug delivery |
US5283257A (en) * | 1992-07-10 | 1994-02-01 | The Board Of Trustees Of The Leland Stanford Junior University | Method of treating hyperproliferative vascular disease |
US6527802B1 (en) * | 1993-01-19 | 2003-03-04 | Scimed Life Systems, Inc. | Clad composite stent |
US6569441B2 (en) * | 1993-01-28 | 2003-05-27 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US5733925A (en) * | 1993-01-28 | 1998-03-31 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US5624411A (en) * | 1993-04-26 | 1997-04-29 | Medtronic, Inc. | Intravascular stent and method |
US5417961A (en) * | 1993-04-30 | 1995-05-23 | Colgate-Palmolive Company | Sunscreen compositions |
US5716981A (en) * | 1993-07-19 | 1998-02-10 | Angiogenesis Technologies, Inc. | Anti-angiogenic compositions and methods of use |
US5616608A (en) * | 1993-07-29 | 1997-04-01 | The United States Of America As Represented By The Department Of Health And Human Services | Method of treating atherosclerosis or restenosis using microtubule stabilizing agent |
US5879370A (en) * | 1994-02-25 | 1999-03-09 | Fischell; Robert E. | Stent having a multiplicity of undulating longitudinals |
US5733303A (en) * | 1994-03-17 | 1998-03-31 | Medinol Ltd. | Flexible expandable stent |
US5725572A (en) * | 1994-04-25 | 1998-03-10 | Advanced Cardiovascular Systems, Inc. | Radiopaque stent |
US6391052B2 (en) * | 1994-04-29 | 2002-05-21 | Scimed Life Systems, Inc. | Stent with collagen |
US5735871A (en) * | 1994-12-09 | 1998-04-07 | Sgro; Jean-Claude | Self-expanding endoprosthesis |
US6171609B1 (en) * | 1995-02-15 | 2001-01-09 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US5608829A (en) * | 1995-03-10 | 1997-03-04 | The Whitaker Corporation | Optical connector having optical fiber protection member |
US5605696A (en) * | 1995-03-30 | 1997-02-25 | Advanced Cardiovascular Systems, Inc. | Drug loaded polymeric material and method of manufacture |
US6358556B1 (en) * | 1995-04-19 | 2002-03-19 | Boston Scientific Corporation | Drug release stent coating |
US6059810A (en) * | 1995-05-10 | 2000-05-09 | Scimed Life Systems, Inc. | Endovascular stent and method |
US20040047909A1 (en) * | 1995-06-07 | 2004-03-11 | Ragheb Anthony O. | Coated implantable medical device |
US20030028243A1 (en) * | 1995-06-07 | 2003-02-06 | Cook Incorporated | Coated implantable medical device |
US20030028244A1 (en) * | 1995-06-07 | 2003-02-06 | Cook Incorporated | Coated implantable medical device |
US20030036794A1 (en) * | 1995-06-07 | 2003-02-20 | Cook Incorporated | Coated implantable medical device |
US5609629A (en) * | 1995-06-07 | 1997-03-11 | Med Institute, Inc. | Coated implantable medical device |
US5873904A (en) * | 1995-06-07 | 1999-02-23 | Cook Incorporated | Silver implantable medical device |
US5772864A (en) * | 1996-02-23 | 1998-06-30 | Meadox Medicals, Inc. | Method for manufacturing implantable medical devices |
US6200960B1 (en) * | 1996-03-07 | 2001-03-13 | Unisearch Limited | Inhibition of proliferation of cells |
US6200337B1 (en) * | 1996-03-10 | 2001-03-13 | Terumo Kabushiki Kaisha | Implanting stent |
US5861027A (en) * | 1996-04-10 | 1999-01-19 | Variomed Ag | Stent for the transluminal implantation in hollow organs |
US5916585A (en) * | 1996-06-03 | 1999-06-29 | Gore Enterprise Holdings, Inc. | Materials and method for the immobilization of bioactive species onto biodegradable polymers |
US5755781A (en) * | 1996-08-06 | 1998-05-26 | Iowa-India Investments Company Limited | Embodiments of multiple interconnected stents |
US6066325A (en) * | 1996-08-27 | 2000-05-23 | Fusion Medical Technologies, Inc. | Fragmented polymeric compositions and methods for their use |
US6200589B1 (en) * | 1996-09-13 | 2001-03-13 | The University Of Akron | Biological implants of semipermeable amphiphilic membranes |
US6530951B1 (en) * | 1996-10-24 | 2003-03-11 | Cook Incorporated | Silver implantable medical device |
US5911732A (en) * | 1997-03-10 | 1999-06-15 | Johnson & Johnson Interventional Systems, Co. | Articulated expandable intraluminal stent |
US6720350B2 (en) * | 1997-03-31 | 2004-04-13 | Scimed Life Systems, Inc. | Therapeutic inhibitor of vascular smooth muscle cells |
US6723120B2 (en) * | 1997-04-15 | 2004-04-20 | Advanced Cardiovascular Systems, Inc. | Medicated porous metal prosthesis |
US6245537B1 (en) * | 1997-05-12 | 2001-06-12 | Metabolix, Inc. | Removing endotoxin with an oxdizing agent from polyhydroxyalkanoates produced by fermentation |
US6734194B2 (en) * | 1997-06-02 | 2004-05-11 | Janssen Pharmaceutica N.V. | Method of use of (imidazol-5-yl)methyl-2-quinolinone derivatives to inhibit smooth muscle cell proliferation |
US6743805B2 (en) * | 1997-06-02 | 2004-06-01 | Janssen Pharmaceutica Nv | Method of use of (imidazol-5-yl)methyl-2-quinolinone derivatives to inhibit smooth muscle cell proliferation |
US6583251B1 (en) * | 1997-09-08 | 2003-06-24 | Emory University | Modular cytomimetic biomaterials, transport studies, preparation and utilization thereof |
US6209604B1 (en) * | 1997-12-22 | 2001-04-03 | Bridgestone Corporation | Pneumatic tire for passenger cars with sidewall portions having a rubber reinforcing layer and a rubber-filament fiber composite |
US6676937B1 (en) * | 1998-03-09 | 2004-01-13 | Caritas St. Elizabeth's Medical Center Of Boston Inc. | Compositions and methods for modulating vascularization |
US6730699B2 (en) * | 1998-03-30 | 2004-05-04 | Pg-Txl Company, L.P. | Water soluble paclitaxel derivatives |
US6206916B1 (en) * | 1998-04-15 | 2001-03-27 | Joseph G. Furst | Coated intraluminal graft |
US6356600B1 (en) * | 1998-04-21 | 2002-03-12 | The United States Of America As Represented By The Secretary Of The Navy | Non-parametric adaptive power law detector |
US6399144B2 (en) * | 1998-04-29 | 2002-06-04 | Medtronic Inc. | Medical device for delivering a therapeutic substance and method therefor |
US6379379B1 (en) * | 1998-05-05 | 2002-04-30 | Scimed Life Systems, Inc. | Stent with smooth ends |
US20020032414A1 (en) * | 1998-08-20 | 2002-03-14 | Ragheb Anthony O. | Coated implantable medical device |
US6730064B2 (en) * | 1998-08-20 | 2004-05-04 | Cook Incorporated | Coated implantable medical device |
US6335029B1 (en) * | 1998-08-28 | 2002-01-01 | Scimed Life Systems, Inc. | Polymeric coatings for controlled delivery of active agents |
US6709379B1 (en) * | 1998-11-02 | 2004-03-23 | Alcove Surfaces Gmbh | Implant with cavities containing therapeutic agents |
US6517571B1 (en) * | 1999-01-22 | 2003-02-11 | Gore Enterprise Holdings, Inc. | Vascular graft with improved flow surfaces |
US6749554B1 (en) * | 1999-02-25 | 2004-06-15 | Amersham Plc | Medical tools and devices with improved ultrasound visibility |
US6730349B2 (en) * | 1999-04-19 | 2004-05-04 | Scimed Life Systems, Inc. | Mechanical and acoustical suspension coating of medical implants |
US6368658B1 (en) * | 1999-04-19 | 2002-04-09 | Scimed Life Systems, Inc. | Coating medical devices using air suspension |
US20030026840A1 (en) * | 1999-06-25 | 2003-02-06 | Christian Plank | Combinations for introducing nucleic acids into cells |
US6569195B2 (en) * | 1999-07-02 | 2003-05-27 | Scimed Life Systems, Inc. | Stent coating |
US6379381B1 (en) * | 1999-09-03 | 2002-04-30 | Advanced Cardiovascular Systems, Inc. | Porous prosthesis and a method of depositing substances into the pores |
US6365171B1 (en) * | 1999-11-04 | 2002-04-02 | The University Of Akron | Amphiphilic networks, implantable immunoisolatory devices and methods of preparation |
US20030064098A1 (en) * | 1999-12-08 | 2003-04-03 | Kararli Tugrul T. | Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect |
US6369065B1 (en) * | 2000-05-15 | 2002-04-09 | Ucb S.A. | CD40 signal blocking agent |
US6555619B1 (en) * | 2000-06-29 | 2003-04-29 | The University Of Akron | Physically crosslinked amphiphilic networks, methods of preparation, and uses thereof |
US6367658B1 (en) * | 2000-07-20 | 2002-04-09 | David Joseph Kenney | Windshield washer fluid dispensing system |
US6555157B1 (en) * | 2000-07-25 | 2003-04-29 | Advanced Cardiovascular Systems, Inc. | Method for coating an implantable device and system for performing the method |
US6695833B1 (en) * | 2000-09-27 | 2004-02-24 | Nellix, Inc. | Vascular stent-graft apparatus and forming method |
US6545097B2 (en) * | 2000-12-12 | 2003-04-08 | Scimed Life Systems, Inc. | Drug delivery compositions and medical devices containing block copolymer |
US20020082679A1 (en) * | 2000-12-22 | 2002-06-27 | Avantec Vascular Corporation | Delivery or therapeutic capable agents |
US20030083646A1 (en) * | 2000-12-22 | 2003-05-01 | Avantec Vascular Corporation | Apparatus and methods for variably controlled substance delivery from implanted prostheses |
US6506536B2 (en) * | 2000-12-29 | 2003-01-14 | Kodak Polychrome Graphics, Llc | Imageable element and composition comprising thermally reversible polymers |
US6726923B2 (en) * | 2001-01-16 | 2004-04-27 | Vascular Therapies, Llc | Apparatus and methods for preventing or treating failure of hemodialysis vascular access and other vascular grafts |
US6528584B2 (en) * | 2001-04-12 | 2003-03-04 | The University Of Akron | Multi-component polymeric networks containing poly(ethylene glycol) |
US6753071B1 (en) * | 2001-09-27 | 2004-06-22 | Advanced Cardiovascular Systems, Inc. | Rate-reducing membrane for release of an agent |
US20030093141A1 (en) * | 2001-11-02 | 2003-05-15 | Boston Scientific Corporation/Scimed Life Systems, Inc. | Vapor deposition process for producing a stent-graft and a stent-graft produced therefrom |
US20030099712A1 (en) * | 2001-11-26 | 2003-05-29 | Swaminathan Jayaraman | Therapeutic coating for an intravascular implant |
US20040093077A1 (en) * | 2002-08-06 | 2004-05-13 | Jason White | Stent with micro-latching hinge joints |
US20040093076A1 (en) * | 2002-08-06 | 2004-05-13 | Jason White | Helical stent with micro-latches |
Cited By (379)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7959664B2 (en) * | 1996-12-26 | 2011-06-14 | Medinol, Ltd. | Flat process of drug coating for stents |
US20070077347A1 (en) * | 1996-12-26 | 2007-04-05 | Jacob Richter | Flat process of drug coating for stents |
US20090062904A1 (en) * | 1998-04-15 | 2009-03-05 | Icon Interventional Systems, Inc. | Stent coating |
US8114152B2 (en) | 1998-04-15 | 2012-02-14 | Icon Interventional Systems, Inc. | Stent coating |
US8603158B2 (en) | 1998-04-15 | 2013-12-10 | Icon Interventional Systems, Inc | Irradiated stent coating |
US7967855B2 (en) | 1998-07-27 | 2011-06-28 | Icon Interventional Systems, Inc. | Coated medical device |
US8070796B2 (en) | 1998-07-27 | 2011-12-06 | Icon Interventional Systems, Inc. | Thrombosis inhibiting graft |
US20060136051A1 (en) * | 1998-07-27 | 2006-06-22 | Icon Interventional Systems, Inc. | Coated medical device |
US7807211B2 (en) | 1999-09-03 | 2010-10-05 | Advanced Cardiovascular Systems, Inc. | Thermal treatment of an implantable medical device |
US20050233062A1 (en) * | 1999-09-03 | 2005-10-20 | Hossainy Syed F | Thermal treatment of an implantable medical device |
US20050238686A1 (en) * | 1999-12-23 | 2005-10-27 | Advanced Cardiovascular Systems, Inc. | Coating for implantable devices and a method of forming the same |
US7691401B2 (en) | 2000-09-28 | 2010-04-06 | Advanced Cardiovascular Systems, Inc. | Poly(butylmethacrylate) and rapamycin coated stent |
US20070198081A1 (en) * | 2000-09-28 | 2007-08-23 | Daniel Castro | Poly(butylmethacrylate) and rapamycin coated stent |
US20080132592A1 (en) * | 2000-10-31 | 2008-06-05 | Advanced Cardiovascular Systems Inc. | Hemocompatible polymers on hydrophobic porous polymers |
US20080125857A1 (en) * | 2000-10-31 | 2008-05-29 | Advanced Cardiovascular Systems, Inc. | Hemocompatible polymers on hydrophobic porous polymers |
US7807210B1 (en) | 2000-10-31 | 2010-10-05 | Advanced Cardiovascular Systems, Inc. | Hemocompatible polymers on hydrophobic porous polymers |
US8465758B2 (en) | 2001-01-11 | 2013-06-18 | Abbott Laboratories | Drug delivery from stents |
US8753659B2 (en) | 2001-01-11 | 2014-06-17 | Abbott Laboratories | Drug delivery from stents |
US20100275431A1 (en) * | 2001-01-11 | 2010-11-04 | Abbott Laboratories | Drug delivery from stents |
US20050100609A1 (en) * | 2001-03-30 | 2005-05-12 | Claude Charles D. | Phase-separated polymer coatings |
US20020198344A1 (en) * | 2001-04-10 | 2002-12-26 | Wolfgang Voigt | Stabilized medium and high voltage cable insulation composition |
US20040182312A1 (en) * | 2001-05-31 | 2004-09-23 | Pacetti Stephen D | Apparatus and method for coating implantable devices |
US6629994B2 (en) | 2001-06-11 | 2003-10-07 | Advanced Cardiovascular Systems, Inc. | Intravascular stent |
US8741378B1 (en) | 2001-06-27 | 2014-06-03 | Advanced Cardiovascular Systems, Inc. | Methods of coating an implantable device |
US7985440B2 (en) | 2001-06-27 | 2011-07-26 | Advanced Cardiovascular Systems, Inc. | Method of using a mandrel to coat a stent |
US10064982B2 (en) | 2001-06-27 | 2018-09-04 | Abbott Cardiovascular Systems Inc. | PDLLA stent coating |
US20060065193A1 (en) * | 2001-06-27 | 2006-03-30 | Advanced Cardiovascular Systems, Inc. | Device for supporting a stent during coating of the stent |
US20060035012A1 (en) * | 2001-06-27 | 2006-02-16 | Advanced Cardiovascular Systems, Inc. | Method of using a mandrel to coat a stent |
US8303651B1 (en) | 2001-09-07 | 2012-11-06 | Advanced Cardiovascular Systems, Inc. | Polymeric coating for reducing the rate of release of a therapeutic substance from a stent |
US20070016284A1 (en) * | 2001-09-07 | 2007-01-18 | Advanced Cardiovascular Systems, Inc. | Polymeric coating for reducing the rate of release of a therapeutic substance from a stent |
US20070111008A1 (en) * | 2001-09-27 | 2007-05-17 | Pacetti Stephen D | Rate-reducing membrane for release of an agent |
US20060121179A1 (en) * | 2001-09-27 | 2006-06-08 | Pacetti Stephen D | Rate-reducing membrane for release of an agent |
US20040234737A1 (en) * | 2001-09-27 | 2004-11-25 | Advanced Cardiovascular Systems Inc. | Rate-reducing membrane for release of an agent |
US20070123973A1 (en) * | 2001-10-26 | 2007-05-31 | Roth Noah M | Biodegradable device |
US8740973B2 (en) | 2001-10-26 | 2014-06-03 | Icon Medical Corp. | Polymer biodegradable medical device |
US20060193892A1 (en) * | 2001-10-26 | 2006-08-31 | Icon Medical Corp. | Polymer biodegradable medical device |
US8100963B2 (en) | 2001-10-26 | 2012-01-24 | Icon Medical Corp. | Biodegradable device |
US20070020381A1 (en) * | 2002-03-27 | 2007-01-25 | Advanced Cardiovascular Systems, Inc. | 40-O-(2-hydroxy)ethyl-rapamycin coated stent |
US20070020382A1 (en) * | 2002-03-27 | 2007-01-25 | Advanced Cardiovascular Systems, Inc. | 40-O-(2-hydroxy)ethyl-rapamycin coated stent |
US8961588B2 (en) | 2002-03-27 | 2015-02-24 | Advanced Cardiovascular Systems, Inc. | Method of coating a stent with a release polymer for 40-O-(2-hydroxy)ethyl-rapamycin |
US8173199B2 (en) | 2002-03-27 | 2012-05-08 | Advanced Cardiovascular Systems, Inc. | 40-O-(2-hydroxy)ethyl-rapamycin coated stent |
US7803394B2 (en) | 2002-06-21 | 2010-09-28 | Advanced Cardiovascular Systems, Inc. | Polycationic peptide hydrogel coatings for cardiovascular therapy |
US8506617B1 (en) | 2002-06-21 | 2013-08-13 | Advanced Cardiovascular Systems, Inc. | Micronized peptide coated stent |
US20060062821A1 (en) * | 2002-06-21 | 2006-03-23 | Simhambhatla Murthy V | Polycationic peptide coatings and methods of making the same |
US8067023B2 (en) | 2002-06-21 | 2011-11-29 | Advanced Cardiovascular Systems, Inc. | Implantable medical devices incorporating plasma polymerized film layers and charged amino acids |
US20060002974A1 (en) * | 2002-06-21 | 2006-01-05 | Advanced Cardiovascular Systems, Inc. | Polycationic peptide coatings and methods of coating implantable medical devices |
US7794743B2 (en) | 2002-06-21 | 2010-09-14 | Advanced Cardiovascular Systems, Inc. | Polycationic peptide coatings and methods of making the same |
US9084671B2 (en) | 2002-06-21 | 2015-07-21 | Advanced Cardiovascular Systems, Inc. | Methods of forming a micronized peptide coated stent |
US7875286B2 (en) | 2002-06-21 | 2011-01-25 | Advanced Cardiovascular Systems, Inc. | Polycationic peptide coatings and methods of coating implantable medical devices |
US7901703B2 (en) | 2002-06-21 | 2011-03-08 | Advanced Cardiovascular Systems, Inc. | Polycationic peptides for cardiovascular therapy |
US7803406B2 (en) | 2002-06-21 | 2010-09-28 | Advanced Cardiovascular Systems, Inc. | Polycationic peptide coatings and methods of coating implantable medical devices |
US8016881B2 (en) | 2002-07-31 | 2011-09-13 | Icon Interventional Systems, Inc. | Sutures and surgical staples for anastamoses, wound closures, and surgical closures |
US20050038472A1 (en) * | 2002-07-31 | 2005-02-17 | Icon Interventional Systems, Inc. | Sutures and surgical staples for anastamoses, wound closures, and surgical closures |
US20040098118A1 (en) * | 2002-09-26 | 2004-05-20 | Endovascular Devices, Inc. | Apparatus and method for delivery of mitomycin through an eluting biocompatible implantable medical device |
US20080161908A1 (en) * | 2002-09-26 | 2008-07-03 | Endovascular Devices, Inc. | Apparatus and Method for Delivery of Mitomycin Through an Eluting Biocompatible Implantable Medical Device |
US20050191332A1 (en) * | 2002-11-12 | 2005-09-01 | Hossainy Syed F. | Method of forming rate limiting barriers for implantable devices |
US7758880B2 (en) | 2002-12-11 | 2010-07-20 | Advanced Cardiovascular Systems, Inc. | Biocompatible polyacrylate compositions for medical applications |
US8647655B2 (en) | 2002-12-11 | 2014-02-11 | Abbott Cardiovascular Systems Inc. | Biocompatible polyacrylate compositions for medical applications |
US8871883B2 (en) | 2002-12-11 | 2014-10-28 | Abbott Cardiovascular Systems Inc. | Biocompatible coating for implantable medical devices |
US7776926B1 (en) | 2002-12-11 | 2010-08-17 | Advanced Cardiovascular Systems, Inc. | Biocompatible coating for implantable medical devices |
US8986726B2 (en) | 2002-12-11 | 2015-03-24 | Abbott Cardiovascular Systems Inc. | Biocompatible polyacrylate compositions for medical applications |
US8871236B2 (en) | 2002-12-11 | 2014-10-28 | Abbott Cardiovascular Systems Inc. | Biocompatible polyacrylate compositions for medical applications |
US20100292426A1 (en) * | 2002-12-11 | 2010-11-18 | Hossainy Syed F A | Biocompatible coating for implantable medical devices |
US20060207501A1 (en) * | 2002-12-12 | 2006-09-21 | Advanced Cardiovascular Systems, Inc. | Clamp mandrel fixture and a method of using the same to minimize coating defects |
US20060210702A1 (en) * | 2002-12-12 | 2006-09-21 | Advanced Cardiovascular Systems, Inc. | Clamp mandrel fixture and a method of using the same to minimize coating defects |
US7648725B2 (en) | 2002-12-12 | 2010-01-19 | Advanced Cardiovascular Systems, Inc. | Clamp mandrel fixture and a method of using the same to minimize coating defects |
US8586069B2 (en) | 2002-12-16 | 2013-11-19 | Abbott Cardiovascular Systems Inc. | Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders |
US8435550B2 (en) | 2002-12-16 | 2013-05-07 | Abbot Cardiovascular Systems Inc. | Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders with an implantable medical device |
US20090286761A1 (en) * | 2002-12-16 | 2009-11-19 | Jin Cheng | Anti-Proliferative and Anti-Inflammatory Agent Combination for Treatment of Vascular Disorders with an Implantable Medical Device |
US20050186248A1 (en) * | 2003-02-26 | 2005-08-25 | Hossainy Syed F. | Stent coating |
US11291812B2 (en) | 2003-03-14 | 2022-04-05 | Intersect Ent, Inc. | Sinus delivery of sustained release therapeutics |
US9175162B2 (en) | 2003-05-08 | 2015-11-03 | Advanced Cardiovascular Systems, Inc. | Methods for forming stent coatings comprising hydrophilic additives |
US20080021008A1 (en) * | 2003-05-08 | 2008-01-24 | Advanced Cardiovascular Systems, Inc. | Stent coatings comprising hydrophilic additives |
US8673334B2 (en) | 2003-05-08 | 2014-03-18 | Abbott Cardiovascular Systems Inc. | Stent coatings comprising hydrophilic additives |
US20080118543A1 (en) * | 2003-05-08 | 2008-05-22 | Advanced Cardiovascular Systems, Inc. | Stent Coatings comprising hydrophilic additives |
US7785512B1 (en) | 2003-07-31 | 2010-08-31 | Advanced Cardiovascular Systems, Inc. | Method and system of controlled temperature mixing and molding of polymers with active agents for implantable medical devices |
US8197879B2 (en) | 2003-09-30 | 2012-06-12 | Advanced Cardiovascular Systems, Inc. | Method for selectively coating surfaces of a stent |
US20050085898A1 (en) * | 2003-10-21 | 2005-04-21 | Cook Incorporated. | Natural tissue stent |
US7056337B2 (en) | 2003-10-21 | 2006-06-06 | Cook Incorporated | Natural tissue stent |
US20070065480A1 (en) * | 2003-11-14 | 2007-03-22 | Advanced Cardiovascular Systems, Inc. | Block copolymers of acrylates and methacrylates with fluoroalkenes |
US7875073B2 (en) | 2003-11-14 | 2011-01-25 | Advanced Cardiovascular Systems, Inc. | Block copolymers of acrylates and methacrylates with fluoroalkenes |
US9446173B2 (en) | 2003-11-14 | 2016-09-20 | Abbott Cardiovascular Systems Inc. | Block copolymers of acrylates and methacrylates with fluoroalkenes |
US8883175B2 (en) | 2003-11-14 | 2014-11-11 | Abbott Cardiovascular Systems Inc. | Block copolymers of acrylates and methacrylates with fluoroalkenes |
US20070073002A1 (en) * | 2003-11-14 | 2007-03-29 | Advanced Cardiovascular Systems, Inc. | Block copolymers of acrylates and methacrylates with fluoroalkenes |
US20050106204A1 (en) * | 2003-11-19 | 2005-05-19 | Hossainy Syed F. | Biologically beneficial coatings for implantable devices containing fluorinated polymers and methods for fabricating the same |
US9114198B2 (en) | 2003-11-19 | 2015-08-25 | Advanced Cardiovascular Systems, Inc. | Biologically beneficial coatings for implantable devices containing fluorinated polymers and methods for fabricating the same |
US20050112171A1 (en) * | 2003-11-21 | 2005-05-26 | Yiwen Tang | Coatings for implantable devices including biologically erodable polyesters and methods for fabricating the same |
US8192752B2 (en) | 2003-11-21 | 2012-06-05 | Advanced Cardiovascular Systems, Inc. | Coatings for implantable devices including biologically erodable polyesters and methods for fabricating the same |
US8052912B2 (en) | 2003-12-01 | 2011-11-08 | Advanced Cardiovascular Systems, Inc. | Temperature controlled crimping |
USRE45744E1 (en) | 2003-12-01 | 2015-10-13 | Abbott Cardiovascular Systems Inc. | Temperature controlled crimping |
US20050131201A1 (en) * | 2003-12-16 | 2005-06-16 | Pacetti Stephen D. | Biologically absorbable coatings for implantable devices based on poly(ester amides) and methods for fabricating the same |
US20070249801A1 (en) * | 2003-12-16 | 2007-10-25 | Advanced Cardiovascular Systems, Inc. | Biologically absorbable coatings for implantable devices based on poly(ester amides) and methods for fabricating the same |
US20090012606A1 (en) * | 2003-12-19 | 2009-01-08 | Pacetti Stephen D | Biobeneficial polyamide/polyethylene glycol polymers for use with drug eluting stents |
US20090012259A1 (en) * | 2003-12-19 | 2009-01-08 | Pacetti Stephen D | Biobeneficial polyamide/polyethylene glycol polymers for use with drug eluting stents |
US7786249B2 (en) | 2003-12-19 | 2010-08-31 | Advanced Cardiovascular Systems, Inc. | Biobeneficial polyamide/polyethylene glycol polymers for use with drug eluting stents |
US20090012243A1 (en) * | 2003-12-19 | 2009-01-08 | Pacetti Stephen D | Biobeneficial polyamide/polyethylene glycol polymers for use with drug eluting stents |
US7772359B2 (en) | 2003-12-19 | 2010-08-10 | Advanced Cardiovascular Systems, Inc. | Biobeneficial polyamide/polyethylene glycol polymers for use with drug eluting stents |
US20050137381A1 (en) * | 2003-12-19 | 2005-06-23 | Pacetti Stephen D. | Biobeneficial polyamide/polyethylene glycol polymers for use with drug eluting stents |
US8658194B2 (en) | 2003-12-24 | 2014-02-25 | Advanced Cardiovascular Systems, Inc. | Coatings for implantable medical devices comprising hydrophilic substances and methods for fabricating the same |
US20110033517A1 (en) * | 2003-12-24 | 2011-02-10 | Advanced Cardiovascular Systems, Inc. | Coatings for implantable medical devices comprising hydrophilic substances and methods for fabricating the same |
US8871829B2 (en) * | 2003-12-24 | 2014-10-28 | Biotronik Vi Patent Ag | Radio-opaque marker for medical implants |
US20070191708A1 (en) * | 2003-12-24 | 2007-08-16 | Bodo Gerold | Radio-opaque marker for medical implants |
US8309112B2 (en) * | 2003-12-24 | 2012-11-13 | Advanced Cardiovascular Systems, Inc. | Coatings for implantable medical devices comprising hydrophilic substances and methods for fabricating the same |
US20050147647A1 (en) * | 2003-12-24 | 2005-07-07 | Thierry Glauser | Coatings for implantable medical devices comprising hydrophilic substances and methods for fabricating the same |
US20050159802A1 (en) * | 2004-01-15 | 2005-07-21 | Icon Interventional Systems, Inc., An Ohio Corporation | Method for verifying position on an angioplasty balloon |
US20110196618A1 (en) * | 2004-01-15 | 2011-08-11 | Icon Interventional Systems, Inc. | Method for verifying position on an angioplasty balloon |
US7945409B2 (en) | 2004-01-15 | 2011-05-17 | Icon Interventional Systems, Inc. | Method for verifying position on an angioplasty balloon |
US20050165476A1 (en) * | 2004-01-23 | 2005-07-28 | Furst Joseph G. | Vascular grafts with amphiphilic block copolymer coatings |
US20050171596A1 (en) * | 2004-02-03 | 2005-08-04 | Furst Joseph G. | Stents with amphiphilic copolymer coatings |
US8057841B2 (en) | 2004-02-12 | 2011-11-15 | University Of Akron | Mechanically attached medical device coatings |
US20050208091A1 (en) * | 2004-03-16 | 2005-09-22 | Pacetti Stephen D | Biologically absorbable coatings for implantable devices based on copolymers having ester bonds and methods for fabricating the same |
US8685431B2 (en) | 2004-03-16 | 2014-04-01 | Advanced Cardiovascular Systems, Inc. | Biologically absorbable coatings for implantable devices based on copolymers having ester bonds and methods for fabricating the same |
US8778014B1 (en) | 2004-03-31 | 2014-07-15 | Advanced Cardiovascular Systems, Inc. | Coatings for preventing balloon damage to polymer coated stents |
US8293890B2 (en) | 2004-04-30 | 2012-10-23 | Advanced Cardiovascular Systems, Inc. | Hyaluronic acid based copolymers |
US7820732B2 (en) | 2004-04-30 | 2010-10-26 | Advanced Cardiovascular Systems, Inc. | Methods for modulating thermal and mechanical properties of coatings on implantable devices |
US9101697B2 (en) | 2004-04-30 | 2015-08-11 | Abbott Cardiovascular Systems Inc. | Hyaluronic acid based copolymers |
US20050244363A1 (en) * | 2004-04-30 | 2005-11-03 | Hossainy Syed F A | Hyaluronic acid based copolymers |
US9561309B2 (en) | 2004-05-27 | 2017-02-07 | Advanced Cardiovascular Systems, Inc. | Antifouling heparin coatings |
US20100196438A1 (en) * | 2004-05-27 | 2010-08-05 | Medtronic, Inc. | Methods including medical devices having a surface including a biologically active agent therein |
US20100196437A1 (en) * | 2004-05-27 | 2010-08-05 | Medtronic, Inc. | Medical devices having a surface including a biologically active agent therein |
US20050266038A1 (en) * | 2004-05-27 | 2005-12-01 | Thierry Glauser | Antifouling heparin coatings |
WO2005120549A3 (en) * | 2004-06-07 | 2007-11-15 | Conor Medsystems Inc | Local delivery of growth factors for stem cell transplantation |
US9364498B2 (en) | 2004-06-18 | 2016-06-14 | Abbott Cardiovascular Systems Inc. | Heparin prodrugs and drug delivery stents formed therefrom |
US9375445B2 (en) | 2004-06-18 | 2016-06-28 | Abbott Cardiovascular Systems Inc. | Heparin prodrugs and drug delivery stents formed therefrom |
US20050287184A1 (en) * | 2004-06-29 | 2005-12-29 | Hossainy Syed F A | Drug-delivery stent formulations for restenosis and vulnerable plaque |
US8017140B2 (en) | 2004-06-29 | 2011-09-13 | Advanced Cardiovascular System, Inc. | Drug-delivery stent formulations for restenosis and vulnerable plaque |
US20060002977A1 (en) * | 2004-06-30 | 2006-01-05 | Stephen Dugan | Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders with an implantable medical device |
US7758881B2 (en) | 2004-06-30 | 2010-07-20 | Advanced Cardiovascular Systems, Inc. | Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders with an implantable medical device |
US20060002968A1 (en) * | 2004-06-30 | 2006-01-05 | Gordon Stewart | Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders |
US20060013853A1 (en) * | 2004-07-19 | 2006-01-19 | Richard Robert E | Medical devices having conductive substrate and covalently bonded coating layer |
US8758801B2 (en) | 2004-07-30 | 2014-06-24 | Abbott Cardiocascular Systems Inc. | Coatings for implantable devices comprising poly(hydroxy-alkanoates) and diacid linkages |
US8586075B2 (en) | 2004-07-30 | 2013-11-19 | Abbott Cardiovascular Systems Inc. | Coatings for implantable devices comprising poly(hydroxy-alkanoates) and diacid linkages |
US20060034888A1 (en) * | 2004-07-30 | 2006-02-16 | Advanced Cardiovascular Systems, Inc. | Coatings for implantable devices comprising poly (hydroxy-alkanoates) and diacid linkages |
US9580558B2 (en) | 2004-07-30 | 2017-02-28 | Abbott Cardiovascular Systems Inc. | Polymers containing siloxane monomers |
US20080262606A1 (en) * | 2004-07-30 | 2008-10-23 | Ni Ding | Polymers containing siloxane monomers |
US8357391B2 (en) | 2004-07-30 | 2013-01-22 | Advanced Cardiovascular Systems, Inc. | Coatings for implantable devices comprising poly (hydroxy-alkanoates) and diacid linkages |
US20060045901A1 (en) * | 2004-08-26 | 2006-03-02 | Jan Weber | Stents with drug eluting coatings |
US7648727B2 (en) | 2004-08-26 | 2010-01-19 | Advanced Cardiovascular Systems, Inc. | Methods for manufacturing a coated stent-balloon assembly |
US8119153B2 (en) * | 2004-08-26 | 2012-02-21 | Boston Scientific Scimed, Inc. | Stents with drug eluting coatings |
US20070228345A1 (en) * | 2004-08-31 | 2007-10-04 | Advanced Cardiovascular Systems, Inc. | Polymers of fluorinated monomers and hydrophilic monomers |
US20060047095A1 (en) * | 2004-08-31 | 2006-03-02 | Pacetti Stephen D | Polymers of fluorinated monomers and hydrophilic monomers |
US7766884B2 (en) | 2004-08-31 | 2010-08-03 | Advanced Cardiovascular Systems, Inc. | Polymers of fluorinated monomers and hydrophilic monomers |
US20060269586A1 (en) * | 2004-08-31 | 2006-11-30 | Advanced Cardiovascular Systems, Inc. | Polymers of fluorinated monomers and hydrophilic monomers |
US20060062824A1 (en) * | 2004-09-22 | 2006-03-23 | Advanced Cardiovascular Systems, Inc. | Medicated coatings for implantable medical devices including polyacrylates |
US8110211B2 (en) | 2004-09-22 | 2012-02-07 | Advanced Cardiovascular Systems, Inc. | Medicated coatings for implantable medical devices including polyacrylates |
US9011831B2 (en) | 2004-09-30 | 2015-04-21 | Advanced Cardiovascular Systems, Inc. | Methacrylate copolymers for medical devices |
US20060067908A1 (en) * | 2004-09-30 | 2006-03-30 | Ni Ding | Methacrylate copolymers for medical devices |
US9345814B2 (en) | 2004-09-30 | 2016-05-24 | Advanced Cardiovascular Systems, Inc. | Methacrylate copolymers for medical devices |
US20060070626A1 (en) * | 2004-10-04 | 2006-04-06 | Andrew Frazier | System and method for airway manipulation |
US9022024B2 (en) * | 2004-10-04 | 2015-05-05 | Koninklijke Philips N.V. | System and method for airway manipulation |
US7997266B2 (en) * | 2004-10-04 | 2011-08-16 | Koninklijke Philips Electronics N.V. | System and method for airway manipulation |
US20080177008A1 (en) * | 2004-10-06 | 2008-07-24 | Advanced Cardiovascular Systems Inc. | Blends Of Poly(Ester Amide) Polymers |
US20060074191A1 (en) * | 2004-10-06 | 2006-04-06 | Desnoyer Jessica R | Blends of poly(ester amide) polymers |
US20080095815A1 (en) * | 2004-10-22 | 2008-04-24 | The Board Of Trustees Of The University Of Illinois | Hollow and Porous Orthopaedic or Dental Implant that Delivers a Biological Agent |
US8337873B2 (en) * | 2004-10-22 | 2012-12-25 | The Board Of Trustees Of The University Of Illinois | Hollow and porous orthopaedic or dental implant that delivers a biological agent |
US8603634B2 (en) | 2004-10-27 | 2013-12-10 | Abbott Cardiovascular Systems Inc. | End-capped poly(ester amide) copolymers |
US20060089485A1 (en) * | 2004-10-27 | 2006-04-27 | Desnoyer Jessica R | End-capped poly(ester amide) copolymers |
US9067000B2 (en) | 2004-10-27 | 2015-06-30 | Abbott Cardiovascular Systems Inc. | End-capped poly(ester amide) copolymers |
US20090232865A1 (en) * | 2004-10-27 | 2009-09-17 | Abbott Cardiovascular Systems Inc. | End-Capped Poly(Ester Amide) Copolymers |
US20080167712A1 (en) * | 2004-10-29 | 2008-07-10 | Advanced Cardiovascular Systems, Inc. | Poly(ester amide) filler blends for modulation of coating properties |
US20060095122A1 (en) * | 2004-10-29 | 2006-05-04 | Advanced Cardiovascular Systems, Inc. | Implantable devices comprising biologically absorbable star polymers and methods for fabricating the same |
US20060093842A1 (en) * | 2004-10-29 | 2006-05-04 | Desnoyer Jessica R | Poly(ester amide) filler blends for modulation of coating properties |
US7749263B2 (en) | 2004-10-29 | 2010-07-06 | Abbott Cardiovascular Systems Inc. | Poly(ester amide) filler blends for modulation of coating properties |
US20070167602A1 (en) * | 2004-11-24 | 2007-07-19 | Advanced Cardiovascular Systems | Biologically absorbable coatings for implantable devices based on polyesters and methods for fabricating the same |
US20060115513A1 (en) * | 2004-11-29 | 2006-06-01 | Hossainy Syed F A | Derivatized poly(ester amide) as a biobeneficial coating |
US8609123B2 (en) | 2004-11-29 | 2013-12-17 | Advanced Cardiovascular Systems, Inc. | Derivatized poly(ester amide) as a biobeneficial coating |
US7892592B1 (en) | 2004-11-30 | 2011-02-22 | Advanced Cardiovascular Systems, Inc. | Coating abluminal surfaces of stents and other implantable medical devices |
US20060115449A1 (en) * | 2004-11-30 | 2006-06-01 | Advanced Cardiovascular Systems, Inc. | Bioabsorbable, biobeneficial, tyrosine-based polymers for use in drug eluting stent coatings |
US20060134165A1 (en) * | 2004-12-22 | 2006-06-22 | Pacetti Stephen D | Polymers of fluorinated monomers and hydrocarbon monomers |
US9339592B2 (en) | 2004-12-22 | 2016-05-17 | Abbott Cardiovascular Systems Inc. | Polymers of fluorinated monomers and hydrocarbon monomers |
US7699889B2 (en) | 2004-12-27 | 2010-04-20 | Advanced Cardiovascular Systems, Inc. | Poly(ester amide) block copolymers |
US20080206306A1 (en) * | 2004-12-27 | 2008-08-28 | Syed Faiyaz Ahmed Hossainy | Poly(ester amide) block copolymers |
US20060147412A1 (en) * | 2004-12-30 | 2006-07-06 | Hossainy Syed F | Polymers containing poly(hydroxyalkanoates) and agents for use with medical articles and methods of fabricating the same |
US8007775B2 (en) | 2004-12-30 | 2011-08-30 | Advanced Cardiovascular Systems, Inc. | Polymers containing poly(hydroxyalkanoates) and agents for use with medical articles and methods of fabricating the same |
US20060160985A1 (en) * | 2005-01-14 | 2006-07-20 | Pacetti Stephen D | Poly(hydroxyalkanoate-co-ester amides) and agents for use with medical articles |
US20090076589A1 (en) * | 2005-03-03 | 2009-03-19 | Icon Interventional Systems, Inc. | Metal alloy for a stent |
US20060264914A1 (en) * | 2005-03-03 | 2006-11-23 | Icon Medical Corp. | Metal alloys for medical devices |
US8323333B2 (en) | 2005-03-03 | 2012-12-04 | Icon Medical Corp. | Fragile structure protective coating |
US20060224237A1 (en) * | 2005-03-03 | 2006-10-05 | Icon Medical Corp. | Fragile structure protective coating |
US8808618B2 (en) | 2005-03-03 | 2014-08-19 | Icon Medical Corp. | Process for forming an improved metal alloy stent |
US20060200226A1 (en) * | 2005-03-03 | 2006-09-07 | Icon Medical Corp. | Metal alloys for medical devices |
US9107899B2 (en) | 2005-03-03 | 2015-08-18 | Icon Medical Corporation | Metal alloys for medical devices |
US7452502B2 (en) * | 2005-03-03 | 2008-11-18 | Icon Medical Corp. | Metal alloy for a stent |
US7452501B2 (en) * | 2005-03-03 | 2008-11-18 | Icon Medical Corp. | Metal alloy for a stent |
US20060200225A1 (en) * | 2005-03-03 | 2006-09-07 | Icon Interventional Systems, Inc. | Metal alloy for a stent |
US20060201601A1 (en) * | 2005-03-03 | 2006-09-14 | Icon Interventional Systems, Inc. | Flexible markers |
US20060200224A1 (en) * | 2005-03-03 | 2006-09-07 | Icon Interventional Systems, Inc. | Metal alloy for a stent |
US7488444B2 (en) * | 2005-03-03 | 2009-02-10 | Icon Medical Corp. | Metal alloys for medical devices |
US7648591B2 (en) | 2005-03-03 | 2010-01-19 | Icon Medical Corp. | Metal alloys for medical devices |
US7648592B2 (en) | 2005-03-03 | 2010-01-19 | Icon Medical Corp. | Metal alloy for a stent |
US7648590B2 (en) | 2005-03-03 | 2010-01-19 | ICON International Systems, Inc. | Metal alloy for a stent |
US20090123327A1 (en) * | 2005-03-03 | 2009-05-14 | Furst Joseph G | Metal alloy for a stent |
US20090200177A1 (en) * | 2005-03-03 | 2009-08-13 | Icon Medical Corp. | Process for forming an improved metal alloy stent |
US8932615B2 (en) | 2005-03-24 | 2015-01-13 | Abbott Cardiovascular Systems Inc. | Implantable devices formed on non-fouling methacrylate or acrylate polymers |
US7700659B2 (en) | 2005-03-24 | 2010-04-20 | Advanced Cardiovascular Systems, Inc. | Implantable devices formed of non-fouling methacrylate or acrylate polymers |
US20100119571A1 (en) * | 2005-03-24 | 2010-05-13 | Advanced Cardiovascular Systems, Inc. | Implantable devices formed on non-fouling methacrylate or acrylate polymers |
US9381279B2 (en) | 2005-03-24 | 2016-07-05 | Abbott Cardiovascular Systems Inc. | Implantable devices formed on non-fouling methacrylate or acrylate polymers |
US11123091B2 (en) | 2005-04-04 | 2021-09-21 | Intersect Ent, Inc. | Device and methods for treating paranasal sinus conditions |
EP2796112A1 (en) * | 2005-04-05 | 2014-10-29 | Elixir Medical Corporation | Degradable implantable medical devices |
US10350093B2 (en) | 2005-04-05 | 2019-07-16 | Elixir Medical Corporation | Degradable implantable medical devices |
WO2007004067A3 (en) * | 2005-04-15 | 2007-05-18 | Interface Biologics Inc | Methods and compositions for the delivery of biologically active agents |
AU2006264574B2 (en) * | 2005-04-15 | 2012-09-27 | Interface Biologics Inc. | Methods and compositions for the delivery of biologically active agents |
US8574604B2 (en) | 2005-04-15 | 2013-11-05 | Interface Biologics, Inc. | Methods and compositions for the delivery of biologically active agents |
CN101203250A (en) * | 2005-04-15 | 2008-06-18 | 界面生物公司 | Methods and compositions for the delivery of biologically active agents |
US20070037891A1 (en) * | 2005-04-15 | 2007-02-15 | Roseita Esfand | Methods and compositions for the delivery of biologically active agents |
US7795467B1 (en) | 2005-04-26 | 2010-09-14 | Advanced Cardiovascular Systems, Inc. | Bioabsorbable, biobeneficial polyurethanes for use in medical devices |
US8778375B2 (en) | 2005-04-29 | 2014-07-15 | Advanced Cardiovascular Systems, Inc. | Amorphous poly(D,L-lactide) coating |
US20100100171A1 (en) * | 2005-06-20 | 2010-04-22 | Advanced Cardiovascular Systems, Inc. | Method Of Manufacturing An Implantable Polymeric Medical Device |
US8728149B2 (en) | 2005-06-20 | 2014-05-20 | Advanced Cardiovascular Systems, Inc. | Assembly for making a polymeric medical device |
US8066762B2 (en) * | 2005-06-20 | 2011-11-29 | Advanced Cardiovascular Systems, Inc. | Assembly for manufacturing an implantable polymeric medical device |
US7823533B2 (en) | 2005-06-30 | 2010-11-02 | Advanced Cardiovascular Systems, Inc. | Stent fixture and method for reducing coating defects |
US8021676B2 (en) | 2005-07-08 | 2011-09-20 | Advanced Cardiovascular Systems, Inc. | Functionalized chemically inert polymers for coatings |
US10369033B2 (en) | 2005-07-14 | 2019-08-06 | Merit Medical Ireland Limited | Delivery system and method of use for deployment of self-expandable vascular device |
US20070016280A1 (en) * | 2005-07-14 | 2007-01-18 | Cappella, Inc. | Delivery System And Method Of Use For Deployment Of Self-Expandable Vascular Device |
US20070198080A1 (en) * | 2005-07-25 | 2007-08-23 | Ni Ding | Coatings including an antioxidant |
US20070020380A1 (en) * | 2005-07-25 | 2007-01-25 | Ni Ding | Methods of providing antioxidants to a drug containing product |
US7785647B2 (en) | 2005-07-25 | 2010-08-31 | Advanced Cardiovascular Systems, Inc. | Methods of providing antioxidants to a drug containing product |
US7735449B1 (en) | 2005-07-28 | 2010-06-15 | Advanced Cardiovascular Systems, Inc. | Stent fixture having rounded support structures and method for use thereof |
WO2007022201A2 (en) * | 2005-08-16 | 2007-02-22 | Poly-Med, Inc. | Absorbable endo-urological devices and applications therefor |
WO2007022201A3 (en) * | 2005-08-16 | 2007-10-11 | Poly Med Inc | Absorbable endo-urological devices and applications therefor |
US20070043422A1 (en) * | 2005-08-18 | 2007-02-22 | Cappella, Inc. | Delivery system and method of use for accurate positioning of a device in a bifurcation |
US20070043381A1 (en) * | 2005-08-19 | 2007-02-22 | Icon Medical Corp. | Medical device deployment instrument |
US20070088428A1 (en) * | 2005-09-15 | 2007-04-19 | Cappella, Inc. | Intraluminal device with asymmetric cap portion |
US20070061003A1 (en) * | 2005-09-15 | 2007-03-15 | Cappella, Inc. | Segmented ostial protection device |
WO2007065016A2 (en) * | 2005-12-02 | 2007-06-07 | Au Jessie L S | Methods and compositions to improve activity and reduce toxicity of stents |
WO2007065016A3 (en) * | 2005-12-02 | 2009-01-08 | Jessie L S Au | Methods and compositions to improve activity and reduce toxicity of stents |
US20070128246A1 (en) * | 2005-12-06 | 2007-06-07 | Hossainy Syed F A | Solventless method for forming a coating |
US20070135909A1 (en) * | 2005-12-08 | 2007-06-14 | Desnoyer Jessica R | Adhesion polymers to improve stent retention |
US7976891B1 (en) | 2005-12-16 | 2011-07-12 | Advanced Cardiovascular Systems, Inc. | Abluminal stent coating apparatus and method of using focused acoustic energy |
US7867547B2 (en) | 2005-12-19 | 2011-01-11 | Advanced Cardiovascular Systems, Inc. | Selectively coating luminal surfaces of stents |
US20070191926A1 (en) * | 2006-02-14 | 2007-08-16 | Advanced Cardiovascular Systems, Inc. | Stent pattern for high stent retention |
US8067025B2 (en) | 2006-02-17 | 2011-11-29 | Advanced Cardiovascular Systems, Inc. | Nitric oxide generating medical devices |
US20070196424A1 (en) * | 2006-02-17 | 2007-08-23 | Advanced Cardiovascular Systems, Inc. | Nitric oxide generating medical devices |
US20070196428A1 (en) * | 2006-02-17 | 2007-08-23 | Thierry Glauser | Nitric oxide generating medical devices |
US20070202323A1 (en) * | 2006-02-28 | 2007-08-30 | Kleiner Lothar W | Coating construct containing poly (vinyl alcohol) |
US20070207181A1 (en) * | 2006-03-03 | 2007-09-06 | Kleiner Lothar W | Coating containing PEGylated hyaluronic acid and a PEGylated non-hyaluronic acid polymer |
US7713637B2 (en) | 2006-03-03 | 2010-05-11 | Advanced Cardiovascular Systems, Inc. | Coating containing PEGylated hyaluronic acid and a PEGylated non-hyaluronic acid polymer |
US20110238152A1 (en) * | 2006-03-15 | 2011-09-29 | Medinol Ltd. | Flat process of preparing drug eluting stents |
US8828077B2 (en) | 2006-03-15 | 2014-09-09 | Medinol Ltd. | Flat process of preparing drug eluting stents |
US20070231363A1 (en) * | 2006-03-29 | 2007-10-04 | Yung-Ming Chen | Coatings formed from stimulus-sensitive material |
US20070259101A1 (en) * | 2006-05-02 | 2007-11-08 | Kleiner Lothar W | Microporous coating on medical devices |
US8069814B2 (en) | 2006-05-04 | 2011-12-06 | Advanced Cardiovascular Systems, Inc. | Stent support devices |
US20070259102A1 (en) * | 2006-05-04 | 2007-11-08 | Mcniven Andrew | Methods and devices for coating stents |
US8465789B2 (en) | 2006-05-04 | 2013-06-18 | Advanced Cardiovascular Systems, Inc. | Rotatable support elements for stents |
US8596215B2 (en) | 2006-05-04 | 2013-12-03 | Advanced Cardiovascular Systems, Inc. | Rotatable support elements for stents |
US8741379B2 (en) | 2006-05-04 | 2014-06-03 | Advanced Cardiovascular Systems, Inc. | Rotatable support elements for stents |
US8003156B2 (en) | 2006-05-04 | 2011-08-23 | Advanced Cardiovascular Systems, Inc. | Rotatable support elements for stents |
US7985441B1 (en) | 2006-05-04 | 2011-07-26 | Yiwen Tang | Purification of polymers for coating applications |
US8637110B2 (en) | 2006-05-04 | 2014-01-28 | Advanced Cardiovascular Systems, Inc. | Rotatable support elements for stents |
US8304012B2 (en) | 2006-05-04 | 2012-11-06 | Advanced Cardiovascular Systems, Inc. | Method for drying a stent |
US20080226812A1 (en) * | 2006-05-26 | 2008-09-18 | Yung Ming Chen | Stent coating apparatus and method |
US8616152B2 (en) * | 2006-05-26 | 2013-12-31 | Abbott Cardiovascular Systems Inc. | Stent coating apparatus |
US20120291703A1 (en) * | 2006-05-26 | 2012-11-22 | Advanced Cardiovascular Systems, Inc. | Stent coating apparatus |
US7775178B2 (en) | 2006-05-26 | 2010-08-17 | Advanced Cardiovascular Systems, Inc. | Stent coating apparatus and method |
US8568764B2 (en) | 2006-05-31 | 2013-10-29 | Advanced Cardiovascular Systems, Inc. | Methods of forming coating layers for medical devices utilizing flash vaporization |
US9561351B2 (en) | 2006-05-31 | 2017-02-07 | Advanced Cardiovascular Systems, Inc. | Drug delivery spiral coil construct |
US8703167B2 (en) | 2006-06-05 | 2014-04-22 | Advanced Cardiovascular Systems, Inc. | Coatings for implantable medical devices for controlled release of a hydrophilic drug and a hydrophobic drug |
US20080124372A1 (en) * | 2006-06-06 | 2008-05-29 | Hossainy Syed F A | Morphology profiles for control of agent release rates from polymer matrices |
US8778376B2 (en) | 2006-06-09 | 2014-07-15 | Advanced Cardiovascular Systems, Inc. | Copolymer comprising elastin pentapeptide block and hydrophilic block, and medical device and method of treating |
US20070286882A1 (en) * | 2006-06-09 | 2007-12-13 | Yiwen Tang | Solvent systems for coating medical devices |
US20080038310A1 (en) * | 2006-06-09 | 2008-02-14 | Hossainy Syed F A | Coating comprising an elastin-based copolymer |
US8029816B2 (en) | 2006-06-09 | 2011-10-04 | Abbott Cardiovascular Systems Inc. | Medical device coated with a coating containing elastin pentapeptide VGVPG |
US8062350B2 (en) | 2006-06-14 | 2011-11-22 | Abbott Cardiovascular Systems Inc. | RGD peptide attached to bioabsorbable stents |
US8808342B2 (en) | 2006-06-14 | 2014-08-19 | Abbott Cardiovascular Systems Inc. | Nanoshell therapy |
US8118863B2 (en) | 2006-06-14 | 2012-02-21 | Abbott Cardiovascular Systems Inc. | RGD peptide attached to bioabsorbable stents |
US20110144741A1 (en) * | 2006-06-14 | 2011-06-16 | Advanced Cardiovascular Systems, Inc. | Coating Construct With Enhanced Interfacial Compatibility |
US8114150B2 (en) | 2006-06-14 | 2012-02-14 | Advanced Cardiovascular Systems, Inc. | RGD peptide attached to bioabsorbable stents |
US20080095918A1 (en) * | 2006-06-14 | 2008-04-24 | Kleiner Lothar W | Coating construct with enhanced interfacial compatibility |
US8603530B2 (en) | 2006-06-14 | 2013-12-10 | Abbott Cardiovascular Systems Inc. | Nanoshell therapy |
US8048448B2 (en) | 2006-06-15 | 2011-11-01 | Abbott Cardiovascular Systems Inc. | Nanoshells for drug delivery |
US8293367B2 (en) | 2006-06-23 | 2012-10-23 | Advanced Cardiovascular Systems, Inc. | Nanoshells on polymers |
US8017237B2 (en) | 2006-06-23 | 2011-09-13 | Abbott Cardiovascular Systems, Inc. | Nanoshells on polymers |
US8592036B2 (en) | 2006-06-23 | 2013-11-26 | Abbott Cardiovascular Systems Inc. | Nanoshells on polymers |
US8956640B2 (en) | 2006-06-29 | 2015-02-17 | Advanced Cardiovascular Systems, Inc. | Block copolymers including a methoxyethyl methacrylate midblock |
US20080003253A1 (en) * | 2006-06-29 | 2008-01-03 | Thierry Glauser | Block copolymers including a methoxyethyl methacrylate midblock |
US20080008736A1 (en) * | 2006-07-06 | 2008-01-10 | Thierry Glauser | Random copolymers of methacrylates and acrylates |
US20080008739A1 (en) * | 2006-07-07 | 2008-01-10 | Hossainy Syed F A | Phase-separated block copolymer coatings for implantable medical devices |
US9028859B2 (en) | 2006-07-07 | 2015-05-12 | Advanced Cardiovascular Systems, Inc. | Phase-separated block copolymer coatings for implantable medical devices |
US20100131044A1 (en) * | 2006-07-13 | 2010-05-27 | Udayan Patel | Stent |
US20170363554A1 (en) * | 2006-07-13 | 2017-12-21 | Abbott Cardiovascular Systems Inc. | Radio frequency identification monitoring of stents |
US9772299B2 (en) * | 2006-07-13 | 2017-09-26 | Abbott Cardiovascular Systems Inc. | Radio frequency identification monitoring of stents |
US10145811B2 (en) * | 2006-07-13 | 2018-12-04 | Abbott Cardiovascular Systems Inc. | Radio frequency identification monitoring of stents |
US7757543B2 (en) * | 2006-07-13 | 2010-07-20 | Advanced Cardiovascular Systems, Inc. | Radio frequency identification monitoring of stents |
US20080021307A1 (en) * | 2006-07-13 | 2008-01-24 | Abigail Freeman | Radio frequency identification monitoring of stents |
US20150146758A1 (en) * | 2006-07-13 | 2015-05-28 | Abbott Cardiovascular Systems Inc. | Radio frequency identification monitoring of stents |
US20100245055A1 (en) * | 2006-07-13 | 2010-09-30 | Abigail Freeman | Radio frequency identification monitoring of stents |
US9188558B2 (en) | 2006-07-13 | 2015-11-17 | Advanced Cardiovascular Systems, Inc. | Radio frequency identification monitoring of stents |
US8703169B1 (en) | 2006-08-15 | 2014-04-22 | Abbott Cardiovascular Systems Inc. | Implantable device having a coating comprising carrageenan and a biostable polymer |
WO2008022258A3 (en) * | 2006-08-16 | 2008-07-24 | Surmodics Inc | Methods and materials for increasing the adhesion of elution control matrices to substrates |
US20080171087A1 (en) * | 2006-08-16 | 2008-07-17 | Chappa Ralph A | Methods and materials for increasing the adhesion of elution control matrices to substrates |
WO2008022258A2 (en) * | 2006-08-16 | 2008-02-21 | Surmodics, Inc. | Methods and materials for increasing the adhesion of elution control matrices to substrates |
US20080075753A1 (en) * | 2006-09-25 | 2008-03-27 | Chappa Ralph A | Multi-layered coatings and methods for controlling elution of active agents |
US8142836B2 (en) * | 2006-09-25 | 2012-03-27 | Surmodics, Inc. | Multi-layered coatings and methods for controlling elution of active agents |
WO2008039749A2 (en) * | 2006-09-25 | 2008-04-03 | Surmodics, Inc. | Multi-layered coatings and methods for controlling elution of active agents |
WO2008039749A3 (en) * | 2006-09-25 | 2009-05-14 | Surmodics Inc | Multi-layered coatings and methods for controlling elution of active agents |
US20110008526A1 (en) * | 2006-09-25 | 2011-01-13 | Surmodics, Inc. | Multi-layered coatings and methods for controlling elution of active agents |
US8778009B2 (en) | 2006-10-06 | 2014-07-15 | Abbott Cardiovascular Systems Inc. | Intravascular stent |
US20080086194A1 (en) * | 2006-10-06 | 2008-04-10 | Advanced Cardiovascular Systems, | Intravascular stent |
US20100143332A1 (en) * | 2006-11-17 | 2010-06-10 | Schering Corporation | Combination therapy for proliferative disorders |
US7713541B1 (en) | 2006-11-21 | 2010-05-11 | Abbott Cardiovascular Systems Inc. | Zwitterionic terpolymers, method of making and use on medical devices |
US7928177B2 (en) | 2006-11-21 | 2011-04-19 | Abbott Laboratories | Amino acid mimetic copolymers and medical devices coated with the copolymers |
US20080147178A1 (en) * | 2006-11-21 | 2008-06-19 | Abbott Laboratories | Zwitterionic copolymers, method of making and use on medical devices |
US8658749B2 (en) | 2006-11-21 | 2014-02-25 | Abbott Laboratories | Methods for manufacturing amino acid mimetic copolymers and use of same |
US20080139746A1 (en) * | 2006-11-21 | 2008-06-12 | Abbott Laboratories | Copolymers having zwitterionic moieties and dihydroxyphenyl moieties and medical devices coated with the copolymers |
US8202956B2 (en) | 2006-11-21 | 2012-06-19 | Abbott Laboratories | Copolymers having zwitterionic moieties and dihydroxyphenyl moieties and medical devices coated with the copolymers |
US20100152402A1 (en) * | 2006-11-21 | 2010-06-17 | Abbott Cardiovascular Systems, Inc. | Zwiterionic terpolymers, method of making and use on medical devices |
US8846839B2 (en) | 2006-11-21 | 2014-09-30 | Abbott Laboratories | Copolymers having zwitterionic moieties and dihdroxyphenyl moieties and medical devices coated with the copolymers |
US20110160417A1 (en) * | 2006-11-21 | 2011-06-30 | Abbott Laboratories | Amino acid mimetic copolymers and medical devices coated with the copolymers |
US8071705B2 (en) | 2006-11-21 | 2011-12-06 | Abbott Laboratories | Amino acid mimetic copolymers and medical devices coated with the copolymers |
US8101156B2 (en) | 2006-11-21 | 2012-01-24 | Abbott Laboratories | Methods of manufacturing copolymers with zwitterionic moieties and dihydroxyphenyl moieties and use of same |
US8063151B2 (en) | 2006-11-21 | 2011-11-22 | Abbott Laboratories | Methods for manufacturing copolymers having 1-methyl-2-methoxyethyl moieties and use of same |
US8399584B2 (en) | 2006-11-21 | 2013-03-19 | Abbott Laboratories | Copolymers having zwitterionic moieties and dihydroxyphenyl moieties and medical devices coated with the copolymers |
US8431665B2 (en) | 2006-11-21 | 2013-04-30 | Abbott Cardiovascular Systems Inc. | Zwitterionic terpolymers, method of making and use on medical devices |
US8722826B2 (en) | 2006-11-21 | 2014-05-13 | Abbott Cardiovascular Systems Inc. | Zwitterionic terpolymers, method of making and use on medical devices |
US7910678B2 (en) | 2006-11-21 | 2011-03-22 | Abbott Laboratories | Copolymers having 1-methyl-2-methoxyethyl moieties |
US20080118541A1 (en) * | 2006-11-21 | 2008-05-22 | Abbott Laboratories | Use of a terpolymer of tetrafluoroethylene, hexafluoropropylene, and vinylidene fluoride in drug eluting coatings on medical devices |
US8048975B2 (en) | 2006-11-21 | 2011-11-01 | Abbott Laboratories | Amino acid mimetic copolymers and medical devices coated with the copolymers |
US7928176B2 (en) | 2006-11-21 | 2011-04-19 | Abbott Laboratories | Copolymers having zwitterionic moieties and dihydroxyphenyl moieties and medical devices coated with the copolymers |
US20080125560A1 (en) * | 2006-11-21 | 2008-05-29 | Abbott Laboratories | Copolymers having 1-methyl-2-methoxyethyl moieties |
US20080153923A1 (en) * | 2006-11-21 | 2008-06-26 | Abbott Laboratories | Methods of manufacturing copolymers with zwitterionic moieties and dihydroxyphenyl moieties and use of same |
US20080125514A1 (en) * | 2006-11-21 | 2008-05-29 | Abbott Laboratories | Amino acid mimetic copolymers and medical devices coated with the copolymers |
US20110166250A1 (en) * | 2006-11-21 | 2011-07-07 | Abbott Laboratories | Copolymers having zwitterionic moieties and dihydroxyphenyl moieties and medical devices coated with the copolymers |
US8569435B2 (en) | 2006-11-21 | 2013-10-29 | Abbott Laboratories | Amino acid mimetic copolymers and medical devices coated with the copolymers |
US7781551B2 (en) | 2006-11-21 | 2010-08-24 | Abbott Laboratories | Zwitterionic copolymers, method of making and use on medical devices |
US20080145393A1 (en) * | 2006-12-13 | 2008-06-19 | Trollsas Mikael O | Coating of fast absorption or dissolution |
US8597673B2 (en) | 2006-12-13 | 2013-12-03 | Advanced Cardiovascular Systems, Inc. | Coating of fast absorption or dissolution |
US8591934B2 (en) | 2006-12-15 | 2013-11-26 | Abbott Cardiovascular Systems Inc. | Coatings of acrylamide-based copolymers |
US20080146992A1 (en) * | 2006-12-15 | 2008-06-19 | Hossainy Syed F A | Coatings of acrylamide-based copolymers |
US8333984B2 (en) | 2006-12-15 | 2012-12-18 | Abbott Cardiovascular Systems, Inc. | Coatings of acrylamide-based copolymers |
US8017141B2 (en) | 2006-12-15 | 2011-09-13 | Advanced Cardiovascular Systems, Inc. | Coatings of acrylamide-based copolymers |
US9180225B2 (en) | 2007-05-14 | 2015-11-10 | Abbott Laboratories | Implantable medical devices with a topcoat layer of phosphoryl choline acrylate polymer for reduced thrombosis, and improved mechanical properties |
US8147769B1 (en) | 2007-05-16 | 2012-04-03 | Abbott Cardiovascular Systems Inc. | Stent and delivery system with reduced chemical degradation |
US9056155B1 (en) | 2007-05-29 | 2015-06-16 | Abbott Cardiovascular Systems Inc. | Coatings having an elastic primer layer |
US7994213B2 (en) * | 2007-06-01 | 2011-08-09 | Taewoong Medical Co., Ltd. | Coating agent for drug releasing stent, preparation method thereof and drug releasing stent coated therewith |
US20090286864A1 (en) * | 2007-06-01 | 2009-11-19 | Taewoong Medical Co., Ltd. | Coating agent for drug releasing stent, preparation method thereof and drug releasing stent coated therewith |
US8109904B1 (en) | 2007-06-25 | 2012-02-07 | Abbott Cardiovascular Systems Inc. | Drug delivery medical devices |
US8048441B2 (en) | 2007-06-25 | 2011-11-01 | Abbott Cardiovascular Systems, Inc. | Nanobead releasing medical devices |
US20090041845A1 (en) * | 2007-08-08 | 2009-02-12 | Lothar Walter Kleiner | Implantable medical devices having thin absorbable coatings |
US10471185B2 (en) * | 2007-12-18 | 2019-11-12 | Intersect Ent, Inc. | Self-expanding devices and methods therefor |
US11110210B2 (en) | 2007-12-18 | 2021-09-07 | Intersect Ent, Inc. | Self-expanding devices and methods therefor |
US11826494B2 (en) | 2007-12-18 | 2023-11-28 | Intersect Ent, Inc. | Self-expanding devices and methods therefor |
US11497835B2 (en) | 2007-12-18 | 2022-11-15 | Intersect Ent, Inc. | Self-expanding devices and methods therefor |
US20190125935A1 (en) * | 2007-12-18 | 2019-05-02 | Intersect Ent, Inc. | Self-expanding devices and methods therefor |
US11654216B2 (en) * | 2007-12-18 | 2023-05-23 | Intersect Ent, Inc. | Self-expanding devices and methods therefor |
US20110238163A1 (en) * | 2008-09-08 | 2011-09-29 | Laboratorios Farmaceuticos Rovi S.A. | Multi-layered Device |
US11484693B2 (en) | 2009-05-15 | 2022-11-01 | Intersect Ent, Inc. | Expandable devices and methods for treating a nasal or sinus condition |
US8398916B2 (en) | 2010-03-04 | 2013-03-19 | Icon Medical Corp. | Method for forming a tubular medical device |
US20110214785A1 (en) * | 2010-03-04 | 2011-09-08 | Icon Medical Corp. | method for forming a tubular medical device |
US9034245B2 (en) | 2010-03-04 | 2015-05-19 | Icon Medical Corp. | Method for forming a tubular medical device |
US10549077B2 (en) | 2010-03-12 | 2020-02-04 | TriReme Medical, LLC | Device and method for compartmental vessel treatment |
US11529500B2 (en) | 2010-03-12 | 2022-12-20 | TriReme Medical, LLC | Device and method for compartmental vessel treatment |
US10076591B2 (en) | 2010-03-31 | 2018-09-18 | Abbott Cardiovascular Systems Inc. | Absorbable coating for implantable device |
US20110282430A1 (en) * | 2010-05-14 | 2011-11-17 | Boston Scientific Scimed, Inc. | Endoprosthesis |
US9314551B2 (en) * | 2010-05-14 | 2016-04-19 | Boston Scientific Scimed, Inc. | Block copolymer-coated endoprosthesis |
US9510936B2 (en) | 2011-06-03 | 2016-12-06 | Vascutek Limited | Stent element |
WO2012164294A1 (en) * | 2011-06-03 | 2012-12-06 | Vascutek Limited | Stent element |
US10220193B2 (en) | 2012-02-01 | 2019-03-05 | TriReme Medical, LLC | Device for compartmental dilatation of blood vessels |
US9179936B2 (en) * | 2012-02-08 | 2015-11-10 | Quattro Vascular Pte Ltd. | Constraining structure with non-linear axial struts |
US9216033B2 (en) * | 2012-02-08 | 2015-12-22 | Quattro Vascular Pte Ltd. | System and method for treating biological vessels |
US20140066960A1 (en) * | 2012-02-08 | 2014-03-06 | Quattro Vascular Pte Ltd. | System and method for treating biological vessels |
US10524825B2 (en) | 2012-02-08 | 2020-01-07 | TriReme Medical, LLC | Constraining structure with non-linear axial struts |
US20160100964A1 (en) * | 2012-02-08 | 2016-04-14 | Quattro Vascular Pte Ltd. | System and method for treating biological vessels |
US11583424B2 (en) | 2012-02-08 | 2023-02-21 | TriReme Medical, LLC | Constraining structure with non-linear axial struts |
US11234843B2 (en) * | 2012-02-08 | 2022-02-01 | TriReme Medical, LLC | System and method for treating biological vessels |
US20130218181A1 (en) * | 2012-02-08 | 2013-08-22 | Quattro Vascular PE Ltd. | Constraining structure with non-linear axial struts |
KR102116936B1 (en) | 2012-05-14 | 2020-06-01 | 씨. 알. 바드, 인크. | Uniformly expandable stent |
US10588765B2 (en) | 2012-05-14 | 2020-03-17 | C. R. Bard, Inc. | Uniformly expandable stent |
EP2849688B1 (en) * | 2012-05-14 | 2023-08-23 | C. R. Bard, Inc. | Uniformly expandable stent |
US9066825B2 (en) | 2012-05-14 | 2015-06-30 | C.R. Bard, Inc. | Uniformly expandable stent |
WO2013172938A1 (en) * | 2012-05-14 | 2013-11-21 | C.R. Bard, Inc. | Uniformly expandable stent |
KR20150008401A (en) * | 2012-05-14 | 2015-01-22 | 씨. 알. 바드, 인크. | Uniformly expandable stent |
US20140163586A1 (en) * | 2012-12-11 | 2014-06-12 | Dolly Jeanne Holt | Tissue repair devices and methods |
USD723165S1 (en) | 2013-03-12 | 2015-02-24 | C. R. Bard, Inc. | Stent |
US11672960B2 (en) | 2013-03-14 | 2023-06-13 | Intersect Ent, Inc. | Systems, devices, and method for treating a sinus condition |
US11779685B2 (en) | 2014-06-24 | 2023-10-10 | Mirus Llc | Metal alloys for medical devices |
US11000680B2 (en) | 2014-11-17 | 2021-05-11 | TriReme Medical, LLC | Balloon catheter system and method of using same |
US10232148B2 (en) | 2014-11-17 | 2019-03-19 | TriReme Medical, LLC | Balloon catheter system and method of using same |
US11766506B2 (en) | 2016-03-04 | 2023-09-26 | Mirus Llc | Stent device for spinal fusion |
US10238513B2 (en) | 2017-07-19 | 2019-03-26 | Abbott Cardiovascular Systems Inc. | Intravascular stent |
Also Published As
Publication number | Publication date |
---|---|
WO2003037398A2 (en) | 2003-05-08 |
JP2005507711A (en) | 2005-03-24 |
US20090062904A1 (en) | 2009-03-05 |
WO2003037398A3 (en) | 2003-11-13 |
US8114152B2 (en) | 2012-02-14 |
EP1453557A2 (en) | 2004-09-08 |
AU2002341567A1 (en) | 2003-05-12 |
EP1453557A4 (en) | 2005-07-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8114152B2 (en) | Stent coating | |
US8603158B2 (en) | Irradiated stent coating | |
US6979347B1 (en) | Implantable drug delivery prosthesis | |
US8740973B2 (en) | Polymer biodegradable medical device | |
US8100963B2 (en) | Biodegradable device | |
JP5797226B2 (en) | Stent | |
US8070796B2 (en) | Thrombosis inhibiting graft | |
US8323333B2 (en) | Fragile structure protective coating | |
US7967855B2 (en) | Coated medical device | |
US7455688B2 (en) | Ostial stent | |
US6758859B1 (en) | Increased drug-loading and reduced stress drug delivery device | |
US20070032856A1 (en) | Drug eluting stent | |
US20060287709A1 (en) | Drug-eluting stent and methods of making the same | |
US20100305682A1 (en) | Specially configured and surface modified medical device with certain design features that utilize the intrinsic properties of tungsten, zirconium, tantalum and/or niobium | |
JP2006523132A (en) | Implantable medical device and method for selective adjustment of agent delivery in place | |
US20080306581A1 (en) | Streamlined Stents | |
US20070288085A1 (en) | Absorbable medical devices with specific design features | |
US7435255B1 (en) | Drug-eluting stent and methods of making |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: ICON TECHNOLOGIES, INC., OHIO Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:FURST, JOSEPH G.;REEL/FRAME:013449/0255 Effective date: 20021010 |
|
AS | Assignment |
Owner name: YADAV, JAY S. AS COLLATERAL AGENT C/O THE CLEVELAN Free format text: SECURITY INTEREST;ASSIGNOR:ICON INTERVENTIONAL SYSTEMS, INC.;REEL/FRAME:013842/0405 Effective date: 20030711 |
|
AS | Assignment |
Owner name: ICON INTERVENTIONAL SYSTEMS INC., OHIO Free format text: TERMINATION OF PATENT SECURITY INTEREST;ASSIGNOR:YADAV AS COLLATERAL AGENT, JAY S;REEL/FRAME:014824/0589 Effective date: 20040515 |
|
AS | Assignment |
Owner name: ICON INTERVENTIONAL SYSTEMS, INC., OHIO Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ICON TEHCNOLOGIES, LLC;REEL/FRAME:015766/0458 Effective date: 20040901 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |